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1.1 Introduction 
 
Skeletal muscle engineering is a challenging field that can significantly 
contribute to clinical applications for a wide variety of muscle injuries 
such as strains, trauma, muscular dystrophies, and congenital 
malformations (figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Possible therapeutic areas for skeletal muscle engineering. The treatment 
of strain injuries in sports, muscle defects after trauma, genetic muscle diseases such as 
Duchenne muscular dystrophy, and congenital malformations such as cleft lip and/or 
palate can benefit from skeletal muscle engineering. 
 
Muscle strain injuries occur in sports with high intensity sprinting 
such as football, rugby and soccer, and have an incidence of about 30%. 
One of the most common affected muscle group is the hamstring and 
treatment is still not optimal as shown by the recurrence rate of 30%.
1,2
 
Loss of muscle tissue commonly occurs in patients with large wounds 
such as military personnel, victims of car accidents and gunshots, and in 
surgical patients. The standard treatment for these patients is the 
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transplantation of autologous muscle tissue. However, this leads to new 
defects that may lead to muscle fibrosis. Eventually these patients still 
end up with a permanent physical handicap.
3,4
 Muscular dystrophies are 
inherited myogenic disorders and show progressive muscle wasting and 
weakness. Duchenne muscular dystrophy (DMD) is the most common 
form affecting about 1 out of 3,500 male newborns. It is characterized by 
the absence of the protein dystrophin, which provides structural strength 
to the muscle tissue. Currently, no effective treatments are available for 
any of the muscular dystrophies. Gene and stem cell therapy might offer 
new solutions, but still major problems exist regarding safety and the 
delivery into all affected muscles.
5-7
 Malformations of muscle tissue such 
as in cleft lip and/or palate (CLP), are characterized by disorganized 
muscle fibers and impaired function. About 45% of the CLP patients 
show clefts in the soft palate.
8
 These patients have difficulties with 
feeding and speech, and surgery is required to close the defect. However, 
in many patients speech and feeding problems persist after surgical 
closure, which is often due to the formation of fibrotic tissue in the 
levator veli palatini (LVP), the major muscle of the soft palate.
8-11
  
In all of these muscle disorders, a main problem is the formation of 
fibrotic tissue after restoration.
11
 This prevents the regeneration of 
oriented muscle fibers, and therefore impairs full functional recovery. 
Fibrosis is also one of the main causes of recurrent strain injuries. Present 
therapies are often insufficient to treat muscle injuries because of the 
development of fibrosis. In the field of tissue engineering and 
regenerative medicine, new approaches are being developed with the 
ultimate aim to restore muscle function by improving muscle 
regeneration and reducing fibrosis. 
 
 
1.2 Skeletal muscle regeneration 
 
In order to design and optimize treatment strategies for muscle disorders, 
muscle development and regeneration have been studied extensively 
(reviewed in chapter 2). Briefly, muscle regeneration occurs in three 
phases: inflammation, regeneration, and remodeling, which may lead to 
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fibrosis.
11,12
 During inflammation, macrophages phagocytose necrotic 
debris, and produce factors that, together with factors released from the 
extra cellular matrix (ECM), start the regeneration phase.
11-14 
 
Skeletal muscles regenerate by the activation of a small population 
of stem cells, which are associated with the myofibers.
15,16
 These satellite 
cells are able to migrate to the site of injury where they proliferate 
extensively and subsequently differentiate to form new muscle fibers. 
This process is regulated by many growth factors such as insulin-like 
growth factor (IGF)-I, fibroblast growth factor (FGF)-II, and hepatocyte 
growth factor (HGF).
11-13
 A crucial event during regeneration is the self-
renewal of satellite cells to replenish their numbers for future 
regeneration cycles, which is a key characteristic of all stem cells.
17
 
Factors in the satellite cell niche are crucial for self-renewal and 
regeneration (reviewed in chapter 3). The direct contact of the satellite 
cell with the myofiber and the basal lamina appears to be essential for 
maintaining their stem cell status.
18
 Loss of contact with the niche leads 
to proliferation and differentiation of the satellite cell. 
Fibrotic tissue is often formed during the final remodeling phase, 
which contributes to incomplete functional recovery and recurrent muscle 
injuries.
11,12,19
 A key regulator of fibrosis in many tissues is transforming 
growth factor (TGF)-β.20 Thus, prevention of fibrosis might be achieved 
by decreasing TGF-β activity in the tissue. 
 
 
1.3 Strategies to improve skeletal muscle regeneration 
 
In order to prevent the formation of fibrotic tissue, and to optimize 
muscle regeneration, several strategies have been developed (figure 2, 
reviewed in chapters 2 and 3). Firstly, growth factors that stimulate 
muscle regeneration can be injected into the muscle defect.
21-24
 Secondly, 
satellite cells alone, myofibers including satellite cells, or other cell types 
with myogenic capacity can be injected into the injured muscles.
25-33
 All 
these approaches partly improve regeneration in muscle injury models 
such as strains, contusions, and lacerations. However, for the 
regeneration of large muscle defects such as after trauma or clefts of the 
Chapter 1 
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soft palate, the injection of growth factors and/or satellite cells is not 
sufficient. This type of defects, require three-dimensional scaffolds that 
serve as a template for migrating satellite cells, and guide regenerating 
myofibers across the defect. Several types of scaffolds have been used 
either or not loaded with growth factors and/or cells.
34-37
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Strategies for skeletal muscle engineering. For strains, contusions and 
lacerations, growth factors and/or cells can be injected directly into the defect. For 
genetic muscle diseases, genetically transformed (stem) cells need to be used. For large 
muscle defects, scaffolds loaded with cells and/or growth factors are needed to provide 
structural cues for tissue regeneration. 
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However, muscle fibers are generally not able to grow into the scaffold, 
which is eventually replaced by fibrotic tissue. Loading the scaffolds 
with cells generally improves the outcome but major problems still exist 
in satellite cell isolation and culture, and in their survival and migration 
after transplantation.
28,29,38,39
 To overcome these problems, scaffolds need 
to be developed that attract resident satellite cells towards the defect, and 
support their proliferation and differentiation into functional muscle 
fibers.  
 
 
1.4 Aim of the study 
 
Models for full-thickness muscle defects that generate fibrotic lesions are 
lacking up to now. Such models are required to develop approaches to 
regenerate muscle defects after surgical trauma or clefts of the soft 
palate. As the implantation of scaffolds loaded with satellite cells still 
faces major problems in the isolation and culture of these cells, we chose 
a different approach. The first aim was to develop a fibrosis model by 
making full-thickness muscle defects and then to implant scaffolds 
loaded with factors that attract resident satellite cells and reduce fibrosis. 
In chapter 4, we developed a new model for recurrent strain injuries 
in which fibrotic tissue is mimicked by the implantation of cross-linked 
collagen scaffolds. This model can be used to evaluate new treatment 
modalities for existing fibrosis. In chapter 5, we developed a new muscle 
injury model in which large fibrotic lesions form spontaneously. This 
model can be used to test scaffolds loaded with growth factors that 
improve muscle regeneration and prevent fibrosis. In order to improve 
muscle regeneration, scaffolds with stromal derived factor-1α (SDF-1α) 
were implanted. SDF-1α regulates satellite cell migration.40,41 The results 
of this study are also presented in chapter 5. In order to prevent fibrosis, 
the activity of TGF-β, the main fibrosis-inducing factor, needs to be 
reduced. Decorin, a leucine-rich proteoglycan, is able to bind TGF-β and 
thereby reduces its activity.
21,42,43
 We tested scaffolds with decorin and 
SDF-1α in our fibrosis model to simultaneously promote satellite cell 
migration and prevent fibrosis (chapter 6). Cultured satellite cells, or 
Chapter 1 
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muscle progenitor cells (MPCs), can also be used for therapy. In vivo, 
niche factors from the myofiber and the basal lamina regulate satellite 
cell behavior.
44
 Therefore, we investigated the effect of ECM molecules 
from the basal lamina on the myogenic potential of MPCs in 2D and 3D 
cultures in vitro (chapter 7). In chapter 8, we made a start to translate the 
results of these studies towards a therapy for the repair of the muscles in 
the soft palate. As a first step, we compared the myogenic capacity of 
MPCs isolated from a limb muscle and a craniofacial muscle. Finally, the 
most important results of this thesis and suggestions for future research 
on muscle regeneration are discussed in chapter 9. 
 
In summary, the research aims of this thesis are: 
• To develop new fibrosis models to study the effect of implanted 
 scaffolds on muscle regeneration (chapters 4 & 5).  
• To test scaffolds loaded with growth factors for their ability to 
 improve muscle regeneration and to inhibit fibrosis (chapters 5 & 
 6). 
• To develop a 3D culture system for satellite cells to analyze the 
 effects of ECM components on their myogenic capacity (chapter 7). 
• To compare the myogenic capacity of satellite cells derived from a 
 limb and a craniofacial muscle (chapter 8).  
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Abstract 
 
In the late stages of muscle development, a unique cell population 
emerges that is a key player in postnatal muscle growth and muscle 
regeneration. The location of these cells next to the muscle fibers triggers 
their designation as satellite cells. During the healing of injured muscle 
tissue, satellite cells are capable of forming completely new muscle fibers 
or restoring damaged muscle fibers. A major problem in muscle healing 
is the formation of dysfunctional scar tissue, which leads to incomplete  
functional recovery. Therefore, the identification of factors that improve 
the process of muscle healing and reduce the formation of scar tissue is 
of great interest. Because satellite cells possess the capability of self-
renewal, a unique feature of stem cells, they play a central role in the  
search for therapies to improve muscle healing. Growth factor-based and 
(satellite) cell-based therapies are being investigated to treat minor 
muscle injuries and intrinsic muscle defects. Major muscle injury that 
involves the loss of muscle tissue requires the use of scaffolds with or 
without (satellite) cells. Scaffolds are also being developed to generate 
muscle tissue in vitro. These approaches aim to restore the structure and 
function of the injured muscle without dysfunctional scarring. 
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2.1 Introduction 
 
Skeletale muscle represents nearly half of the total body mass and thus is 
the most abundant tissue of the human body. The skeletal muscles  induce 
smooth and coordinated body movements through their attachment to the 
skeleton. To ensure proper function, the skeletal muscles are highly 
vascularized and extensively innervated. A skeletal muscle is composed 
of many bundles of myofibers, which are the functional units. A single 
myofiber is derived from the fusion of numerous myoblasts and therefore 
contains many nuclei. Each myofiber contains many myofibrils, which 
are composed of repeating sarcomeres. A sarcomere is an arrangement of 
the contractile proteins myosin and actin, which form the thick and thin 
filaments, respectively (figure 1). These proteins are key elements for the 
contractile properties of skeletal muscle. For skeletal muscle to contract, 
the myofibers depolarize as a consequence of nerve activation. This 
results in the release of intracellular calcium from the sarcoplasmatic 
reticulum. Calcium causes binding of myosin to actin, and subsequently 
contraction of the myofibers and the entire skeletal muscle. Most human 
skeletal muscles contain a mixture of three different types of myofibers. 
Type 1 myofibers are slow twitch and fatigue resistant, type 2A 
myofibers are fast twitch and moderately fatigue resistant, and type 2B 
myofibers are fast twitch and not fatigue resistant. The proportions of 
these myofibers within skeletal muscles is dynamic and can change 
throughout life.
1–4
 
Skeletal muscles are able to self-regenerate after injury. Crucial cells 
in this process are the satellite cells, which are located between the 
sarcolemma and the basal lamina of the myofiber.
5,6
 After injury these 
cells are activated; they proliferate and eventually fuse to the damaged 
myofibers or fuse together to form new myofibers.
1,7–9
 Injury and 
diseases such as Duchenne muscular dystrophy (DMD) lead to impaired 
muscle function. The formation of a dysfunctional scar tissue during 
regeneration may account for this problem. Thus, the identification of 
factors that influence the regeneration process of injured muscle is of 
great interest. The aim of this review is to give an overview of muscle 
development and regeneration, as well as how this knowledge is now 
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being used to develop treatment modalities for major muscle injuries or 
muscle disease. 
 
 
Figure 1. The structure of skeletal 
muscle. Skeletal muscle is made up of 
clusters of myofibers. A single 
myofiber is composed of many 
myofibrils, which contain repeating 
sarcomeres. Each sarcomere contains 
the proteins actin and myosin, which 
represent the thin and thick filaments, 
respectively. These proteins are 
responsible for muscle contraction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2 Embryonic myogenesis 
 
2.2.1 Somite development 
In the early stages of embryonic development, the major function of 
gastrulation is to create a mesodermal layer between the ectoderm and the 
endoderm. The mesoderm forms the blood, blood vessels, bones, 
cartilage, connective tissue, and the muscles of the body trunk. On either 
side of the neural tube, this mesoderm is divided into the axial mesoderm 
(notochord), intermediate mesoderm, paraxial mesoderm, and the lateral 
plate mesoderm.
10
 With the exception of the craniofacial muscles, nearly 
all embryonic skeletal muscles are derived from the paraxial mesoderm. 
First the paraxial mesoderm separates into cell clusters, called the 
somites, starting at the head region and sequentially added caudally. Cells 
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of the ventral part of the somites undergo an epithelial-to-mesenchymal 
transition, thereby forming the sclerotome, which eventually forms the 
vertebrae and ribs. In the chick, this process is characterized by the 
down-regulation of Pax3 and Pax7, two members of the family of 
paired/homeodomain transcription factors (figure 2). Members of this 
family play an essential role in embryonic organogenesis.
11
 Cells of the 
dorsal part of the somites maintain Pax3 and Pax7 expression, and form 
the dermomyotome. This dermomyotome is responsible for the 
musculature and the dermis and is divided into an epaxial and hypaxial 
part, which forms the deep back muscles and the intercostal, abdominal, 
and limb muscles.
10
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The formation of the somites and the myotomes. The paraxial mesoderm, 
which gives rise to most of the skeletal muscle, segments into the somites. Eventually the 
somites differentiate into a sclerotome and a dermomyotome. In the chick, Pax3 and Pax7 
expression is down-regulated in the sclerotome, but in the dermomyotome both are 
maintained. After the formation of the sclerotome and the dermomyotome, muscle 
progenitor cells delaminate from  the four edges of the dermomyotome. These cells down-
regulate their Pax3 expression and up-regulate the expression of myogenic regulatory 
factors, such as Mrf5, Myf4, MyoD, and myogenin. This results in the differentiation and 
fusion of the muscle progenitor cells, which leads to the formation of the  myotome. In 
time, the dermomyotome disintegrates and muscle progenitor cells, expressing Pax3 and 
Pax7, migrate into the myotome. These cells contribute to the massive muscle development 
in the embryo and give rise for most of the satellite cells. 
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2.2.2 Myotome development 
A crucial step in the formation of skeletal muscle is the appearance of the 
myotome (figure 2). First, muscle progenitors cells delaminate from the 
four edges of the dermomyotome.
12
 In addition, muscle progenitor cells 
migrate into the limb buds. It has been described that c-Met, a tyrosine 
kinase receptor that binds hepatocyte growth factor (HGF),
13
 and Pax3 
are major contributors to this delamination and migration, because mouse 
embryos lacking functional c-Met and Pax3 do not form skeletal muscle 
in the limbs. At the edges of the dermomyotome, Pax3 is also important 
to the survival of these cell.
14–17
 These delaminating progenitor cells 
down-regulate Pax3 and become myoblasts through the action of the 
myogenic regulatory factors (MRFs), a family of basic helix–loop–helix 
transcription factors that regulate myogenesis. These myoblasts increase 
their expression of Myf5, Mrf4, and MyoD,
18–20
 and differentiate into 
myocytes through the action of myogenin, Mrf4, and MyoD.
21
 The 
myocytes eventually fuse and mature into multinucleated muscle fibers 
forming a continuous muscle layer, the myotome. It is known that these 
processes are influenced by signals from adjacent structures. Sonic 
hedgehog (Shh) and Wnt proteins, both representing a family of secreted 
signaling molecules, are involved in muscle development. These proteins 
are released from the neural tube, notochord, and surface ectoderm, and 
provide stimulatory signals during myogenesis. Bone morphogenic 
proteins (BMPs), another family of secreted signaling proteins involved 
in developmental processes, are released from the neural tube and the 
lateral plate mesoderm and inhibit myogenesis.
1,22–25
 
 
2.2.3 Embryonic muscle and satellite cells 
Given that the dermomyotome progressively disintegrates
10
 and the 
myotome is already post-mitotic, these structures cannot account for the 
massive muscle development in the embryo. Several groups describe that 
cells expressing Pax3 and Pax7, but not the myogenic markers, migrate 
from the central dermomyotome directly into the myotome. During 
muscle development, these cells contribute to muscle growth and are 
maintained within the muscle mass. Before skeletal muscle forms in the 
limb buds, these precursor cells probably proliferate extensively to create 
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the skeletal muscle tissue.
26–29
 As mentioned before, c-Met and Pax3 are 
involved in the migration of cells from the somite into the limb buds, and 
only upon arrival in the limb do these cells start to express MyoD and 
Myf5.
30
 Furthermore, the Pax3- and Pax7-positive cells derived from the 
central dermomyotome also give rise to most if not all satellite cells, 
which emerge during the later phases of embryonic development.
26–28
 
Although the paraxial mesoderm in the embryonic body is completely 
segmented into somites, in the head it is incompletely segmented into 
seven mesenchymal structures, called somitomeres. Most head muscles 
such as the matistactory, jaw opening, and eye muscles, are derived from 
the paraxial head mesoderm, but the tongue muscles are derived from the 
somites.
10,31
 In addition, differences have been described in the regulation 
of myogenesis in the head and these are reviewed elsewhere.
1,31,32
 
During embryonic development, two distinct types of skeletal 
muscle fibers appear. The first muscle fibers that emerge are called 
primary or embryonic fibers; the secondary or fetal fibers arise later. The 
primary and secondary fibers have distinct morphological and 
biochemical properties and can be classified into slow-twitch and fast-
twitch fibers.
33–36
 Moreover, it seems that this commitment is 
independent from the surroundings and occurs in the somite .
37
 Toward 
the end of embryogenesis, the satellite cells appear. They are the major 
players in postnatal muscle growth and regeneration. 
 
 
2.3 Muscle regeneration 
 
In general, adult skin wound healing occurs in three overlapping phases: 
inflammation, tissue formation and tissue remodeling.
38
 Wound healing 
proceeds similarly in other tissues such as muscle.
2
 A drawback of wound 
healing often is the formation of scar tissue (fibrosis), which can give 
esthetic as well as functional problems. 
 
2.3.1 Fetal tissue regeneration 
In contrast with adult skin wound healing, fetal wound healing of the skin 
can occur without the formation of scar tissue. Since this observation, the 
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search for factors that contribute to scarless healing was of great interest 
because these factors have a promising role in preventing scar formation 
in adult wound healing.
39–41
 In the fetus, rapid wound closure is induced 
without scab formation and inflammation and with specific cytokine 
levels. Additionally, matrix deposition is rapid and similar to the 
uninjured fetal skin, whereas the extracellular matrix is rich in hyaluronic 
acid. Several studies indicate that the fetal environment is not essential 
for scarless tissue repair and that intrinsic factors of the tissue itself are 
vital.
42,43
 However, not all fetal wounds heal without scar tissue, and 
healing takes place only in fetuses up to a certain gestational age.
44–46
 
Also wound size is important, as the extent of scarring increases with 
increasing wound size.
47,48
 In contrast to the healing of fetal skin, wounds 
in gastric tissue, intestine, and nerve tissue always heal with scar 
formation.
49–51
 Moreover in diaphragmatic wounds, muscle regeneration 
is absent, and scar tissue forms.
52
 With the exception of this study, there 
is little further information on fetal muscle healing. 
 
2.3.2 Adult tissue regeneration 
Similar to the healing of adult skin, the healing of adult muscle injury 
caused by trauma occurs in three overlapping phases. As described, these 
phases include inflammation, tissue formation, and tissue remodeling 
resulting in the formation of scar tissue (fibrosis). After muscle injury,  
disruption of the myofiber plasma membrane initiates an influx of 
extracellular calcium, leading to calcium-dependent proteolysis.
53–55
 This 
results in necrosis and degeneration of damaged myofibers, which is 
restricted to the damaged site through the formation of a contraction band 
that seals off the defect.
56
 At the site of injury, blood vessels are also 
damaged, allowing the invasion of inflammatory cells. Factors are 
released in the injured muscle tissue that attract and activate 
inflammatory cells, which secrete chemotactic factors to attract more 
inflammatory cells. Neutrophils are the first inflammatory cells at the site 
of injury, and later macrophages arrive to phagocytose muscle debris.
1
 
Interestingly, satellite cells and macrophages interact to amplify 
chemotaxis and thereby enhance inflammation. Macrophages may also 
support satellite cell survival by cell–cell contact and the release of 
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soluble factors.
57
 Additionally, macrophage infiltration leads to increased 
satellite cell proliferation and differentiation. After macrophage 
depletion, muscle regeneration is completely absent.
58
 In conclusion, 
macrophages are not only important for the resolution of necrosis but are 
also involved in the induction of muscle regeneration.
59
 
 
2.3.3 Satellite cells 
At the site of injury, many growth factors are expressed and several of 
these are able to activate satellite cells. Examples are members of the 
fibroblast growth factor (FGF) and transforming growth factor-β (TGF-β) 
families, insulin-like growth factor-I and -II (IGF-I, IGF-II), hepatocyte 
growth factor (HGF), and interleukin-6 (IL-6). The functions of these 
factors are reviewed extensively elsewhere.
1,2,22,60
 Normally, satellite 
cells are quiescent, located between the basal lamina and the sarcolemma 
of myofibers, and express Pax7.
61,62
 Pax7 in combination with M-
cadherin (figure 3), a calcium-dependent cell adhesion molecule, c-Met, 
or other markers should be used to identify satellite cells.
22
 However, up 
to now, there is no unique marker for quiescent or activated satellite 
cells. Upon injury, activated satellite cells either migrate to adjacent 
myofibers if the basal lamina is destroyed or migrate under the basal 
lamina to the site of injury.
22
 The activation of satellite cells is similar to 
embryonic myogenesis, which is controlled by Pax3, Pax7 and Myf5 
(figure 4).
63
 First the activated satellite cells up-regulate either MyoD or 
Myf5, but eventually these factors are co-expressed. During this stage, 
the satellite cells become proliferative, and are also known as myoblasts. 
Down-regulation of Pax3
63
 and Pax7,
61,64
 and up-regulation of myogenin 
and Mrf4 lead to terminal differentiation of these myoblasts. Pax3 and 
Pax7 activate myogenin via up-regulation of MyoD, but Myf5 is able to 
activate myogenin directly. Ultimately, these differentiated myoblasts 
either fuse to each other, creating new myofibers, or fuse to existing 
damaged myofibers for repair.
1,7–9
 These myofibers are still small, and 
the nuclei are located near the center of the myofiber. Maturation of these 
myofibers is characterized by an increase in size, and the movement of 
the nuclei to the periphery.
22
 Next to growth factors, Notch, Shh, and 
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Wnt, which are important in muscle embryogenesis, may also be involved 
in satellite cell activation and postnatal muscle regeneration.
60
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Identification of a satellite cell in rat muscle by immunostaining with Pax 
7 (red), M-cadherin (green) and DAPI (blue). (S. Grefte, unpublished results). 
 
Another essential factor in the function of satellite cells  is the 
muscle environment. In aging muscle, regeneration is less efficient and 
the number of satellite cells declines. Because exposure of aged mice to 
serum of young mice restores muscle regeneration effectively,
65
 the aged 
stem cells must still have retained their regenerative capacity.
65–67
 These 
local factors are unknown, and further research is needed to identify 
them. Besides satellite cells, other cell types seem to be involved in 
muscle regeneration. Some studies suggest a minor role for non-muscle 
stem cells and for muscle-derived progenitor cells other than satellite 
cells.
1,68
 However, the exact functions of satellite cells and other cell 
types in regenerating muscle defects remain unclear. Moreover, evidence 
exists that satellite cells constitute a heterogeneous population.
69
 Also, 
satellite cell markers such as M-cadherin and Myf5 seem to be 
heterogeneously expressed,
70
 but Pax7 is expressed in almost all 
quiescent satellite cells.
61,62
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Figure 4. The role of satellite cells during muscle regeneration. After injury, 
quiescent satellite cells expressing Pax7 migrate to the site of injury. Environmental 
signals such as growth factors activate the satellite cells to become myoblasts. These 
myoblasts are proliferative and express Pax7, MyoD, and  Myf5. Down-regulation of 
MyoD and maintenance of Pax7 expression might be involved in the self-renewal of 
satellite cells.
61,64
 Differentiation of the myoblasts is marked by the down-regulation of 
Pax7 and up-regulation of Mrf4 and Myogenin. Finally, fusion of the differentiated 
myoblasts occurs to create new myofibers or to repair damaged myofibers. Maturation of 
these new or repaired myofibers is characterized by an increase in size and the movement 
of the nuclei to the periphery. 
 
2.3.4 Self-renewal of satellite cells 
A crucial characteristic of satellite cells is the capacity of self-renewal, 
which is a unique feature of all stem cells. Without self-renewal the 
number of satellite cells would decline after repetitive muscle injury and 
also during normal tissue turnover. Direct evidence for the self-renewal 
of satellite cells was provided using genetically labeled myofibers, but 
the exact mechanism has not yet been determined.
71
 Two mechanisms 
have been proposed that result in satellite cell maintenance.
68,72
 
Skeletal muscle development and regeneration 
 33 
Asymmetric division results in the formation of two daughter cells, of 
which one remains quiescent while the other undergoes myogenic 
activation and differentiation. Alternatively, symmetric division results in 
the activation and proliferation of all daughter cells. While the bulk of 
these proliferated cells down-regulate Pax7 and differentiate into new 
myofibers, a few cells retain Pax7 expression, return to their quiescent 
state, and repopulate the satellite cell pool.
61,64
 In Pax7 knockout mice, 
satellite cells are still present directly after birth, but their number 
declines during postnatal development. It was also shown recently that in 
Pax7 knockout mice apoptosis of satellite cells occurs.
63
 In contrast, Pax3 
is essential for the survival of cells in the hypaxial dermomyotome as 
described before. 
 
2.3.5 Fibrosis 
At the site of injury, fibrosis may also occur leading to the formation of 
scar tissue.
73
 Similar to skin wound healing, a provisional matrix 
provides an initial extracellular matrix for cell invasion. In time, 
(myo)fibroblasts begin to produce extracellular matrix components like 
fibronectin, followed by type III collagen, and ending with excessive 
production of type I collagen. Finally, after tissue remodeling and 
apoptosis of the myofibroblasts, a nearly acellular scar tissue is formed.
3
 
It is unknown whether regenerated myofibers will eventually fuse and 
fully regenerate the muscle tissue, but most muscle injuries  heal without 
dysfunctional scar tissue. In contrast, excessive fibroblast proliferation 
may occur in large muscle injuries, resulting in a scar that limits full 
muscle regeneration.
74,75
 Using a clonal population of muscle-derived 
stem cells it was shown that myogenic precursor cells are able to 
differentiate into myofibroblasts after muscle injury.
76
 TGF-β1 is 
involved in scarring during wound healing in the skin.
38
 In muscle, TGF-
β1 is highly expressed at the site of injury, and it is able to induce 
myofibroblast differentiation of muscle-derived stem cells in vitro.
76
 This 
suggests that some of the (myo)fibroblasts responsible for scar formation 
might be derived from myogenic cells such as satellite cells. 
In summary, the function of satellite cells during muscle 
regeneration is regulated by many growth factors and cytokines. Their 
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capacity of self-renewal provides a source of satellite cells for muscle 
regeneration throughout life. Although most muscle injuries heal without 
dysfunctional scar tissue, this may occur in large muscle defects 
 
 
2.4 Improving muscle regeneration 
 
2.4.1 Growth factor-based therapy 
The effects of growth factors on the activation, proliferation,  and 
differentiation of satellite cells have been reviewed elsewhere.
1,2,22,60
 
Growth factors with stimulatory effects might be used in vivo to enhance 
the regeneration of muscle tissue. Indeed, it appears that the 
administration of growth factors after muscle injury may improve the 
healing process. In mouse models for muscle strain,
77
 contusion,
78
 and 
laceration
79,80 
injuries, direct injection of IGF-I and FGF-2, and to a lesser 
extent nerve growth factor (NGF), improved healing of the muscle. This 
was indicated by an increase in the number and the diameter of 
regenerated myofibers. Additionally, the strength of the myofibers 
improved. The administration of decorin, an inhibitor of TGF-β, also 
induced muscle healing, and in combination with IGF-I it seems to be the 
best strategy to improve muscle healing.
80
 However, based solely upon 
the strength of the myofibers, the administration of decorin alone showed 
the best improvement. These conflicting results stress the use of 
histological as well as functional parameters to evaluate muscle 
regeneration. Because TGF-β is considered to be involved in fibrosis, the 
inhibition of this growth factor might reduce scar formation during 
muscle regeneration. In fact, the administration of decorin indeed inhibits 
fibrosis.
80
 In contrast, it was also shown that administration of FGF-2 did 
not improve muscle regeneration.
81
 Therefore, it is important to exactly 
identify which growth factors enhance muscle regeneration in vivo and 
also at which concentration, location, and time point they should be 
administered.  
Thus, growth factors seem to improve muscle healing after minor 
injury. However, for intrinsic muscle defects such as DMD or large 
muscle defects, growth factor-based therapy might not be the appropriate 
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strategy. To treat DMD, the use of cell-based therapy is a better solution. 
For major muscle injuries, scaffold-based therapy to fill up the large 
defect is the best method. These scaffolds can also be loaded with growth 
factors and/or myogenic cells. 
 
2.4.2 Cell-based therapy 
To regenerate muscle through the delivery of exogenous cells such as 
myofibers or satellite cells, it is crucial that these cells not only 
regenerate the damaged muscle but also replenish the satellite cell pool. 
This allows a long-term normal tissue maintenance and regenerative 
capacity. Although there is evidence that the dystrophic muscle 
environment is hostile for muscle regeneration,
82
 the mdx mouse model 
has been used extensively to study muscle regeneration after cell 
transplantation. The mdx mouse lacks dystrophin, a structural protein that 
is mutated in DMD patients. Repetitive injections of notexin after the 
transplantation of clones of myoblasts into irradiated mdx nu/nu mouse 
muscle resulted in new myofibers of donor origin.
83
 The formation of 
new muscle after repetitive muscle damage indicates that a new satellite 
cell population was established.
83
 Labeling studies showed that myoblasts 
repaired the injured muscle fibers after transplantation and formed new 
satellite cells.
84,85
 Furthermore, labeled satellite cells were detected in 
host muscle fibers, and isolated satellite cells from these fibers were also 
able to become active and to proliferate.
86
 Grafting of myofibers that 
contain satellite cells resulted in the regeneration of damaged muscle and 
the expansion of the satellite cell pool.
71
 Moreover, grafting the satellite 
cells, which were isolated from these myofibers, generated clusters of 
new myofibers. This indicates that the isolation of satellite cells from the 
myofiber does not impair the myogenic potential of these cells.
71
 
Additionally, a pure population of myogenic cells expressing Pax3, Pax7, 
and CD34 contributed to muscle regeneration and the formation of new 
satellite cells.
87
 However, cultured satellite cells gradually loose their 
myogenic potential, and the transplantation of these cells leads to less 
efficient muscle regeneration.
87,88
 Freshly isolated satellite cells may 
induce muscle regeneration more efficiently, but the small number of 
isolated satellite cells might be a problem. Therefore methods for 
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culturing satellite cells must be developed in which they maintain their 
myogenic properties.  
Unfortunately, it has also been shown that the majority of the 
myoblasts die after transplantation in mdx mice.
89–91
 Inflammation may 
be involved because infection of the myoblasts with a retroviral vector 
containing the IL-1 receptor antagonist partly prevented the observed cell 
death.
90
 Although most of the transplanted cells died, a minority of 
myogenic cells were able to survive and to regenerate the host muscle.
91
 
Additionally, a specific myogenic cell population was enriched based 
upon their adhesion capabilities. These cells were able to survive after 
transplantation and fused with host myofibers, thus demonstrating their 
regenerative capacity.
90
 Two additional myogenic populations were found 
based upon M-cadherin and CD34 expression.
92
 In this study, these two 
markers could not be co-localized in skeletal muscle of normal mice, but 
cells expressing M-cadherin or CD34 both reside between the basal 
lamina and the sarcolemma of the myofibers, which is also the niche of 
satellite cells. However, in another study, M-cadherin
+
 satellite cells were 
also positive for CD34.
70
 Cloned myogenic cells from the CD34
+
 
population enhanced muscle regeneration, and partially restored 
dystrophin expression.
92
 In another study, three myogenic cell 
populations were found based upon their adherence capacity. Two of 
these cell populations represented the satellite cells and showed limited 
capacity to regenerate the host muscle. However, the third cell population 
showed a strong capacity to improve muscle regeneration. These cells 
were long-time proliferative and also called muscle derived cells 
(MDSCs).
93
 Interestingly, these cells did not activate T cells, indicating 
that they were not rejected by the immune system of the host. However, it 
was also shown that, on the basis of the mass and functional properties of 
the muscle, transplantation of primary myoblasts or the same MDSCs as 
described before
93
 did not induce muscle regeneration in mdx mice.
94
 
These results suggest that myoblast transplantation is helpful for the 
treatment of DMD by the fusion of myoblasts with host muscle fibers and 
restoring dystrophin expression, but in human experiments this strategy 
was unsuccessful. The translation from mice to humans might have been 
made too easily. Human muscles might be too large to allow transplanted 
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myoblasts to migrate throughout the entire muscle. A discussion of these 
problems and the treatment of DMD in humans has been published 
elsewhere.
95
 In a recent study in the golden retriever muscular dystrophy 
(GRMD) model, a new therapy modality was developed for the treatment 
of DMD. The transplantation of autologous mesangioblasts transfected 
with small dystrophin genes resulted in the expression of dystrophin in 
host muscle and the formation of functional muscle with a normal 
morphology.
96
  
In conclusion, most of these studies show the potential  of 
transplanting myoblasts and MDSCs into muscle tissue to produce new 
muscle fibers or to restore dystrophin expression in host muscle fibers for 
the treatment of DMD. Moreover, the transplanted myoblasts are also 
able to create a new satellite cell pool, necessary for muscle regeneration 
throughout life and normal tissue turnover. Therefore the combination of 
transplanted cells with suitable scaffolds might offer new strategies for 
the repair of major muscle damage. 
 
2.4.3 Scaffold-based therapy 
In contrast to the transplantation of myoblasts and the use of growth 
factors to heal minor muscle injuries, these methods might not be 
appropriate for large defects. The application of a three-dimensional 
scaffold, which fills up the defect and induces the formation of new 
muscle, seems more suitable. The scaffold can be seeded with myoblasts 
or other myogenic cells, and can be implanted into a large muscle defect 
to improve muscle regeneration. However, the transplantation of a 
collagen disc seeded with or without myoblasts into an abdominal wall 
muscle defect in rats did not induce muscle formation.
97
 Similar results 
were obtained after the transplantation of an acellular muscle matrix to 
reconstruct an abdominal wall muscle defect in rabbits
98
 and rats
99
 and a 
dorsal muscle defect in rats.
100
 Eventually these constructs were replaced 
by fibrous tissue.
98–100
 However, seeding the matrix with autologous 
satellite cells reduced the inflammation, and fibrosis occurred at the edge 
of the implant. This indicates that satellite cell seeding improves the 
biocompatibility of the scaffold. In vitro studies showed that an acellular 
muscle matrix supports the growth and differentiation of satellite cells 
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isolated from rats, but in vivo studies showed no convincing evidence of 
skeletal muscle formation inside the matrix after transplantation into a 
dorsal muscle defect in rats.
100
 However, electric activity was detected, 
indicating that skeletal muscle fibers were present within the matrix (99). 
This result shows the potential of using constructs seeded with myoblasts 
to reconstruct injured muscle. Additionally, transplantation of a muscle 
matrix seeded with male rat myoblasts into full-thickness abdominal wall 
defects of female rats resulted in the formation of a dense capillary 
network, skeletal muscle fibers, and evidence for nerve formation.
101
 This 
matrix stained positively for FGF-2 and TGF-β, which could play a role 
in the regeneration of injured muscle. It has also been shown that muscle 
formation occurred only at the border of the matrix after the 
transplantation of an autologous myoblast-seeded muscle matrix 
construct into the abdominal muscle of rats.
102
  
Thus, it seems that growth factors inside the matrix have a positive 
effect on seeded myoblasts and improve the formation of muscle fibers. 
The addition of HGF and FGF-2 to alginate scaffolds seeded with 
myoblasts greatly increased the viability of these cells.
103
 Transplantation 
of such a scaffold seeded with myoblasts resulted in enhanced muscle 
regeneration by the engrafted donor cells.
104
 Also other biomaterials were 
used as a three-dimensional matrix to reconstruct muscle tissue. The 
implantation of degradable polyglycolic acid (PGA) meshes,
105,106
 
alginate, and hyaluronic acid constructs,
107
 all seeded with myoblasts, 
into a nonmuscle environment resulted in vascularization and muscle 
formation. Using fibrin as a three-dimensional matrix, in vitro studies 
showed that myoblasts can fuse into myotubes with physiological 
functions, such as force production.
108
 After injecting fibrinogen with 
male myoblasts into a muscle defect of female rats, the fibrin matrix was 
eventually dissolved and the myoblasts fused with the host muscle.
109
 
More importantly, no inflammation was observed and fibrosis was 
absent.
109
 However, full integration of the scaffolds seeded with 
myoblasts into the host muscle and total functional recovery without 
scarring still remain to be realized.  
In summary, three-dimensional scaffolds might have advantages in 
the treatment of large muscle defects. Seeding of the scaffold with 
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myoblasts appears to be essential to induce the formation of new muscle 
mass. Furthermore, the addition of growth factors might improve the 
proliferation, migration and fusion of these myoblasts into new 
myofibers. A crucial aspect is the vascularization and innervation of the 
construct. It is important to keep in mind that, in line with the problems 
of the treatment of DMD in humans, these studies were carried out in the 
muscles of small animals. Thus, caution must be taken in the translation 
of the data to humans with larger muscles. The migration of myoblasts 
out of the scaffold, and the diffusion of signaling molecules and nutrients 
might be different. 
 
 
2.5 Conclusion 
 
Several strategies are being investigated to improve muscle regeneration 
after muscle trauma. For small defects, the administration of appropriate 
growth factors might increase satellite cell activation and improve muscle 
regeneration, while inhibiting fibrosis. The application of satellite cells or 
other myogenic cells capable of forming new muscle tissue might also 
improve muscle regeneration. These cells, as well as genetically 
corrected satellite cells, might also be used to restore intrinsic molecular 
defects such as DMD. However, for large muscle defects, suitable 
scaffolds must be used to induce muscle regeneration. These scaffolds 
should act as a temporary guide for host muscle cells or seeded satellite 
cells. Additionally, growth factors can be introduced into the scaffolds to 
create a suitable microenvironment for satellite cells. It is essential that 
these scaffolds: (1) initially provide mechanical stability to the defect, (2) 
induce satellite cell proliferation and differentiation into mature muscle, 
(3) induce fusion and alignment of myofibers with host myofibers, and 
(4) provide a niche to harbor satellite cells needed for normal tissue 
turnover and for future muscle regeneration. Furthermore, for a complete 
and functional recovery of damaged muscle the new tissue must be well 
vascularized and innervated. The ultimate goal of these strategies is to 
induce rapid muscle regeneration, leading to a functional muscle without 
the formation of dysfunctional scar tissue. 
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Abstract 
 
Skeletal muscle regeneration is a complex process, which is not yet 
completely understood. Satellite cells, the skeletal muscle stem cells, 
become activated after trauma, proliferate, and migrate to the site of 
injury. Depending on the severity of the myotrauma, activated satellite 
cells form new multinucleated myofibers or fuse to damaged myofibers. 
The specific microenvironment of the satellite cells, the niche, controls 
their behavior. The niche contains several components that maintain 
satellite cells quiescence until they are activated. In addition, a great 
diversity of stimulatory and inhibitory growth factors such as IGF-1 and 
TGF-β1 regulate their activity. Donor-derived satellite cells are able to 
improve muscle regeneration, but their migration through the muscle 
tissue and across endothelial layers is limited. Less than 1% of their 
progeny, the myoblasts, survive the first days upon intra-muscular 
injection. However, a range of other multipotent muscle- and non-
muscle-derived stem cells are involved in skeletal muscle regeneration. 
These stem cells can occupy the satellite cell niche and show great 
potential for the treatment of skeletal muscle injuries and diseases. The 
aim of this review is to discuss the niche factors, growth factors, and 
other stem cells, which are involved in skeletal muscle regeneration. 
Knowledge about the factors regulating satellite cell activity and skeletal 
muscle regeneration can be used to improve the treatment of muscle 
injuries and diseases. 
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3.1 Introduction 
 
Skeletal muscle is the largest tissue in the human body, composing 40-
50% of total human body mass.
1
 The functions of skeletal muscles 
include movement, breathing, and posture maintenance.
2
 Skeletal muscles 
consist of muscle cells, networks of nerves and blood vessels, and 
connective tissues that connect individual fibers into bundles, which form 
the muscle. The epimysium is the fibrous outer layer that surrounds the 
complete muscle, the perimysium surrounds the bundles of myofibers, 
and the endomysium (also called the basement membrane) surrounds 
individual myofibers.
1,3
 Myofibers are the basic structural elements of 
skeletal muscle and are composed of multiple fused myoblasts. Newly 
formed multinucleated fibers exhibit central nucleation, and once the 
nuclei move to a subsarcolemmal position they are called myofibers.
1,3,4
 
The interior of a myofiber contains the sarcomeres, which are the basic 
functional units of skeletal muscle. The sarcomere consists of thick 
myosin filaments that interdigitate with thin actin filaments and is 
specialized to respond to neuromuscular signals. As a response to these 
signals (an acetylcholine-induced action potential), the cell depolarizes 
resulting in calcium release from the sarcoplasmatic reticulum (SR). The 
released calcium induces ATP-driven interactions between myosin and 
actin leading to sarcomere shortening and muscle contraction.
5,6
 
Most skeletal muscles contain a mixture of 3 different types of 
myofibers. Type 1 myofibers are slow twitch and fatigue-resistant, type 
2A myofibers are fast twitch and moderately fatigue-resistant, and type 
2B myofibers are fast twitch and not-fatigue resistant. These different 
fiber types contain either slow myosin heavy chain (MyHC) or fast 
MyHC. These two isoforms have the same subunit structure, but differ in 
the rate of ATPase activity.
7,8
 The composition of myofibers in skeletal 
muscle is dynamic and can change throughout life.
1,3-5
  
In addition, skeletal muscles contain stem cells, which are also 
known as the satellite cells (SCs). SCs are located between the plasma 
membrane (sarcolemma) of the myofiber and the basal membrane 
(BM).
9,10
 These cells are normally quiescent and will be activated after 
myotrauma, proliferate, self-renew, and finally differentiate into 
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multinucleated myofibers.
4,11-13
 Since the original identification of the SC 
in 1961
9
  it has been hypothesized that SCs are remaining embryonic 
myoblasts from the developing somites. Several studies
14-17
 have 
demonstrated that progenitor cells from the dermomyotome give rise to 
SCs, but it remains unclear whether these cells are the only precursors of 
SCs.
18
 After birth, the SCs proliferate extensively and play a major role 
in skeletal muscle growth and regeneration.
15-17
  
Many regulatory processes are involved in skeletal muscle 
regeneration. Mainly the specific microenvironment of the SCs, the 
niche, and many growth factors, play a major role. In addition, a wide 
range of other multipotent stem cells, seem to be involved. The aim of 
this review is to discuss the factors that regulate SC activity and skeletal 
muscle regeneration, and their promising role in the improvement of 
skeletal muscle diseases in the future. In the next section, an overview of 
skeletal muscle regeneration is presented. 
 
 
3.2 Skeletal muscle regeneration 
 
The healing of skeletal muscle in response to trauma depends on the type 
of injury such as contusion, strain, and laceration, and on the severity. 
However, in general, the healing process consists of three phases: the 
destruction phase, the repair phase, and the remodeling phase.
1,3,4,19
 The 
destruction phase is characterized by necrosis, hematoma formation, and 
the influx of inflammatory cells. During the repair phase, the necrotic 
debris is phagocytosed, and regeneration of myofibers occur through the 
action of SCs.
20,21
 Firstly, quiescent SCs expressing Pax7 migrate to the 
site of injury, up-regulate the myogenic regulatory factors (MRFs) MyoD 
and Myf5, and become proliferative.
22-26
 From now on, the SCs are also 
known as myoblasts. Subsequent differentiation of the myoblasts is 
marked by the down-regulation of Pax7
27,28
 and up-regulation of the 
MRFs Mrf4 and Myogenin.
22-24
 Ultimately, these differentiated myoblasts 
form multinucleated myofibers (hyperplasia) or fuse to damaged 
myofibers (hypertrophy) for muscle regeneration.
4,29
 However, some of 
the activated SCs do not proliferate or differentiate, but self-renew and 
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replenish the satellite cell pool, which is a unique and crucial property of 
all stem cells.
28,30-32
 Two different mechanisms have been proposed for 
self-renewal, asymmetric and symmetric division of SCs.
30,33,34
 
Asymmetric division results in two different daughters cells, one is 
beginning to differentiate while the other will remain quiescence and 
self-renew. Recent research demonstrated that asymmetric self-renewal 
of SCs occurs in skeletal muscles.
31,35,36
 The study of Kuang et al. also 
suggests that 10% of the SCs have never expressed Myf5 suggesting that 
they did not proliferated and self-renew using asymmetric cell division.
31
 
In contrast, symmetric division results in the activation and proliferation 
of all daughter SCs. A minority of these cells will self-renew by 
maintaining Pax7 expression while down-regulating MyoD expression. 
However, most of these activated and proliferating cells down-regulate 
Pax7 expression and then differentiate.
27,28
 During the last phase, the 
remodeling phase, the regenerated myofibers mature and contract. 
However, in some cases, reorganization and contraction of unstructured 
connective tissue occur, resulting in scar tissue and subsequent 
incomplete skeletal muscle regeneration.
3,37,38
  
Next to skeletal muscle injury, diseases such as muscular dystrophy 
also lead to impaired muscle function.
39 
Muscular dystrophy is 
characterized by muscle weakness and wasting. Many different forms of 
this disease have been identified.
39,40
 The most severe form is Duchenne 
muscular dystrophy (DMD), which is characterized by the absence of 
dystrophin.
41
 Dystrophin is, together with other membrane-associated 
proteins, required for the structural integrity of the muscle fibers. The 
lack of dystrophin leads to membrane instability and tears in the 
sarcolemma of the muscle fibers.
42-44
 This results in repeated cycles of 
muscle fiber necrosis and regeneration until the regenerative capacity is 
exhausted. Eventually the muscle fibers are mostly replaced by adipose 
and fibrous tissue.
45-47
 The mdx mouse is an animal model for DMD that 
also lacks dystrophin in skeletal muscle fibers.
48
 However, the utrophin-
dystrophin double-mutant mice may represent DMD in patients more 
accurately.
49 
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In general, the direct environment of the SC, which is called the 
niche, and many regulatory factors, play a major role in muscle 
regeneration. These factors will be discussed in the following sections 
 
 
3.3 Regulation of skeletal muscle regeneration 
 
As mentioned before, SCs are normally quiescent, but become activated 
in response to injury, proliferate, differentiate, and fuse to repair or 
replace damaged myofibers. In these processes the stem cell niche, 
growth factors, cytokines, and neurotrophic factors play a prominent role.  
 
3.3.1 The satellite cell niche 
Next to soluble factors, the functioning of SCs is governed by their 
specific niche (figure 1). The most common definition of a stem cell 
niche is “a specific location in a tissue where stem cells can reside for an 
indefinite period of time and produce progeny cells while self-
renewing”.50 The most obvious difference of the SC niche compared to 
other niches, is that the SCs are kept quiescent most of the time.
51
  
In the SC niche many factors influence SC behavior. Structural 
elements of the niche are the BM and the myofiber.
33
 SC behavior is also 
influenced by secreted products from local cells, such as the interstitial 
cells, microvasculature, neuromuscular junction, and immune cells.
52
 
Additionally, experiments using parabiotic pairing demonstrated that 
systemic factors in serum have a major effect on SC activity.
53,54
 
However, it still remains unclear how all these factors cooperatively 
regulate quiescence and activation of the SCs. In the next section we 
describe some of the niche elements, which are in direct contact with, or 
in the proximity of the SCs. 
The SC niche is directly surrounded by the BM and the adjacent 
differentiated myofiber. It has been shown, that mechanical-, electrical-, 
and chemical signals from the adjacent myofiber and the BM, which is a 
component of the extracellular matrix (ECM), are involved in SC 
regulation.
4,34
 Also the microvasculature seems to play a major role. In 
humans and mice, respectively 68% and 82% of the SCs are located 
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within 5 µm from neighboring capillaries or vascular endothelial cells 
(EC).
55
 In addition, there is also correlation between the number of 
capillaries per muscle fiber and the number of SCs.
55
 This strongly 
suggests a correlation between SC and ECs during myogenesis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The satellite cell niche and regulatory factors. SCs are located in a specific 
niche between the sarcolemma (blue long dashed line) and the basal lamina (red solid 
line). The basal side of the SC expresses integrin α7β1 (purple dotted line), which links the 
SC with the laminin (blue crosses) in the basal membrane. The apical side expresses M-
cadherin (green dashed line), which attaches the SC to the adjacent myofiber. These areas 
are essential for signal transduction between the SC and the adjacent structures. SCs are 
normally quiescent and are activated after myotrauma, through the action of many 
regulatory factors. The proximity of the microvasculature suggests a reciprocal 
interaction between SCs and these vessels. ECM, extracellular matrix; MCN, myocyte 
nucleus; SC, satellite cell 
 
In addition, recent studies showed that macrophages, which are 
attracted upon injury, play a crucial role in skeletal muscle regeneration. 
In vivo, macrophage suppression leads to incomplete skeletal muscle 
regeneration.
56
 Furthermore, the prevention of monocyte recruitment to 
the site of injury completely inhibits skeletal muscle regeneration.
57
  
Malerba
58
 and Segawa
56
 suggest that macrophages directly affect SCs by 
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two different mechanisms.
59
 First, the macrophages can secrete soluble 
factors affecting SCs, and second, macrophages can interact with SCs by 
cell-cell contact, and thereby protect them from apoptosis.
60
 However, 
macrophages play a dual role depending on their activity.
57,59,61
 Pro-
inflammatory macrophages induce myogenic precursor cell proliferation, 
while anti-inflammatory macrophages induce differentiation and fusion 
of these cells.
61
 A switch between the pro- and anti-inflammatory 
macrophages has been observed in vivo after injury, and during the 
course of muscular dystrophy.
57,61
  Depletion of the anti-inflammatory 
macrophages reduces the diameter of regenerating myofibers.
59
 In 
addition, a combination of autocrine factors, factors from infiltrating 
inflammatory cells, and to a lesser extent innervating motor neuron-
derived factors, seem to govern the behavior of the SCs.
29
  
The basis for the regulation of SC behavior is the attachment within 
their specific niche, which is established through cell-BM and cell-cell 
interactions. The basal side of the SCs expresses integrin α7β1, which 
links the cytoskeleton with laminin in the BM.
62,63
 It plays a major role in 
the transduction of strain-induced mechanical forces into chemical 
signals, which are involved in the regulation of myogenesis.
64
 The apical 
side expresses M-cadherin that attaches the SC to the adjacent 
myofiber.
22,34
 Both attachment sites are essential for signal transduction 
between the SC and the two flanking structures.
22,62
 In addition, it has 
been suggested that M-cadherin plays a significant role in the attachment 
and fusion of myoblasts to form new and regenerate damaged 
myotubes.
65
 This is supported by a significant increase of M-cadherin in 
activated SCs during skeletal muscle regeneration.
66
  
The main constituents of the BM are type IV collagen, laminin, and 
heparan sulfate proteoglycans (HSPGs).
51
 Laminin connects the collagen 
via the linker protein entactin-1 (or also called nidogen-1) with the 
integrins on the SCs, which in turn anchore the BM with the intracellular 
cytoskeleton.
51,67
 Upon binding, integrins  may influence cell migration, 
cell shape, and cell-cell interaction and thus play a major role in SC 
physiology.
68
 The differential expression of integrins and tissue-specific 
laminin regulates homing and activation of stem cells.
69
 A recent study 
showed that integrin α7β1 is required for SC migration and that 
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hepatocyte growth factor (HGF) plays a crucial role in the guidance of 
SCs. Furthermore, the results suggests that unrelated and divided SCs 
stay in long contact with each other and co-migrate along the myofiber.
70
 
However, specific SC staining should be performed to confirm the SC 
origin. These results indicate that many factors are involved in SC 
migration.  
In addition, the ECM is capable to capture growth factors such as 
HGF. In the ECM, HGF is bound to HSPGs preventing SC 
proliferation.
71,72
 The binding of HSPGs to laminin and collagen IV 
probably integrates these proteins into the BM.
73
 HSPGs are not only 
found in the BM but also on the surface of the SCs. These HSPGs (e.g. 
syndecan) differ in their extracellular domains and play a role in signal 
transduction.
74,75
 They become upregulated upon SC activation and can 
transduce signals directly through binding of signaling molecules, or by 
presenting them to their specific receptors.
76
 In vivo experiments show 
that both fibroblast growth factor (FGF) and HGF, which are critical 
growth factors in skeletal muscle regeneration, require HSPGs for proper 
signaling.
74
 These data suggest HSPGs play a significant role in the 
regulation of skeletal muscle development and regeneration. Finally, the 
integrity of the BM is essential to prevent movement of the cells  through 
the tissue.
77
 
In vitro studies, showed that the frequency of asymmetric cell 
division of SC-derived myoblasts diminishes in time,
35,36
 and that SC-
derived myoblasts have a limited proliferation capacity compared to in 
vivo.
78
 This might be caused by sub-optimal levels of growth factors in 
the culture medium. However, we and others suggest that it could also be 
due to the loss of specific niche factors in vitro.
51
 Although this has not 
been directly demonstrated, knocking out laminin-2 in mice, results in an 
almost complete absence of skeletal muscle BM
79
 and a decrease in the 
total number of SCs.
80
 Thus the integrity of the BM and the ability of SCs 
to bind to it seems to be essential for SC quiescence and proper 
functioning upon activation. Furthermore a depleted SC niche, is able to 
house another stem cell,
81,82
 which may then contribute to skeletal muscle 
regeneration. 
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Recent studies on the molecular signals regulating SC functioning, 
were focused mainly on maintenance of SC quiescence. Caveolin-1 and 
sphingomyelin, which are specifically expressed in the membrane 
invaginations (caveolae) of quiescent SCs,
83
 seem to play a major role in 
this process. Caveolin-1 regulates caveolae formation and seems to 
trigger sphingomyelin, which is a lipid in the plasma membrane that 
facilitates cytoplasmic signaling by concentrating signaling molecules in 
the caveolae.
84,85
 Calcitonin receptors (CTRs) are specifically present in 
quiescent SCs,
83
 suggesting that they are also involved in this process. 
However, the exact molecular processes of are still unknown.
84,86
 Beside 
factors involved in the regulation of SC quiescence, there are also factors 
that regulate SC activation. Recent research suggests that Megf10, a 
transmembrane protein, belongs to this group of factors. Megf10 gene 
silencing induces differentiation and decreases proliferation,  while 
overexpression enhances proliferation.
87
 Overall, many molecular 
processes and signals from the adjacent myofiber, microvasculature, BM, 
the SC itself, inflammatory cells, and motor neurons are involved in 
maintaining SC quiescence, activation, and the subsequent choice 
between self-renewal, proliferation, and differentiation.  
The next section gives an overview of the stimulatory and inhibitory 
growth factors, which are involved in the regulation of skeletal muscle 
regeneration. 
 
3.3.2 Growth factors 
Growth factors are crucial in SC regulation (table 1). Due to growth 
factor-activated intracellular signaling pathways e.g. insulin growth 
factor-1 (IGF-1),
4,88
 both controlled up- and down-regulation of muscle-
specific genes occur.
4,29
 Next to that,  the sequence of their release and 
their cooperation seems also to be important.
89
 Growth factors are mostly 
secreted by active immune cells and by muscle cells after injury. In 
addition, the vasculature, the SCs themselves, and motor neurons are also 
responsible for growth factor production
29,90
 (figure 1). The „indirect‟ 
growth factors are stored in the ECM by binding to proteoglycans
91
 and 
are released from the ECM after skeletal muscle injury. To make this 
possible, SCs may increase matrix metalloproteinases-2 and -9 (MMP-2 
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and -9) release after injury.
92,96
 These MMPs are involved in ECM 
degradation that liberates growth factors and cytokines. In this way, SCs 
can activate themselves indirectly. In addition, MMPs are involved in 
myoblast migration during regeneration.
93,97,98
 
In particular the active neutrophils and macrophages, which infiltrate 
the necrotic area are responsible for growth factor secretion, but also T-
cells and platelets are involved.
29,90
 These secreted growth factors, 
together with the growth factors released from the ECM, attract, activate, 
and induce differentiation the SCs.
1,19
 The activated immune cells also 
produce adhesion molecules, such as selectins
99
 and cytokines, such as 
IL-6 and TNF-α. The latter influences the local blood flow and vascular 
permeability, which accelerates the inflammatory response.
1,51
 
 
Table 1. Key growth factors regulating skeletal muscle regeneration. 
 
Growth  
Factor 
 
Producing cell type Proliferation/ 
differentiation 
Function References 
HGF Active immune cells 
+ vasculature + ECM 
+/+ Induces quiescent SC 
activation 
Allen et al., 1995; Suzuki et al., 
2002; Tatsumi et al., 1998; 
Tatsumi et al., 2001 
Basic FGF Active immune cells 
+ vasculature + 
autocrine + ECM 
+/+ Upregulated during 
regeneration, specific role is 
unclear 
Allen and Boxhorn, 1989; 
Doumit et al., 1993; Haugk et 
al., 1995; Robertson et al., 1993 
IGF-1 Active immune cells 
+ vasculature + 
autocrine + ECM 
++/+ Highly mitogenic for 
myoblasts and promotes cell 
survival 
Adams and McCue, 1998; Allen 
and Boxhorn, 1989; Doumit et 
al., 1993; Haugk et al., 1995; 
Menetrey et al., 2000; Sato et 
al., 2003 
IGF-2 Active immune cells 
+ vasculature + 
autocrine 
+/+ Upregulated after IGF-1 
upregulation, and has a small 
contribution in myoblast 
proliferation/differentiation 
Doumit et al., 1993; Haugk et 
al., 1995 
VEGF Variety of cell types, 
up-regulated during 
hypoxia 
+/? Stimulates angiogenesis Doumit et al., 1993; Gowdak et 
al., 2000; Springer et al., 1998 
PDGF-AA 
PDGF-BB 
Active immune cells 
+ Endothelial cells 
-/+ 
+/- 
Regulate 
proliferation/differentiation in 
opposite ways and support 
ngiogenesis 
Doumit et al., 1993; Robertson 
et al., 1993 
Myostatin Circulation + 
autocrine 
-/- Maintains SC quiescence Amthor et al., 2002; 
McCroskery et al., 2003; 
McPherron and Lee, 1997 
TGF-β1 &  
TGF- α 
Active immune cells 
+ autocrine 
-/- Prevents myoblast 
differentiation and recruitment 
Allen and Boxhorn, 1989; 
Haugk et al., 1995; Robertson et 
al., 1993 
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3.3.3 Stimulatory growth factors  
Many growth factors, such as HGF, FGF-2 and -6, vascular endothelial 
growth factor (VEGF), platelet-derived growth factor-AA and -BB 
(PDGF-AA and -BB), stromal derived factor-1 (SDF-1) and IGF-1 and -2 
play a major role in myogenic proliferation and differentiation
4,29,51,100-104
 
(figure 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Regulatory growth in satellite cell behavior. Following myotrauma (A), 
quiescent satellite cells are activated (by HGF) to enter the cell-cycle for self-renewal (B) 
and proliferation (C). Activated satellite cells are characterized by a high expression of 
Pax7, MyoD, and/or Myf5. Subsequent differentiation is marked by the down-regulation of 
Pax7 and up regulation of Mrf4 and Myogenin. The differentiated myoblasts form new 
immature multinucleated myofibers (D) or fuse to damaged myofibers (not shown). 
Finally, the central SC nuclei migrate to a subsarcolemmal position in mature myofibers 
(E). After SC activation, a subset of activated SCs re-enters the quiescent state to 
replenish the satellite cell pool (F). aSC, activated satellite cell; qSC, quiescent satellite 
cell; MB, myoblast; N, nucleus 
 
In particular IGF-1 is critical for skeletal muscle growth.
105,106
 In vitro, 
IGF-1, and in a later phase IGF-2, are both able to alter the expression of 
myogenic regulatory factors and promote the proliferation and the 
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differentiation of SC-derived myoblasts.
4,107
 Systemic administration of 
IGF-1 results in increased DNA and protein content in muscle.
108
 This 
was confirmed by using transgenic mice demonstrating that 
overexpression of human IGF-1 induces muscle hypertrophy.
108
 In 
addition, direct injection of IGF-1 improves muscle regeneration.
38,105,106
 
In vitro studies showed that this is regulated primarily through the 
phosphatidylinositol 3-kinase (PI3K) pathway and subsequent anti-
apoptotic Akt activation.
67
 PI3K is also involved in the IGF-1-related 
increase in protein production.
109,110
  
Besides IGF-1, also HGF and VEGF are involved.
1
 HGF is the 
primary factor to induce SC proliferation by binding to c-met.
101,111,112
 
Correlating with this property, HGF expression is increased in proportion 
with the degree of injury, during the early proliferation phase of muscle 
regeneration.
112-114
 In correlation with these findings, direct injection of 
HGF in later stages of muscle regeneration does not promote skeletal 
muscle repair.
112,115
 In addition, HGF plays a role in the migration of SCs 
to the site of injury.
116,117
 In contrast to these stimulatory effects, the 
inhibitory effect of HGF on the formation of multinuclear myotubes, 
indicates the pleiotrophic effect of this growth factor.
89
 Finally, it has 
been demonstrated that stretching muscles secrete HGF in a nitric oxide 
(NO)-dependent way, which might also have a role in SC activation.
118
  
VEGF can improve muscle healing by stimulating angiogenesis to 
increase the nutrient and oxygen supply, which is essential for the healing 
process.
119,120
 VEGF acts together with PDGF, which is also involved in 
SC regulation. There are some indications that suggest a role for FGFs. 
FGF-6 expression for example, is muscle specific and is upregulated 
during muscle regeneration.
121
 However, the specific role of these growth 
factors remains unclear. SDF-1, which is secreted by the adjacent 
myofiber as well as by the bone marrow, is mainly functioning as a 
chemoattractant.
103
 Recent research suggests that after injury, 
granulocyte-colony stimulating  factor (G-CSF)
122
 and interferon-γ (IFN-
γ)123 enhance skeletal muscle cell proliferation. Finally it is important to 
know that some combinations of growth factors, e.g. HGF and either 
FGF-2 or -6, have synergistic effects on SC proliferation.
124 
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Overall, highly mitogenic IGF-1 seems to be the main growth factor 
in skeletal muscle regeneration. Also HGF, which is the primary factor 
that induces proliferation of quiescent SCs, and VEGF, which stimulates 
angiogenesis, play a major role. 
 
3.3.4 Inhibitory growth factors  
The major inhibitory factors in skeletal muscle regeneration are 
myostatin, transforming growth factor-α and -β1 (TGF-α and -β1), and 
bone morphogenetic proteins (BMPs), which are all members of the TGF-
β superfamily.125 This family contains many regulatory factors, which 
depending on the tissue, affect cellular behavior. In skeletal muscle, 
TGF-β superfamily members have potent inhibitory effects on both 
muscle development and postnatal regeneration of skeletal muscle.
126
  
The TGF-β signaling pathway consists of three main components: the 
ligand, the receptor, and the intracellular mediators. After ligand binding, 
receptor dimerization occurs between receptor type I and type II, which 
transphosphorylates the type I receptor. This activates the latent kinase 
activity of the receptor complex, which then phosphorylates a receptor-
regulated Smad protein that oligomerizes with a common-Smad (also 
called co-Smad) termed Smad 4. This oligomer translocates into the 
nucleus where it can interact with Smad-binding elements to regulate 
transcription of target genes in a cell type-specific manner.
126
 
Myostatin is expressed in SCs and myoblasts. Myostatin release 
results in a down-regulation of Pax3 and Myf5, and prevents the 
expression of MyoD.
127
 Knock-out mice that lack myostatin have 
extensive muscle hypertrophy.
128
 Myostatin may maintain SC quiescence 
and repress self-renewal through the induction of p21CIP,
13,129
 which is a 
universal inhibitor of cyclin-dependent protein kinase and thus a cell 
cycle inhibitor.
130
 In addition, myostatin and TGF-β1 may reduce 
myoblast recruitment and differentiation.
131
 TGF-β1 also induces 
remodeling and repair of the ECM and the BM by stimulation of 
fibroblasts, which results in collagen and fibronectin production.
131
 This 
can result in the formation of scar tissue. It has been demonstrated that 
decorin, which is an inhibitor of TGF-β, prevents muscle fibrosis and 
enhances skeletal muscle regeneration.
106
 BMPs prevent stem cell 
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proliferation in a number of stem cell niches (e.g. neural crest), which 
can be counteracted by the upregulation of Noggin.
77,132,133
 
In conclusion, TGF-β1 has the most obvious effect on proliferation 
and differentiation of SCs, and seems to be the major inhibitor of skeletal 
muscle regeneration. In addition, other growth factors are involved in 
skeletal muscle development and regeneration, but a lot of research is 
needed to define the exact mechanisms.  
 
 
3.4 Other stem cells in skeletal muscle regeneration 
 
Next to the SCs, recent research also suggests that other precursor cells 
might play a role in skeletal muscle regeneration (table 2).
4,134
 These cells 
can be divided into muscle- and non muscle-derived stem cells.
135
 They 
might also be isolated and subsequently used to treat muscle injuries or 
diseases by systemic injection. From a practical point of view, the ideal 
stem cell population for the treatment of muscle defects should be present 
in easily accessible postnatal tissues, expandable in vitro, able to 
differentiate into skeletal muscle cells in vivo, and should be able to reach 
skeletal muscle through a systemic route.
136
 
Satellite cells are the primary cells involved in skeletal muscle 
regeneration and are therefore a good candidate for the therapy of injured 
or diseased muscle.
21
 Recent studies showed that transplantation of 
freshly isolated SCs or myofibers containing SCs can efficiently 
regenerate skeletal muscles.
30,32,137,138
 In addition, new SCs are found in 
the host muscle.
30-32
 In contrast, cultured SC-derived myoblasts gradually 
lose their myogenic potential, and the transplantation of these cells 
induces regeneration with much lower efficiency.
32,78
 Furthermore, less 
than 1% of these SC-derived myoblasts survive the first days after 
transplantation.
139,140
 Thus, it appears crucial to use freshly isolated SCs 
to treat muscle injuries or diseases. However, SCs lack the ability to cross 
the endothelial lining of the blood vessels in skeletal muscle. Therefore 
the cells must be injected many times intra-muscularly (IM), which make 
them less suitable for systemic delivery.
136,141
 For these reasons, 
alternative stem- and precursor cells that are capable to become myogenic 
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precursor cells were investigated. In the next section, recent 
developments into the quest for precursor cells with myogenic potential 
are discussed. 
 
Table 2. Properties of different stem cells involved in skeletal muscle regeneration. 
 
3.4.1 Stem cells in muscle tissue 
In addition to SCs, several other stem cells in skeletal muscle show 
myogenic potential depending on the environmental cues.
4,134
 They can 
be divided into mesoangioblasts (vessel-associated stem cells), side 
population cells (SP cells), muscle-derived stem cells (MDSCs), 
pericytes, and CD133
+
 stem cells.
134,136,142-145
 Although the origin, 
identity, and localization of these cells remains speculative, recent studies 
suggest that mesoangioblasts and pericytes originate from the walls of 
blood vessels.
134
  
Cell type Developmental 
derivation 
(origin) 
 
Anatomical 
localization 
Lineage 
potential 
Physiological 
function 
References 
Satellite cells 
(Myoblasts) 
 
Mesoderm Attached to the 
muscle fiber 
under the basal 
lamina 
Myogenic Regeneration of 
skeletal muscle 
fibers in 
injured- and 
diseased muscle 
Boldrin et al., 2009; 
Collins et al., 2005; 
Montarras et al., 
2005; Sacco et al., 
2008; Zammit et al., 
2006 
SP cells 60% somatic 
40% unknown 
Interstitial; 
associated to 
blood vessels? 
Myogenic, 
hematopoietic
 
Unknown Asakura et al., 2002; 
Uezumi et al., 2006 
MDSCs Unknown Myofiber 
periphery closely 
associated to 
blood vessels 
Myogenic, 
osteogenic, 
hematopoietic, 
cardiogenic, 
chondrogenic 
Unknown Qu-Petersen et al., 
2002; Torrente et 
al., 2003 
Pericytes Mesectoderm in 
the head; 
mesoderm in the 
body 
Periphery of 
capillaries and 
microvessels 
Myogenic, 
osteogenic, 
adipogenic, 
chondrogenic 
Blood flow 
regulation, 
control of 
angiogenesis 
Dellavalle et al., 
2007 
Mesangioblasts Mesoderm; 
walls of blood 
vessels 
Associated to 
microvessel walls 
Myogenic, 
adipogenic, 
cardiogenic, 
osteogenic  
Unknown Galvez et al., 2006; 
Sampaolesi et al., 
2006; Sampaolesi et 
al., 2003 
Hematopoietic 
stem cells 
Embryonic 
vessel 
endothelium
 
Bone marrow Myogenic, 
myelogenic, 
lymphogenic 
Production of 
blood cells 
Bittner et al., 1999; 
Ferrari et al., 1998; 
LaBarge and Blau, 
2002 
CD133
+
 cells  Mesoderm
 
Myofiber close to 
blood vessels 
Myogenic,  
hematopoietic, 
endothelial 
Angiogenesis 
after injury, 
hematopoiesis 
Negroni et al., 2009; 
Torrente et al., 2004 
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Mesoangioblasts are vessel-associated stem cells derived from the 
embryonic dorsal aorta and are able to differentiate into several 
mesodermal cell types including skeletal muscle.
146,147
 As an alternative 
to myoblast transplantation, allogenic transplantation of mesoangioblasts 
into the blood circulation of dystrophic mice have recently shown great 
potential for skeletal muscle regeneration.
145,148
 One disadvantage, which 
explains the moderate effect after transplantation,
148
 is their limited 
ability to colonize the muscle. This is caused by incomplete adhesion and 
extravasation of these cells.
145,148
 Furthermore, transplantation of 
autologous mesoangioblasts transfected with small dystrophin genes into 
golden retriever dystrophic dogs seems to enhance the formation of 
functional muscle and dystrophin expression in host muscle tissue.
149
 So 
they have potential, but further research on the role of mesoangioblasts in 
tissue skeletal muscle regeneration is required.  
The heterogeneous muscle SP cells, are a rare, poorly-defined 
population in skeletal muscle, but they have the potential to give rise to 
both myocytes and SCs after IM injection.
134,144,150
 Muscle SP cells are 
still present in Pax7-/- mice, which exhibit a severe deficiency in SCs.
144
 
Secondly, in vitro cultured SP cells with a myogenic fate express 
markers, which are also present both on quiescent and activated SCs upon 
a myogenic cell culture.
134
 Finally, unlike SCs, SP cells also possess 
hematopoietic potential.
151
 These data indicate that SP cells and SCs are 
distinct populations with similar properties for skeletal muscle 
regeneration.
144
   
MDSCs are a population of early myogenic progenitor cells which 
have, in contrast to SCs, multi-lineage potential.
134
 The transplantation of 
MDSCs into the skeletal muscle of mice gives better results compared to 
SCs.
152
 One of the advantages of MDSCs, is their prolonged proliferation 
in vivo.
153
 This capacity, combined with their strong tendency for self-
renewal, multi-lineage differentiation, and immune tolerance, explains 
the improvements observed after systemic transplantation of MDSCs 
.
134,153
 However, there is a lack of evidence for their long-term self-
renewal capacity and their efficacy in dystrophic mice.
2,154
 Everything 
considered, MDSCs are possible candidates to treat skeletal muscle 
injuries or disorders such as DMD. 
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Pericytes are localized underneath the basal lamina of the 
microvasculature and interdigitate with the endothelial cells. They give 
stability to the microvessels and also regulate blood flow and 
permeability of the vessels.
155
 It has been suggested that pericytes are 
developmentally derived from mesoangioblasts.
136,146,147
 They become 
myogenic in vitro when differentiation is induced and contribute to 
muscle regeneration in dystrophic mice after intra-arterial injection.
2,136
 
Unlike SCs, pericyte-derived myogenic cells express myogenic markers 
only in differentiated myotubes. When pericytes are injected systemically 
into immune-deficient mice with severe muscular dystrophy (scid-mdx 
mice), they colonize host skeletal muscle and generate many (dystrophin-
rich) muscle fibers.
136
 Furthermore, some pericytes were localized in a 
satellite cell position suggesting that these cells, although at a low 
efficiency, are able to replenish the satellite cells pool.
136
 This make them 
an interesting potential candidate for future cell therapy in (e.g. DMD) 
patients. 
CD133
+
 cells circulate in the blood stream and they are able to 
differentiate, in vitro, into endothelial, hematopoietic, and muscle cell 
types.
143
 CD133
+
 cells express adhesion molecules such as very late 
antigen-4 (VLA-4), which renders them capable to migrate through blood 
vessel walls.
134
 Injection of human CD133
+
 cells into the circulation of 
scid/mdx mice improves skeletal muscle structure and function, and 
replenishes the SC pool.
143
 Muscle exercise 24 hours prior to the injection 
of CD133
+
 cells significantly increases human dystrophin expression.
156
 
The exercise results in an increase of vascular adhesion molecule-1 
(VCAM-1) on the endothelium, which improves recruitment of these 
cells.
156
 Recently, IM injected human CD133
+
 cells showed greater 
regenerative capacity and increased repopulation of the SC pool 
compared to injected human myoblasts.
142
 These results indicate that 
CD133
+
 cells have also a high potential for the treatment of skeletal 
muscle injuries and diseases. 
 
3.4.2 Other stem cells 
The only relevant non muscle-derived stem cell, the hematopoietic stem 
cell (HSC), is also the most important multipotent stem cell participating 
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in skeletal muscle regeneration after the SC.
4,157,158
 Due to their 
developmental plasticity in response to injury, transplantation of HSC 
resulted in the formation of 3.5% GFP
+
 myofibers, and they also 
contribute to the satellite cell pool.
159
 This percentage indicates that other 
stem cells play a marginal role in skeletal muscle regeneration. However, 
IM- or intra-venously injected donor bone marrow cells were clearly 
identified within both muscle connective tissue and SC niches of the host 
musculature.
158
 Other studies also observed the incorporation of donor-
derived HSC cells.
160,161
 Another study,
159
 has demonstrated that HSCs 
also contribute to the muscle SC pool. 
In general stem cells have a high proliferative capacity, which might 
lead to neoplastic transformations. Although there is no direct evidence 
for this, we should keep in mind that systemic stem cell delivery could be 
potentially dangerous.
2,162
 
In summary, many types of stem cells are currently being studied for 
their potential in the treatment of skeletal muscle diseases. Many 
different populations of stem cells might be involved in muscle 
regeneration and can be used in the treatment of diseased skeletal muscle. 
However, there is still a long way to go before skeletal muscle 
regeneration can be routinely induced by injecting stem cells. 
 
 
3.5 Conclusion 
 
Skeletal muscle regeneration is governed by SCs and their niche, a wide 
range of growth factors, and probably also by other stem cells. The role 
of the SC niche factors has become increasingly clear in recent years. The 
basis for the maintenance of SC quiescence is the attachment within their 
specific niche by integrin α7β1, which links to cytoskeleton with laminin 
in the BM, and M-cadherin that attaches the SC to the adjacent myofiber. 
The niche ECM contributes to satellite cell quiescence by capturing 
stimulatory HGF. After injury, the ECM releases HGF, and the 
microvasculature and inflammatory cells release additional activating 
growth factors such as IGF-1. HGF initiates SC proliferation, while IGF-
1 stimulates both proliferation and differentiation of SCs. TGF-β1 
Regulatory factors and cell populations involved in skeletal muscle regeneration 
 69 
negatively influences these processes, and induces the formation of scar 
tissue. Intra-muscular injection of HGF, IGF, or decorin, seem to improve 
muscle regeneration. The latter by binding and inactivating TGF-β1. 
Correct timing of injection is essential for improvement of muscle 
regeneration. Besides SCs, several populations of other stem cells in 
muscle might be involved in the muscle regeneration process. For 
therapy, SCs are unsuitable at the present, because they lack the ability to 
cross endothelial layers, and less than 1% of the SC-derived myoblasts 
survives the first days after injection. Due to the limitations of SCs, the 
MDSCs, mesoangioblasts, pericytes, CD133
+
 cells, and the non muscle-
derived HSCs may prove to be more suitable for the treatment of skeletal 
muscle injuries and diseases. However, their contribution to the satellite 
cell pool and future regeneration cycles remains to be established. In 
particular MDSCs might be promising, because of their prolonged 
proliferation time in vivo. Pericytes, which are able to colonize skeletal 
muscle after systemic injection, may also be suitable. Future research 
should focus on optimizing the homing of these cells to the muscle defect 
after local or systemic injection. Additionally, long-term research into the 
treatment of DMD should be performed to investigate whether these cells 
are able to home to the SC niche, and to participate in future regeneration 
cycles. Ultimately, knowledge about the factors that regulate SC activity, 
and the potential of other stem cells during muscle regeneration will lead 
to new therapies for skeletal muscle diseases. 
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Abstract 
 
Purpose: To establish an in vivo model for muscle regeneration after 
strain injury in the presence of a fibrotic discontinuity.  
Methods: The musculus soleus of 5-week-old male rats was exposed, 
completely lacerated, and sutured together with or without a collagen 
scaffold in between the muscle ends. The scaffold represents a fibrotic 
discontinuity in the muscle. Muscle healing was evaluated after 14 days 
by general histology and staining for myofibroblasts, (activated) satellite 
cells, and inflammatory cells. 
Results: Around all wounds satellite cells were activated. Inside the 
collagen scaffolds satellite cells were absent indicating that muscle 
regeneration was impaired. In the wounds without a collagen scaffold, the 
lacerated and sutured myofibers contacted and had already started to 
regenerate, while this did not occur with an implanted scaffold. 
Conclusion: A fibrotic discontinuity, such as an implanted collagen 
scaffold delays muscle regeneration in skeletal muscle. This model is 
suitable to study skeletal muscle regeneration in the presence of a fibrotic 
lesion, and to evaluate new treatment modalities for muscle strain injuries  
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4.1 Introduction 
 
Muscle strain injuries occur regularly in professional athletes as well as 
in the general population.
1
 The hamstring is the most common muscle 
group affected and is characterized by a recurrence rate of 30% within 
the first year after injury. This indicates that full recovery of a hamstring 
strain injury is often not obtained.
2-4
 MRI analysis shows that during the 
healing of a hamstring injury fibrotic tissue is formed preventing full 
recovery.
5,6
  
In muscle strain injuries, the muscle is sheared, which results in a 
total rupture of the myofibers and their plasma membrane.
7,8
 At this site 
necrosis of the myofibers begins, but is restricted to the injury site by 
contraction bands inside the myofibers.
9
 After injury, satellite cells, 
which are located between the sarcolemma and the basal lamina of the 
muscle fibers,
10,11
 are released, activated, and migrate to the site of 
injury. There they proliferate, differentiate, and fuse to each other or to 
damaged myofibers to regenerate the skeletal muscle.
12,13
 However, blood 
vessels are also torn and a hematoma is formed filling the gap between 
the damaged muscle ends. This forms a primary matrix for inflammatory 
cells, but also for fibroblasts, which synthesize extracellular matrix 
components.
7,8
 These fibroblasts firstly produce fibronectin, followed by 
collagen type III and finally collagen type I.
14
 This might lead to a 
fibrotic tissue that inhibits growth of muscle fibers and thus impairs 
regeneration and muscle function.
8,15-17
 It has been shown that recurrent 
muscle strains occur in proximity of this fibrotic discontinuity probably 
due to its different stiffness and contractility properties.
3,6
 Furthermore, 
recurrent injuries are also more severe and take a longer time to heal than 
primary strain injuries.
2,18
 It is therefore important to prevent or minimize 
the formation of such a fibrotic discontinuity in order to reduce the risk 
of recurrence. 
In order to reduce fibrosis, and to optimize muscle regeneration, 
several strategies have been evaluated. The injection of growth factors 
such as insulin-like growth factor (IGF), fibroblast growth factor-2 (FGF-
2), nerve growth factor (NGF), and granulocyte colony-stimulating factor 
(G-CSF) improves muscle regeneration.
17,19,20
 More importantly, the 
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administration of decorin, which is an inhibitor of transforming growth 
factor-β (TGF-β), reduces fibrosis.19,21 The direct delivery of isolated 
muscle cells is another approach.
22-24
 Although the latter yields promising 
results, a major problem is the poor cell survival and limited migration of 
the injected cells.
25,26
 Alternatively, several different scaffold materials 
have been used for improving muscle regeneration, but with varying 
results.
27-30
 However, a model to study impaired healing in the presence 
of a fibrotic lesion is not yet available. Therefore, the aim of this study is 
to establish an in vivo model for a fibrotic discontinuity in healing 
skeletal muscle by implanting a collagen scaffold. 
 
 
4.2 Materials and methods 
 
4.2.1 Animals 
All animal experiments were approved by the Animal Experiments 
Committee of the Radboud University Nijmegen Medical Centre 
(RUNMC) in accordance to the Dutch laws and regulations on animal 
experiments, which conforms to the ACSM animal care standards. 
Twenty-four 5-week-old male Sprague-Dawley rats (Janvier, Le Genest, 
France) were used for the experiments. The rats were housed under 
normal laboratory conditions, but in the first week after the experimental 
procedure they were housed individually. All the rats were fed normal rat 
chow and water ad libitum. Before the start of the experiments the rats 
had been acclimatized to the animal facility for one week. 
 
4.2.2 Preparation of the collagen scaffolds 
The collagen scaffolds were prepared and chemically crosslinked as 
previously described.
31
 Briefly, a 1% (w/v) homogenized collagen 
suspension was prepared using insoluble type I collagen from bovine 
achilles tendon (Sigma Chemical CO, St. Louis, MO, USA). The collagen 
suspension was degassed to remove air bubbles, frozen overnight at -
25°C in aluminum trays, and lyophilized. The dried collagen scaffolds 
were crosslinked using 1-ethyl-3-(3 dimethylaminopropyl) carbodiimide 
hydrochloride and n-hydroxy-succinimide.
32
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4.2.3 Experimental procedures 
At the day of surgery, the rats received 0.02 mg/kg body weight 
buprenorfine (Temgesic; Schering Plough, Brussels, Belgium) 
subcutaneously as an analgesic and also at the next two days with a 
twelve hour interval. Under 5% (induction) followed by 2-3% 
(continuation) isoflurane anesthesia (Pharmachemie BV, Haarlem, the 
Netherlands), the left lower limb of the rats was shaved. After a 
longitudinal incision in the skin and underlying fascia, the M. soleus was 
gently exposed and transversally lacerated. The two ends were sutured 
together using a 7-0 polysorb suture (Tyco Healthcare UK, Gosport, UK) 
with or without the collagen scaffold in between. Before implantation, 
the collagen scaffolds were sterilized by immersion in 70% ethanol for 1 
hour, and then washed three times with sterile phosphate-buffered saline 
(PBS). The animals were divided into four groups of six rats according to 
the suturing method and the presence of a collagen scaffold: A) knot-
suturing without collagen scaffold, B) knot-suturing with collagen 
scaffold, C) continuous-suturing without collagen scaffold, and D) 
continuous-suturing with collagen scaffold. The easiest method for 
suturing is with one continuous suture around the muscle. However, if 
this one suture breaks, the wound opens and the scaffold might be lost.  
To be sure, we also used a method with multiple sutures. However, none 
of the sutures had broken and there was no different response between the 
two suturing methods. We therefore decided to group the animals 
together (A+C and B+D). The fascia and skin were closed with 5-0 
polysorb and 5-0 Vicryl sutures (Johnson-Johnson, Langhorne, PA, 
USA), respectively. To minimize muscle tension, the paw was splinted 
with an aluminum strip at an angle approximately 45° with respect to the 
tibia for one week. In group B the paws were swollen and reddish when 
the aluminum strips were removed. These rats therefore received 1 mg/kg 
enrofloxacin two times a day (Bayer Healthcare, Brussels, Belgium) for 
seven days. After fourteen days, the rats were sacrificed according to the 
standard CO2/O2 protocol. 
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4.2.4 Histology and immunohistochemistry 
After sacrifice, the left (wound) and right (internal control) M. soleus of 
three rats of each group were fixed in freshly prepared 4% 
paraformaldehyde (PFA) in PBS for 4-6 hours and processed for paraffin 
embedding. The left and right M. soleus of the other three rats of each 
group were immediately frozen in OCT embedding compound (CellPath, 
Newtown, UK) using isopentane precooled in liquid nitrogen. The 
muscles were cut longitudinally and 5 µm-sections were collected on 
superfrost plus slides (Menzel-Gläser, Braunschweig, Germany). For 
general morphology, paraffin sections were stained with hematoxilin and 
eosin (H&E).  
Paraffin sections were also stained with the following antibodies: 
mouse anti-alpha-smooth muscle actin (α-SMA; Sigma), rabbit anti-Ki67 
(Research Diagnostics Inc, Flanders, NJ, USA), mouse anti-ED1 (CD68, 
Serotec, DPC, Breda, the Netherlands), and mouse anti-MyoD (DAKO, 
Dakopatts, Glostrup, Denmark). Briefly, the sections were deparaffinated, 
rehydrated, treated with 3% H2O2 for 20 minutes to inactivate 
endogenous peroxidase, and post-fixed with 4% formaldehyde in PBS. 
For α-SMA and ED1 staining, the sections were heated in citrate buffer 
(pH 6.0) for 10 minutes at 70°C. For Ki67 and MyoD staining the 
sections were heated to 100°C for 10 and 40 minutes, respectively. After 
rinsing with 0.075% glycine in PBS, the sections were pre-incubated with 
10% normal donkey serum (NDS; Chemicon, Temecula, CA, USA) 
followed by the antibodies against α-SMA (1:1600), ED1 (1:100), Ki67 
(1:50) or MyoD (1:25) for 60 minutes. Subsequently, the biotinylated 
secondary antibodies goat-anti-mouse IgG (H+L) (1:500; Jackson Labs, 
West Grove, PA, USA) for α-SMA, ED1, and MyoD, and goat-anti-rabbit 
IgG (H+L) (1:500; Jackson Labs) for Ki67 were added. The bound 
antibodies were visualized using a preformed biotinylated horse radish 
peroxidase and avidin complex (Vector Laboratories, Burlingame, CA, 
USA).  
The frozen sections were double-stained with the antibodies rabbit 
anti-collagen IV (Euro-Diagnostica BV, Arnhem, the Netherlands) and 
mouse anti-Pax7 (Developmental Studies Hybridoma Bank, Iowa City, 
CA, USA). Briefly, the sections were dried in air overnight en post-fixed 
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with 1% PFA in PBS for 10 minutes. After rinsing with 0.05% Triton-
X100 in PBS, the sections were pre-incubated with 10% NDS followed 
by rabbit anti-collagen IV (1:100) for 60 minutes. Collagen IV was then 
detected using the biotinylated donkey anti-rabbit IgG (H+L) (1:500; 
Jackson Labs) for 60 minutes and an AlexaFluor-488-labeled avidin 
(1:500; Molecular Probes, Eugene, OR, USA) for 60 minutes. Thereafter, 
the sections were again pre-incubated with 10% NDS and then incubated 
with mouse anti-Pax7 (1:100) overnight at 4°C. Pax7 was detected using 
an AlexaFluor-594-labeled goat anti-mouse IgG (H+L) (1:200; Molecular 
Probes). All sections were photographed with the Zeiss Imager.Z1 
together with the AxioCam MRc5 camera using the AxioVision 4.6.3 
software (Carl Zeiss Microimaging GmbH, Jena, Germany). 
 
4.2.5 Statistical analysis 
The numbers of Pax7- and MyoD-positive cells were counted in 1) the 
control muscle (C), 2) the cutting zone without the collagen scaffold (W), 
3) the cutting zone with the collagen scaffold (W+S), 4) inside the 
collagen scaffold (S), and 5) in the non-injured muscle tissue of the 
wounded M. soleus (NI). To count the Pax7-positive cells the images 
were divided into 50 squares. In 5 random squares the total number of 
Pax7-positive cells and DAPI-stained nuclei was counted. The total 
number of MyoD-positive cells and nuclei of every group was determined 
in three different fields of an overview image. The numbers of Pax7- and 
MyoD-positive cells were expressed as a percentage ± SD of the total 
number of cells. The differences in the percentages of Pax7- and MyoD-
positive cells were tested for significance using a Kruskal-Wallis One-
Way ANOVA on Ranks followed by Dunn’s method. A value of p < 0.05 
was considered to be significant. 
 
 
4.3 Results 
 
Out of the twenty-four rats, one animal in group A without a collagen 
scaffold did not survive the surgery. After an initial growth arrest, all rats 
in every group had gained about 25% body weight at the tenth day. The 
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groups were not significantly different. The immobilization of the left 
hind leg did not affect the growth of the rats. Macroscopically, the 
wounded muscle adhered partly to the surrounding tissues. Furthermore, 
the collagen scaffolds were not visible anymore and appeared to be 
integrated into the muscle tissue. The sutures did not break and the 
different suturing methods had no effect on muscle morphology and gave 
the same results regarding muscle regeneration. Therefore, the animals of 
group A and C, and B and D were grouped together. 
 
4.3.1 General histology 
H&E staining (figure 1A) revealed properly arranged longitudinal 
myofibers in the controls (C), but not in the wounded muscles. Within the 
wounds, regenerating myofibers were present indicated by centrally 
located nuclei (figure 1A, magnification). Some myofibers in the cutting 
zone had fused properly in the group without the collagen scaffold. On 
the contrary, the implantation of a collagen scaffold prevented fusion of 
the myofibers (W+S). The collagen scaffolds were surrounded by giant 
cells and a cell layer (an interphase). 
 
4.3.2 Immunostainings 
Paraffin sections were stained with antibodies against α-SMA, ED1 
(CD68), Ki67, and MyoD to identify blood vessels and myofibroblasts, 
inflammatory cells, proliferating cells, and activated satellite cells, 
respectively (figure 1B). In the controls (C), ED1-positive inflammatory 
cells and Ki67-positive proliferating cells were present. However, the 
controls hardly contained any MyoD-positive nuclei (indicated by 
arrows). As expected, α-SMA-positive cells were not present in the 
muscle tissue of the controls, but only in blood vessels. Without a 
collagen scaffold (W) there was an increase in the number of ED1- and 
Ki67-positive cells of which the majority surrounded the sutures. More 
importantly, many MyoD-positive nuclei were present (a few are 
indicated by arrows). The number of α-SMA-positive blood vessels was 
also increased, and there were also α-SMA-positive cells in the muscle 
tissue. The implantation of a collagen scaffold (W+S) caused an 
infiltration of ED1-positive giant cells and other inflammatory cells, 
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which surrounded the scaffold. Even inside the scaffolds inflammatory 
cells were present. Proliferating Ki67-positive cells were present in the 
muscle tissue, the interphase, and also inside the collagen. Again, the 
muscle tissue around the scaffold (W+S) contained many MyoD-positive 
nuclei (a few are indicated by arrows), but all the cells inside the 
scaffolds were negative for MyoD. The expression pattern of α-SMA was 
similar to the wounds without the scaffold (W). Inside the scaffolds α-
SMA-positive blood vessels were also found. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Histology of the M. soleus at 14 days post-surgery. A) H&E staining of the 
control (C), wound without the collagen scaffold (W; group C), and wound with the 
collagen scaffold (W+S; group D) revealed the disruption of the aligned myofibers at the 
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cutting zone after laceration. The implanted collagen scaffold is surrounded by an 
interphase and prevented myofiber fusion. B) Immunohistochemistry of the control (C), 
wound without the collagen scaffold (W; group C), and wound with the collagen scaffold 
(W+S; group D) with antibodies directed against ED1, Ki67, MyoD, and α-SMA. Only a 
few ED1-, Ki67-, and MyoD-positive cells (indicated by arrows) and α-SMA-positive 
blood vessels are present in the control (C). In the wound (W) the number of these cells 
are higher and α-SMA-positive cells are present. The collagen scaffold (W+S) is 
surrounded by an ED1-positive interphase. In the wounded muscles and around the 
scaffold many Ki67-, MyoD- (a few are indicated by arrows) and α-SMA positive cells are 
present. The scaffold also contains ED1-, Ki67, and α-SMA-positive cells and blood 
vessels, but no MyoD-positive cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Fluorescent immunohistochemistry of the M. soleus at 14 days post-
surgery. The control (C), wound without the collagen scaffold (W; group A), and wound 
with the collagen scaffold (W+S; group B) were stained with the antibody directed against 
Pax7. In the control only a few Pax7-positive cells are present, while in the wound (W) the 
number of these cells is increased. In the wounded muscle tissue around the collagen 
scaffold (W+S) the number of Pax7-positive cells is also increased. On the contrary, these 
cells are absent in the interphase and the collagen scaffold. 
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To identify the resident satellite cells, cryosections were stained with 
the Pax7 antibody (figure 2). In the controls (C) only a few satellite cells 
were present, but around the cutting zone in the wounded muscle tissue 
with (W+S) or without (W) a collagen scaffold the number of satellite 
cells was increased. However, no satellite cells were present within the 
collagen scaffolds. 
 
4.3.3 Quantifications 
The percentage of MyoD- and Pax7-positive cells were determined on the 
paraffin (figure 1B) and cryosections (figure 2), respectively (figure 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Quantification of Pax7- and MyoD-positive (activated) satellite cells. The 
number of Pax7- and MyoD-positive cells are expressed as a mean percentage ± SD of the 
total number of cells. Compared to the controls (C; N=11), the number of Pax7- and 
MyoD-positive cells is significantly increased in the wounded muscle tissue of wounds 
with (W+S; N=6) or without (W; N=5) the collagen scaffold. In the non-injured area of 
the wounded muscles (NI; N=11) the number of Pax7- and MyoD-positive cells is also, 
but not significant, increased. In the scaffolds (S; N=6) no Pax7- and MyoD-positive cells 
are found. * significantly increased (P < 0,05) compared to the control. 
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The controls contained only a low number of Pax7-positive satellite cells 
(2.7 ± 0.4%), which significantly (p < 0.05) increased to 7.2 ± 0.6% and 
6.2 ± 0.6% in the wounded tissue without (W) or with (W+S) the 
collagen scaffold, respectively. The number of MyoD-positive cells also 
significantly (p < 0.05) increased from 6.2 ± 1.1% in the controls to 16 ± 
4.3% and 15.9 ± 4.9% in the wounds without (W) or with (W+S) the 
collagen scaffold, respectively. Furthermore, there was a slight but non-
significant increase of Pax7- (3.9 ± 0.5%) and MyoD-positive cells (9.1 ± 
1.9%) in the non-injured area (NI) of the wounded muscles compared to 
the controls. However, no Pax7- and MyoD-positive cells were found 
inside the collagen scaffolds. 
 
 
4.4 Discussion 
 
The successful treatment of muscle strains in sports medicine is still a 
problem. Fibrotic lesions are often formed during muscle regeneration 
causing incomplete functional recovery. More importantly, recurrent 
muscle injuries may occur near this fibrotic tissue.
3,5,6
 Since fibrotic 
tissue consist mainly of collagen type I,
33,34
 we developed an in vivo 
model for a fibrotic discontinuity by implanting a type I collagen scaffold 
between the lacerated muscle ends. Using this method it is possible to 
standardize the wounds with a collagen scaffold, but it is important to be 
aware that this is an extreme version of a muscle strain. In this model we 
evaluated muscle regeneration after a two-week healing period. The 
numbers of Pax7- and MyoD-positive (activated) satellite cells or 
myoblasts were increased about two-fold in the wounded muscle tissue 
and around the collagen scaffolds compared to the control muscle. This 
indicates that the muscle fibers were regenerating, and that the scaffold 
did not inhibit the activation of satellite cells in the adjacent muscle 
tissue. However, inside the collagen scaffold these cells were absent. 
Thus, in the presence of a fibrotic discontinuity the skeletal muscle 
cannot regenerate properly since activated satellite cells do not migrate 
into the fibrotic tissue. Similar to our results, others have also shown that 
after a strain injury, inflammation occurs, followed by the production of 
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fibrous tissue, which could eventually develop into a fibrotic lesion.
1,35
 
Another study on rectus femoris strain in humans showed a chronic 
inflammation and a mixture of regenerating muscle fibers and fibrotic 
tissue in the wound.
36
 Although muscle regeneration was only evaluated 
after two weeks in this initial study, collagen scaffolds can persist in the 
muscle tissue for up to 50 days.
37
 Therefore, our model can be used to 
evaluate treatment strategies for recurrent muscle strains. 
Optimal treatment should diminish or prevent the formation of 
fibrotic tissue, and reduce the risk of recurrence. We and others
38,39
 
observed that suturing the lacerated muscle ends directly together allows 
full regeneration of the muscle. Currently, the treatment principle of 
muscle strains consist of rest, ice, compression, and elevation (RICE).
14
 
With specific compression, which could serve as a splint, it may also be 
possible to bring the muscle ends to each other and diminish the onset of 
fibrosis. Surgical treatment to suture the muscle ends together, is only 
indicated in cases with extensive injury to the muscle.
14
 If a fibrotic 
tissue from a previous injury is already present, additional treatment with 
matrix metalloproteinase-1 (MMP-1) might offer a solution. Previous 
research has shown that treatment with injection of MMP-1 improves 
muscle regeneration and that a fibrotic lesion can be partially 
resolved.
33,40
 Thus, combining the injection of MMP-1 with specific 
compression therapy might diminish a pre-existing fibrotic discontinuity 
or minimize the risk of a secondary fibrosis.  
In this study the M. soleus in rats is used as a wound model, because 
all the myofibers run parallel. However, the M. soleus consist mainly of 
type I (slow) fibers,
41
 while the hamstring, which is the most common 
muscle group affected in muscle strains, consist of type II (fast) fibers.
42
 
It has been shown that type II muscles regenerate better than type I 
muscles, which more often develop fibrotic lesions.
43
 This indicates that 
the results obtained in this study may differ from a hamstring injury, in 
which the regeneration proces could be more efficient. However, it also 
demonstrates that the M. soleus is a good model to study the effects of 
the presence of a fibrotic discontinuity on muscle regeneration.  
In this study we only analyzed 14 days post-surgery because satellite 
cell activation is a relatively early event in muscle healing.
12,13
 In future 
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studies, analysis at later time-points is necessary to exclude the 
possibility that implantation of a collagen scaffold only delays muscle 
regeneration. In addition, it is important that functional studies are 
performed to further evaluate this model. 
In conclusion, we generated a model for the regeneration of skeletal 
muscle in the presence of a fibrotic discontinuity. This model can be used 
to evaluate new treatment strategies for recurrent muscle strains.  
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Abstract 
 
Aim: To develop a model for muscle fibrosis based on full-thickness 
muscle defects, and to evaluate the effects of implanted stromal-derived 
factor (SDF)-1-loaded collagen scaffolds.  
Methods: Full-thickness defects 2 mm in diameter were made in the 
musculus soleus of 48 rats and either left alone or filled with SDF-1-
loaded collagen scaffolds. At 3, 10, 28 and 56 days post-surgery, muscles 
were analyzed for collagen deposition, satellite cells, myofibroblasts and 
macrophages.  
Results: A significant amount of collagen-rich fibrotic tissue was 
formed, which persisted over time. Increased numbers of satellite cells 
were present around, but not within, the wounds. Satellite cells were 
further upregulated in regenerating tissue when SDF-1-loaded collagen 
scaffolds were implanted. The scaffolds also attracted macrophages, but 
collagen deposition and myofibroblast numbers were not affected. 
Conclusion: Persistent muscle fibrosis is induced by full-thickness 
defects 2 mm in diameter. SDF-1-loaded collagen scaffolds accelerated 
muscle regeneration around the wounds, but did not reduce muscle 
fibrosis. 
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5.1 Introduction 
 
Skeletal muscle tissue repairs itself by the activation of satellite cells, 
which are associated with the myofibers.
1,2
 Activated satellite cells 
migrate to the site of injury and generate myoblasts, which eventually 
differentiate and fuse to each other or to damaged myofibers to restore 
muscle structure and function.
3-5
 The satellite cells also have the capacity 
to replenish their numbers by self-renewal for future regeneration 
cycles.
6-8
 However, fibrosis can also occur, which prevents full functional 
recovery of the muscle.
3,4,9,10
 Many approaches have been developed to 
improve muscle regeneration. The application of growth factors such as 
insulin growth factor (IGF)-I, fibroblast growth factor (FGF)-II, 
hepatocyte growth factor (HGF) nerve growth factor (NGF), or 
granulocyte-colony stimulating factor (G-CSF), has been shown to 
improve muscle regeneration by inducing satellite cell proliferation and 
differentiation.
11-15
 Inhibition of transforming growth factor (TGF)- can 
reduce the extent of fibrosis, and promotes muscle regeneration.
11,16 
The 
injection of cell types such as satellite cell-derived myoblasts, side-
population (SP) cells, muscle-derived stem cells (MDSC), 
mesoangioblasts, pericytes, and CD133
+
 stem cells improves muscle 
regeneration after muscle injury, but also in muscle diseases, like 
Duchene Muscular Dystrophy (DMD).
8,17-22
 Many muscle injury models 
exist such as crush injury, freeze injury, toxin-induced injury, strains, 
contusions, lacerations, and muscle disease models, which can induce 
minor muscle fibrosis.
3,4,23
 However, full-thickness defects, which result 
in the loss of muscle tissue and the formation of large fibrotic lesions, are 
not widely studied. Such a model represents muscle resection after tumor 
ablation or other surgical muscle traumas. It can be used to develop 
methods to (re)generate skeletal muscle tissue and inhibit the formation 
of fibrotic tissue by implantation of a regenerative scaffold. To achieve 
this, the addition of growth factors or cells alone is not sufficient. Tissue-
engineered constructs are required to fill up the defect and provide the 
necessary structural cues for the satellite cells. Several studies using such 
scaffolds have been performed with varying results, but loading of the 
scaffolds with growth factors and/or cells generally improves muscle 
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regeneration.
24-27
 However, the myogenic potential of satellite cells is 
readily lost during culture.
8,28
 Furthermore, transplanted satellite cells and 
myoblasts hardly survive and their migration into the muscle tissue is 
limited.
17,29
 Since satellite cells are the primary cells for muscle 
regeneration, we loaded collagen scaffolds with stromal-derived factor 
(SDF)-1 to attract resident sattelite cells into the defect. SDF-1 is a 
CXC chemokine, which controls processes such as trafficking and 
transendothelial migration of hematopoietic cells.
30
SDF-1 binds to 
CXCR4, which is also present on satellite cells.
31
 During embryogenesis, 
SDF-1 regulates the migration of muscle precursor cells.32,33 Moreover, 
in adulthood, SDF-1 is expressed by myofibers and induces migration 
of satellite cells.
34,35
 Therefore, the aim of this study was to induce 
muscle fibrosis with a full-thickness muscle defect, and to evaluate the 
effects of SDF-1-loaded non-crosslinked collagen scaffolds. 
 
 
5.2 Materials and methods 
 
5.2.1 Rats 
All animal experiments were approved by the Animal Experiments 
Committee of the Radboud University Nijmegen Medical Centre 
(RUNMC) in accordance to the Dutch laws and regulations on animal 
experiments. Forty-eight 5-week-old male Sprague-Dawley rats (Janvier, 
Le Genest, France) were used for the experiments. The rats were housed 
under normal laboratory conditions and fed normal rat chow and water ad 
libitum. Before the start of the experiments the rats had been acclimatized 
to the animal facility for one week. 
 
5.2.2 Experimental procedures 
At the day of surgery, the rats received 0.02 mg/kg body weight 
buprenorfine (Temgesic; Schering Plough, Brussels, Belgium) 
subcutaneously as an analgesic, and also at the next two days with a 
twelve hour interval. Under 5% (induction) followed by 2-3% 
(continuation) isoflurane anesthesia (Pharmachemie BV, Haarlem, the 
Netherlands), the M. soleus of the left lower limb of the rats was gently 
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exposed. Using a 2mm biopsy punch, a full-thickness defect was made in 
the centre of the M. soleus. The rats were divided into two groups of 24 
animals: 1) Ø 2mm wounds without a scaffold and 2) Ø 2mm wounds 
with collagen scaffold + SDF-1 
The collagen scaffolds were prepared with a 1% (w/v) homogenized 
collagen suspension with insoluble type I collagen from bovine achilles 
tendon (Sigma Chemical CO, St. Louis, MO, USA). The collagen 
suspension was degassed, frozen overnight at -25°C in aluminum trays, 
and lyophilized. Before implantation, the collagen scaffolds were 
sterilized by immersion in 70% EtOH for 30 min, washed three times 
with sterile phosphate-buffered-saline (PBS), and then incubated in PBS 
containing 0,1 % (w/v) bovine serum albumin (BSA) and 2 g/ml SDF-
1 (R&D Systems, Minneapolis, MN, USA) at room temperature for 48 
hours. Then the scaffold were directly implanted into the muscle defects. 
The fascia and skin were closed with 5-0 polysorb and 5-0 Vicryl sutures 
(Johnson-Johnson, Langhorne, PA, USA), respectively. Rats were 
sacrificed according to the standard CO2/O2 protocol at 3, 10, 28, and 56 
days post-surgery (6 rats per group for every time point). 
 
5.2.3 Histology 
The left (wound) and right (internal control) M. soleus of the rats were 
excised and fixed in freshly prepared 4% paraformaldehyde (PFA) in 
PBS for 24 hours, and processed for paraffin embedding. Longitudinal 
muscle sections (5µm) were collected on superfrost plus slides (Menzel-
Gläser, Braunschweig, Germany). For general morphology, paraffin 
sections were stained with hematoxiline and eosin (H&E according to 
Delafield, not shown). To detect collagen fibers, the sections were 
stained with azocarmine G and aniline blue (AZAN) according to 
standard protocols. 
 
5.2.4 Immunohistochemistry 
Sections were deparaffinated, rehydrated, treated with 3% H2O2 for 20 
minutes to inactivate endogenous peroxidase, and post-fixed with 4% 
formaldehyde in PBS. The sections were incubated with mouse anti-
alpha-smooth muscle actin (-SMA, 1:1600; Sigma), mouse anti-ED1 
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(CD68, 1:100; Serotec, DPC, Breda, the Netherlands), and mouse anti-
MyoD (1:25; DAKO, Dakopatts, Glostrup, Denmark) overnight at 4°C as 
described previously.
36
 Paraffin sections were also incubated with mouse 
anti-Pax7 (1:100; Developmental Studies Hybridoma Bank, Iowa City, 
CA, USA), mouse anti-collagen type I (1:1000; Sigma), rabbit anti-
collagen type III (1:1600; Chemicon International, Temecula, USA), 
mouse anti-Hsp47 (1:24000; Assay Design, Ann Harbor, MI, USA), and 
mouse anti-Myogenin (F5D, 1:100; Developmental Studies Hybridoma 
Bank). For collagen type I, Hsp47, and Myogenin staining, the sections 
were heated in citrate buffer (pH 6,0) for 10 min at 70°C, and 
subsequently treated with 0,075% trypsin in PBS (pH 7.4) for 15 minutes. 
For Pax7 and collagen type III staining, the sections were first heated in 
0.25mM EDTA/10mM TRIS buffer (pH 9,0) at 100°C for 10 minutes. 
After rinsing with 0.075% glycine in PBS, all sections were pre-
incubated with 10% normal donkey serum (NDS; Chemicon, Temecula, 
CA, USA), then followed by the primary antibodies overnight at 4°C. 
Subsequently, the bound antibodies were visualized using the 
biotinylated secondary antibodies donkey-anti-mouse IgG (H+L) (1:500; 
Jackson Labs, West Grove, PA, USA) for Pax7 and collagen type I, and 
donkey-anti-rabbit IgG (H+L) (1:500; Jackson Labs) for collagen type 
III, and a preformed biotinylated horse radish peroxidase and avidin 
complex (Vector Laboratories, Burlingame, CA, USA). The sections 
were stained with 3,3-diaminobenzidine (DAB) and photographed with a 
Zeiss Imager.Z1 together with an AxioCam MRc5 camera using 
AxioVision 4.6.3 software (Carl Zeiss Microimaging GmbH, Jena, 
Germany). 
 
5.2.5 Quantification 
The relative amount of collagen was analyzed on the AZAN-stained 
muscle sections in 1) the control muscle (C), 2) wounded muscle without 
the scaffold (W), and 3) wounded muscle with the collagen scaffold + 
SDF-1 (W+SDF-1) at every time-point. The amounts of collagen 
(blue) and muscle tissue (red) were analyzed in a fixed span of 0.5 cm 
muscle tissue containing the wound area, and quantified using Qwin 
software (Leica Imaging Systems, Cambridge, UK). The amount of 
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collagen was expressed as the mean area percentage ± SD of the total 
area. The number of Pax7
+
 and MyoD
+
 cells was counted in the C and in 
the regenerative zone (regenerating muscle tissue at the border of the 
2mm wound) of the groups W and W+SDF-1 at every time-point. The 
numbers of Pax7
+
 and MyoD
+
 cells were expressed as a mean percentage 
± SD of the total number of cells. 
 
5.2.6 Statistics 
The differences in the percentages of collagenous tissue and Pax7
+
 cells 
were tested for significance using a Two-Way ANOVA with Holm-Sidak 
post-hoc analysis. A value of p < 0.05 was considered to be significant. 
The percentages of MyoD
+
 cells were not normally distributed and 
therefore the One-Way ANOVA with post-hoc Holm-Sidak analysis was 
used to test significance at individual time points. A value of p < 0.01 
was then considered to be significant (Bonferroni correction). 
 
 
5.3 Results 
 
In the experimental group without the collagen scaffold (W) one rat died 
during surgery. All the other rats showed an initial growth arrest, but all 
had gained about 25% body weight at the tenth day post-surgery. 
Macroscopically, the collagen scaffolds were only visible at day three 
post-surgery and remained inside the defect. 
 
5.3.1 AZAN staining 
Paraffin sections were stained with AZAN to identify muscle tissue (red) 
en collagen (blue) (figure 1A). In the control (C)-group only little 
collagen was present. At three days post-surgery, the defect is still visible 
in the wound (W)-group, and some collagen is already deposited at the 
borders of the defects. At 10 days, large collagen deposits are present in 
and around the wounds, which persist at 28 and 56 days. In the wound 
with SDF-1-loaded collagen scaffold (W+SDF-1-group, the scaffolds 
are clearly visible and surrounded by a fibrin blood clot at three days. 
Collagen is also visible at the borders of the defects. At 10 days, the 
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scaffold has become smaller and has completely disappeared at 28 and 56 
days, but extensive collagen depositions are still present in these wounds. 
Few regenerating myofibers are found within the collagen depositions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. AZAN staining and quantification. A) The wounds without (W) and with 
SDF-1-loaded collagen scaffolds (W+ SDF-1) were stained with AZAN (muscle tissue 
red, collagen blue). B) Quantification of collagen in the controls (C), wounds without (W) 
and with SDF-1-loaded collagen scaffolds (W+SDF-1). The area of collagen is 
expressed as a mean percentage ± SD compared to the total tissue area. * significantly 
different from C (p < 0.05).The scale bar represents 500 m and the marked area 
represents the regenerative zone used for Pax7 and MyoD quantification. 
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Quantification of the relative amount of collagen is presented in 
figure 1B. At three days post-surgery, the amount of collagen is 
significantly increased from 8.6 ± 2.9% in the C-group to 26.7 ± 2.1% 
and 31.1 ± 1.9 % in the W- and W+SDF-1-groups, respectively. At 10 
days, the amount of collagen in both wounds is further increased to 
approximately 45% and remains constant up to 56 days post-surgery. The 
amount of collagen between the W- and W+SDF-1-group is not 
significantly different at any time-point. 
 
5.3.2 Pax7 and MyoD immunostaining 
Paraffin sections are stained with antibodies against Pax7 (figure 2A) and 
MyoD (figure 3A) to identify activated satellite cells. In the C-group only 
few Pax7
+
 cells are found in the muscle tissue. In both the W- and 
W+SDF-1-group many Pax7+ cells are present after three and ten days 
at the border of the wounds (indicated in figure 1A) in the regenerative 
zone. The number of these cells is clearly diminished at 28 and 56 days. 
Within the wounds no Pax7
+
 cells are found at any time point. The 
relative numbers of Pax7
+
 cells are presented in figure 2B. At three days, 
the numbers of Pax7
+
 cells are significantly increased from 7.8 ± 0.9% in 
the C-group to 14.5 ± 1.2% in the W-group. In the W+SDF-1-group it is 
further increased to 18.6 ± 1.4%. At ten days, the numbers of Pax7
+
 cells 
are compared to the C-group significantly increased to 12.7 ± 1.1% in the 
W-group, and in the W+SDF-1-group even further to 16.7 ± 1.4%. At 
28 days the numbers of Pax7
+
 cells are still significantly increased to 
approximately 11% in both the W- and W+SDF-1-groups. At 56 days it 
is normalized to control levels in both groups. In the C-group the 
numbers of Pax7
+
 cells are diminished significantly in time, and in the 
wounds their numbers are upregulated in the first 10 days and then 
gradually diminish to control levels. 
In the C-group only a few numbers of MyoD
+
 cells are found, but in 
the W- and W+SDF-1-group many MyoD+ cells and myofibers are 
present in the regenerative zone around the wounds. In the W- and 
W+SDF-1-group, the numbers of MyoD+ cells seem to have increased 
at 3 and 10 days and then diminish again. The quantification of the 
relative numbers of MyoD
+
 cells and myofibers is presented in figure 3B. 
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The numbers of MyoD
+
 cells in the C-group diminish in time and is 
always significantly lower than in the W- and W+ SDF-1-group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Pax7 immunohistochemistry and quantification. A) Sections of the wounds 
without (W) and with SDF-1-loaded collagen scaffolds (W+SDF-1) are shown. 
Pictures were taken at the border of the wound in the regenerative zone as indicated in 
figure 1A. B) Quantification of Pax7
+ 
cells in the controls (C), wounds without (W) and 
with SDF-1-loaded collagen scaffolds (W+SDF-1). The numbers of Pax7
+
 cells are 
expressed as a mean percentage ±  SD of the total numbers of cells. # significant 
difference with C (p < 0.05). * significant difference between W and W+ SDF-1 (p < 
0.05). The scale bar represents 100 m. 
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Figure 3. MyoD immunohistochemistry and quantification. A) Sections of the 
wounds without (W) and with SDF-1–loaded collagen scaffolds (W+SDF-1) are 
shown. Pictures were taken at the border of the wounds in the regenerative zone as 
indicated in figure 1A. B) Quantification of MyoD
+ 
cells in the controls (C), wounds 
without (W) and with SDF-1-loaded collagen scaffolds (W+SDF-1). The numbers of 
MyoD
+
 cells are expressed as a mean percentage ± SD of the total numbers of cells. # 
significant difference with C (p < 0.01).* significant difference between W and W+ SDF-
1 (p < 0.01). The scale bar represents 100 m. 
 
At three days post-surgery, the numbers of MyoD
+
 cells and myofibers in 
the W-group (14.9 ± 3.3%) and in the W+SDF-1-group (15.4 ± 2.2)% 
are not significantly different. At 10 days the numbers of MyoD
+
 cells 
and myofibers are significantly higher in the W+SDF-1-group (23.5 ± 
2.5%) than in the W-group (17.7 ± 2.8%), but at 28 days the number of 
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MyoD
+
-cells and myofibers is significantly lower in the W+SDF-1-
group (9.9 ± 3.1%) than in the W-group (18.4 ± 3.3%). At day 56 post-
surgery, there are no differences found between the W- and W+SDF-1-
group. 
 
5.3.3 Collagen I and III immunostaining 
Paraffin sections are stained with antibodies against collagen I and III 
(figure 4). In the C-group collagen I expression is only found near blood-
vessels.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Collagen I and III immunohistochemistry. Sections of the wounds without 
(W) and with SDF-1-loaded collagen scaffolds (W+SDF-1) are shown. Pictures were 
taken around the wound, which is marked by an asterisk at days 3 and 10. The scale bar 
represents 100 m. 
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In time, the expression pattern of collagen I is not different between the 
W- and W+SDF-1-group. At three days post-surgery there is no 
expression of collagen I around the wounds in both the W- and W+SDF-
1-group. At 10 days, collagen I is expressed around the wounds in both 
groups. At these time points, the collagen scaffold is also positive for 
collagen I. At 28 and 56 days more collagen I is expressed and bundles of 
collagen is formed, but the expression varies within the wounds in both 
groups.  
In the C-group collagen III is only expressed around blood-vessels. 
Between the W- and W+SDF-1-group no differences are found in 
collagen III expression. At 3 days post-surgery, collagen III is expressed 
around the wounds in the W- and W+SDF-1-group. In time, the 
expression of collagen III diminishes in both groups. 
 
5.3.4 -SMA and ED1 immunostaining 
Sections are also stained with antibodies against -SMA to identify 
myofibroblasts and blood vessels, and ED1 to identify macrophages 
(figure 5). In the C-group only -SMA+ blood vessels are found. In both 
the W- and W+SDF-1-group the expression pattern of -SMA is similar 
in time. At three days, -SMA+ myofibroblasts are found around the 
wounds in the W- and W+SDF-1-group. Inside the scaffold -SMA 
expression is absent. At 10 days, the wound in the W-group is filled with 
-SMA+ myofibroblasts. In the W+SDF-1-group, the scaffold is 
surrounded by -SMA+ myofibroblasts. Within the scaffolds some -
SMA
+
 blood vessels are also found. At 28 days, the wounds in both 
groups still contain -SMA+ myofibroblasts, which is diminished after 56 
days.  
Only a small number of ED1
+
 cells are found in the C-group. In both 
the W- and W+SDF1-group, the tissue around the wounds is infiltrated 
by many ED1
+
 cells at three days. In the W+SDF-1group, it seems that 
more ED1
+
 cells have infiltrated the tissue around and inside the scaffold. 
At 10 days, the numbers of ED1
+
 cells are greatly reduced in the tissue 
around the wounds in both groups. The scaffold itself is still completely 
filled with ED1
+
 cells. At 28 and 56 days the numbers of ED1
+
 cells have 
decreased further and seem to be equal in the W- and W+SDF-1-group. 
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Figure 5. SMA and ED1 immunohistochemistry. Sections of the wounds without 
(W) and with SDF-1-loaded collagen scaffolds (W+SDF-1) are shown. The scale bar 
represents 500 m. 
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5.4 Discussion 
 
Full-thickness defects in the M. soleus impair muscle regeneration. 
Histology showed that regenerating fibers are present at the border of the 
defects, and only small numbers of regenerating myofibers are present 
within the defect, but these do not cross the wound. The defect is 
replaced by fibrotic tissue at 10 days, which persists for up to 56 days, 
and it is unlikely that complete regeneration of the M. soleus will occur. 
We assume that the function of these muscles will be severely impaired 
although this was not studied. It has recently been reported that large 
defects in the M. gastrocnemius also show impaired regeneration and 
significant loss of function.
37
 Therefore, the full-thickness wound model 
presented here provides a solid basis to develop tissue engineering 
therapies to improve muscle regeneration, prevent fibrosis, and restore 
muscle function. Nevertheless, future studies should also include 
functional testing. 
Tissue engineering is a powerful and promising strategy to repair 
full-thickness tissue defects.
25-27
 The constructs should provide the 
necessary cues for the cells to regenerate the muscle tissue. In this study, 
SDF-1-loaded collagen scaffolds are used for the first time to attract 
resident sattelite cells to induce muscle regeneration. It has been 
previously demonstrated that only part of the SDF-1 is released from 
the scaffold in vitro in time.
38
 Therefore, SDF-1 is probably gradually 
released into the muscle tissue and provides a migratory gradient for 
satellite cells directed towards the defect. Although SDF-1 has the 
potential to attract satellite cells by binding to the CXCR4 receptor ,
34,35
 
these cells are absent within the scaffold, and regeneration of the defect 
does not occur. In contrast, during the first 10 days, the number of 
satellite cells, myoblasts and myofibers are significantly increased in the 
regenerative zone around the SDF-1-loaded collagen scaffolds. At 28 
days, the number of satellite cells is equal in the W- and W+SDF-1-
group. However, the number of MyoD
+
 myoblasts and myofibers is 
decreased. Therefore it is likely that SDF-1 creates an influx of satellite 
cells towards the regenerative zone in the first days, which will produce 
MyoD
+
 myoblasts and myotubes in time, and thereby accelerate muscle 
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regeneration around the scaffolds. According to myogenin expression 
these satellite cells and myoblasts do not migrate into the scaffold to form 
new myofibers. This indicates that internal muscle regeneration does not 
occur. Since we found many other cells, and also blood-vessels inside the 
scaffold, it remains unclear why the satellite cells did not migrate into the 
scaffold. Collagen type I might not be a suitable substrate for satellite 
cells.
39
 
Implanting SDF-1-loaded collagen scaffolds also creates a larger 
influx of macrophages around and inside the scaffolds. It might be 
possible that the collagen scaffold exerts an immune response, but 
immune cells also express CXCR4,
40
 which could also explain this. It has 
been shown that macrophages and monocytes play a crucial role in 
muscle regeneration.
41-43
 Macrophages secrete soluble factors regulating 
satellite cell activity, and they protect the satellite cells from apoptosis 
through cell-cell contact.
44
 In the initial inflammatory phase of muscle 
regeneration, M1 (early) macrophages are present, which stimulate the 
proliferation of satellite cells. Later, M2 (late) macrophages appear and 
stimulate the differentiation of satellite cells.
45
 Therefore, the influx of 
macrophages might be beneficial for muscle regeneration. It is possible 
that macrophages are attracted by the collagen scaffold  itself, and induce 
the increase of Pax7
+
 cells, MyoD
+
 cells and myotubes in the regenerative 
zone. However, in a previous laceration wound model, we implanted an 
empty cross-linked collagen scaffold, which induced a similar 
inflammatory response and influx of macrophages.
36
 This did not increase 
the number of Pax7
+ 
cells (figure 6). Therefore, we conclude that the 
increased influx of Pax7
+
 cells, and MyoD
+
 cells and myotubes in the 
regenerative zone is a specific effect of the SDF-1
Furthermore, macrophages are probably responsible for the 
degradation of the collagen scaffold. This is necessary before the defect 
can be replaced with functional muscle tissue. However, in this study the 
SDF-1-loaded collagen scaffold seems to be replaced by de novo 
collagen deposition, as in the wound only group (W). In the first days 
collagen III is predominantly expressed, which diminish in time. In 
contrast, collagen I deposition is increased in time. The same results are 
also found in other studies.
46,47
 However, the expression of collagen I 
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varies within the wound, and is not as strong as in skin wounds (own 
results). 








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


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
Figure 6. Pax7 fluorescent immunohistochemistry. A) Sections of the control (C), 
wound without the collagen scaffold (W), and wound with the collagen scaffold (W+S) are 
shown. Pax7 is stained in red (indicated by arrows) and nuclei in blue. B) Quantification 
of Pax7
+
 cells in the controls (C), wounds without (W) and with the collagen scaffold 
(W+S). The numbers of Pax7
+
 cells are expressed as a mean percentage ± SD of the total 
numbers of cells. # significant difference with C (p < 0.05). The scale bar represents 100 
m. Adapted from.
36
 
 
Myofibroblasts, generally identified by the expression of -SMA, 
produce large amounts of collagen, and play an important role in 
fibrosis.
48
 They rapidly appear in both wound groups, and persist up to 56 
days. However, it has been shown that myoblasts can also express -
SMA.
49
 The fibrotic areas are also positive for Hsp47 (figure 7), which is 
related to collagen production in (myo)fibroblasts, and thus further 
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identifies these cells.
50
 Unfortunately, myoblasts and regenerating 
myofibers can also express Hsp47.
51
 The fact that all -SMA+ and 
Hsp47
+
 cells do not show Pax7, MyoD, and Myogenin staining (figure 7), 
indicates that the vast majority of these cells are myofibroblasts and not 
myoblasts. The expression pattern of -SMA and Hsp47 is also mirrored 
by collagen type I and III expression, which confirms the role of 
myofibroblasts in muscle fibrosis. In both groups, the area of 
myofibroblasts and collagen expands outside the defect. Factors from the 
wound might attract myofibroblasts into the surrounding muscle tissue, 
which produce collagen and enlarge the fibrotic area. The remodeling of 
the fibrotic tissue seems to go on up to 56 days as myofibroblasts are still 
present. Within the scaffold -SMA+ blood vessels are also present 
indicating that they are well-vascularized and support cell survival.  
 
 
 
 
 
 
 
 
 
Figure 7. -SMA, Hsp47, Pax7, MyoD and Myogenin (MyoG) 
immunohistochemistry. Representative consecutive sections of the wounds without 
scaffold at 10 days post-surgery are shown. The scale bar represents 100 m. 
 
In order to reduce the formation of fibrotic tissue, other scaffolds 
might be used. It is possible that collagen type I scaffolds trigger 
degradation and replacement with de novo collagen. Other scaffolds, such 
as alginate hydrogels, fibrin gels, and synthetic scaffolds could be 
used.
25,27,52
 Furthermore, the incorporation of anti-fibrotic components in 
the scaffold might further inhibit the formation of fibrotic tissue. Decorin 
is a proteoglycan that can bind TGF-, which plays a major role in tissue 
fibrosis.
53
 Several studies show that decorin reduces fibrosis, leading to 
improved functional muscle regeneration.
11,16
 However, in these studies, 
decorin was injected into lacerated muscle, but no studies have been 
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performed on the implantation of scaffolds loaded with decorin into full -
thickness muscle defects. Additional growth factors such as SDF-1, 
HGF, IGF-I, FGF-II, NGF, or G-CSF can be incorporated into the 
scaffold. This type of approach might be promising to induce functional 
muscle regeneration in full-thickness muscle defects. 
 
 
5.5 Conclusion 
 
Taken together, these data show that full-thickness defects impair muscle 
regeneration leading to muscle fibrosis. This model can be used to study 
therapeutic modalities to improve muscle regeneration. Implantation of 
an SDF-1-loaded collagen scaffold into the defect increases the number 
of Pax7
+
 satellite cells, and MyoD
+
 myoblasts and myofibers in the 
regenerative zone around, but not within the scaffolds. In time, the 
scaffold is replaced by fibrotic tissue. Future experiments should focus 
on growth factor-loaded scaffolds to accelerate muscle regeneration in 
combination with anti-fibrotic components to inhibit the formation of 
fibrotic tissue. 
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Abstract 
 
Many approaches have been used to improve skeletal muscle 
regeneration, but constructs that prevent the formation of fibrotic tissue 
in large muscle defects are not yet available. It has been shown that 
decorin, a small leucine-rich proteoglycan, binds and inactivates TGF-β1 
leading to less fibrosis. In addition, SDF-1α induces the migration of 
muscle satellite cells towards the defect. Therefore, decorin-loaded 
collagen scaffolds with or without SDF-1α were implanted into a muscle 
fibrosis model to reduce fibrosis and to improve muscle regeneration.  
In vitro studies showed that the bulk of decorin was released within 
the first 3 days, inducing a short-term release of decorin into the muscle 
defect. Circular (2 mm) full-thickness defects were made in the musculus 
soleus of 20 rats and filled with an empty collagen scaffold, a decorin-
loaded collagen scaffold, or a decorin- and SDF1-α-loaded collagen 
scaffold.  
Immunohistochemistry was performed at 56 days post-surgery to 
identify myofibroblasts, activated fibroblasts, satellite cells, and fused 
myoblasts. Histology revealed that fibrosis, measured as collagen 
deposition, was the same in all treatment groups. The group with the 
empty scaffolds showed large numbers of (myo)fibroblasts, but low 
numbers of satellite cells and fused myoblasts. The SDF-1α and/or 
decorin groups showed virtually the same frequency of these cells.  
Therefore, we conclude that the release window of decorin was 
probably too short to prevent fibrosis. Future studies should aim to 
develop scaffolds resulting in a timely-tuned delivery of factors out of the 
scaffold and thereby inhibit fibrosis and improve muscle regeneration.  
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6.1 Introduction 
 
Regenerative medicine deals with the treatment of skeletal muscle 
diseases and injuries. In muscle healing the myofiber-associated satellite 
cells play a central role.
1,2
 After injury, these cells regenerate the muscle 
tissue by generating myoblasts, which then differentiate and fuse to 
damaged myofibers or form new ones.
3-5
 More importantly, satellite cells 
self-renew and therefore form a continuous cell source for regeneration.
6,7
 
Unfortunately, muscle healing can lead to fibrosis, which prevents full 
functional recovery.
3,4,8
  
Over the years, satellite cell functioning has been associated with 
many growth factors such as insulin growth factor (IGF)-I, fibroblast 
growth factor (FGF)-II, hepatocyte growth factor (HGF), nerve growth 
factor (NGF), or granulocyte-colony stimulating factor (G-CSF).
9-12
 
These growth factors together with satellite cells are the main tools for 
developing strategies to repair skeletal muscle injuries. Injection of 
growth factors or satellite cells enhances muscle regeneration up to a 
certain extent.
6,9-17
 However, in full-thickness defects leading to fibrosis, 
tissue engineered scaffolds are required to provide structural cues for the 
satellite cells and regenerating myofibers. Such scaffolds have been used, 
but with varying results.
18-22
 Loading the scaffolds with cells and/or 
growth factors usually improves their efficacy.  
To obtain sufficient satellite cells for seeding the scaffolds, in vitro 
expansion is required. Unfortunately, this often results in the loss of 
myogenic potential.
14,23
 Furthermore, satellite cells and myoblasts hardly 
survive and do not migrate into the defect after transplantation.
15,24
 
Loading the scaffolds with appropriate growth factors to attract resident 
satellite cells, and to induce their proliferation and differentiation might 
eliminate the requirement of cultured satellite cells. We already showed 
that collagen scaffolds loaded with stromal-derived factor (SDF)-1α 
attract satellite cells towards the border of the defect, but does not 
prevent fibrosis.
22
  
One of the major factors involved in tissue fibrosis is transforming 
growth factor (TGF)-β1,25 which is also a key factor in muscle 
fibrosis.
9,13,26
 The small leucine-rich proteoglycan decorin can bind and 
Decorin/SDF-1α-loaded collagen scaffolds in skeletal muscle regeneration 
 133 
inactivate TGF-β1, and therefore inhibit fibrosis and improve muscle 
regeneration.
9,13,26
 A sustained delivery of decorin induce by gene 
transfection, showed an increased differentiation rate of myoblasts, which 
improved muscle regeneration.
27
  
Previously, we showed that in full-thickness defects fibrosis starts 
already within 3 days according to the presence of myofibroblasts and 
collagen depositions at the border of the wounds.
22
 This strongly suggests 
that the fibrotic process already starts early after injury. It has also been 
shown that the reduction of TGF-β1 activity directly after skin wounding 
reduces fibrosis.
28,29
 Therefore, we studied the development of fibrosis 
after a short-term release of decorin by implanting decorin-loaded non-
crosslinked collagen scaffolds with or without SDF-1α in our fibrosis 
model in the M. soleus of the rat.  
 
 
6.2 Materials and methods 
 
6.2.1 Rats 
Twenty 5-week-old male Sprague-Dawley rats (Janvier, Le Genest, 
France) were used for the experiments. The rats were housed under 
normal laboratory conditions and received normal rat chow and water ad 
libitum. Before the start of the experiments the rats had been acclimatized 
to the animal facility for one week. All animal experiments were 
approved by the Animal Experiments Committee of the Radboud 
University Nijmegen Medical Centre (RUNMC) in accordance to the 
Dutch laws and regulations on animal experiments. 
 
6.2.2 Scaffold preparation and characterization 
Insoluble type I collagen from bovine achilles tendon (Sigma Chemical 
CO, St. Louis, MO, USA) was homogenized to a 1% (w/v) collagen 
suspension. To obtain a scaffold, the collagen suspension was degassed, 
frozen overnight at -25°C in aluminum trays, and lyophilized. For 
characterization, small pieces of the scaffold were fixed with 2% 
glutaraldehyde (v/v) and 50% (v/v) osmium oxide and evaluated using 
scanning electron microscopy. 
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6.2.3 Decorin release from the scaffolds 
Round (2mm) collagen scaffolds were incubated in PBS containing 0.1% 
(w/v) bovine serum albumin (BSA) and 1.6 mg/ml decorin (from bovine 
cartilage; Sigma Chemical CO, St Louis, MO, USA) at room temperature 
for 48 hours. Then, scaffolds were incubated in PBS for 0, 3, 6, and 10 
days. At the indicated time points, scaffolds were fixed in freshly 
prepared 4% paraformaldehyde (PFA) in PBS for 2 hours and processed 
for paraffin embedding and histological analyses. 
 
6.2.4 Experimental procedures 
At the day of surgery, the rats received 0.02 mg/kg body weight 
buprenorfine (Temgesic; Schering Plough, Brussels, Belgium) 
subcutaneously as an analgesic and also at the next two days with a 
twelve hour interval. Under 5% (induction) followed by 2-3% 
(continuation) isoflurane anesthesia (Pharmachemie BV, Haarlem, the 
Netherlands), the M. soleus of the left lower limb of the rats was gently 
exposed. Using a 2 mm round biopsy punch, a full-thickness defect was 
made in de middle of the M. soleus. The rats were divided into three 
groups according to the presence of the different collagen scaffolds: 1) an 
empty scaffold (W; N = 6), 2) decorin-loaded collagen scaffold (DEC; N 
= 7), and 3) decorin + SDF-1 -loaded collagen scaffold (DEC/SDF-1 N 
= 7). These abbreviations are used further in this article.  
Before implantation, twenty scaffolds were sterilized in 70% EtOH 
for 30 minutes and washed in PBS. Then six scaffold were incubated in 
PBS containing 0.1 % (w/v) (BSA), seven scaffolds were incubated in 
PBS containing 0.1 % (w/v) BSA and 1.6 mg/ml decorin, and seven 
scaffolds were incubated in PBS containing 0.1 % (w/v) BSA, 2 g/ml 
SDF-1 , and 1.6 mg/ml decorin at room temperature for 48 hours and 
then directly implanted into the muscle wounds. After implantation, the 
fascia and skin were both closed with 5-0 Vicryl sutures (Johnson-
Johnson, Langhorne, PA, USA). In every group, the rats were sacrificed 
according to the standard CO2/O2 protocol at 56 days post-surgery.  
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6.2.5 Histology and immunohistochemistry 
The left (wound) and right (internal control) M. soleus of the rats were 
fixed in freshly prepared 4% paraformaldehyde (PFA) in PBS for 22-23 
hours and processed for paraffin embedding. Longitudinal muscle 
sections (5µm) were collected on superfrost plus slides (Menzel-Gläser, 
Braunschweig, Germany). To discriminate collagen fibers (blue color) 
from the muscle tissue (red color), the sections were stained with 
azocarmine G and aniline blue (AZAN) according to standard protocols. 
For immunohistochemistry, the sections were treated and stained as 
described previously.
22
 The primary antibodies, mouse anti-alpha-smooth 
muscle actin (α-SMA, 1:1600; Sigma), mouse anti-Hsp47 (1:24000; 
Assay Design, Ann Harbor, MI, USA), mouse anti-Pax7 (1:100; 
Developmental Studies Hybridoma Bank, Iowa City, CA, USA), mouse 
anti-Myogenin (F5D, 1:100; Developmental Studies Hybridoma Bank), 
mouse anti-decorin (3B3, 1:1; Developmental Studies Hybridoma Bank) 
were visualized using the biotinylated secondary antibody donkey-anti-
mouse IgG (H+L) (1:500; Jackson Labs, West Grove, PA, USA), and a 
preformed biotinylated horse radish peroxidase and avidin complex 
(Vector Laboratories, Burlingame, CA, USA). The sections were colored 
with 3,3-diaminobenzidine (DAB) and photographed with the Zeiss 
Imager.Z1 together with the AxioCam MRc5 camera using the 
AxioVision 4.6.3 software (Carl Zeiss Microimaging GmbH, Jena, 
Germany). 
 
6.2.6 Quantification 
The relative area of fibrosis was quantified on the AZAN-stained muscle 
sections, and the relative area of -SMA and Hsp47 was quantified in the 
immunostained muscle sections of the control muscle (C) and the 
experimental groups W, DEC, and DEC/SDF-1 using the Qwin software 
(Leica Imaging Systems, Cambridge, UK). The area of fibrotic tissue 
(blue) and muscle tissue (red) and the -SMA
+
 and Hsp47
+
 area (brown) 
and muscle tissue (blue) were quantified on a fixed length of 0.9 cm 
muscle tissue containing the wound area. The results were expressed as a 
mean percentage ± SD of the total amount of tissue.  
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The number of Pax7
+
 and Myogenin
+
 cells was counted in the C and 
in the regenerative zone (regenerating muscle tissue at the border of the 2 
mm wound) of the groups W, DEC, and  DEC/SDF-1- The numbers of 
Pax7
+
 and Myogenin
+
 cells were expressed as a mean percentage ± SD of 
the total number of cells.  
The differences in the percentages of AZAN, -SMA
+
 and Hsp47
+
 
tissue and Pax7
+
 and Myogenin
+
 cells were tested for significance using a 
Two-Way ANOVA with Holm-Sidak post-hoc analysis. A value of p < 
0.05 was considered to be significant. 
 
 
6.3 Results  
 
6.3.1 Scaffold characterization 
Scanning electron microscopy shows that the scaffolds have a porous 
structure (figure 1A) with a pore size of approximately 100 µm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Scaffold characterization and decorin immunohistochemistry. A) Scanning 
electron microscopy of the scaffold. B) Sections of decorin-loaded scaffolds are incubated 
in PBS for 0, 3, 6, and 10 days and subsequently stained for decorin. The scale bar 
represents 200 m. 
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The binding of decorin to the scaffold is shown in figure 1B. Directly 
after loading, the scaffolds are filled with decorin. After 3 days in PBS, 
the scaffolds still retain some decorin although less than directly after 
loading. The scaffolds do not contain decorin anymore when incubated in 
the PBS for longer than 6 days.  
 
6.3.2 AZAN, α-SMA, and Hsp47 staining 
All rats survived the experimental procedures and gained weight after a 
short period of growth arrest. Macroscopically, all scaffolds had 
disappeared, and the wounded muscles showed some adherence to the 
surrounding tissue. 
The AZAN-staining (figure 2A) reveals proper aligned muscle fibers 
and little collagenous tissue in the C-group. In the W-, DEC-, and 
DEC/SDF-1α-groups, large collagen depositions are present. 
Regenerating muscle fibers seem to be disorganized and do not penetrate 
through the collagenous tissue. To identify myofibroblasts, sections are 
stained with α-SMA (figure 2A). In the C-group myofibroblasts are 
absent and only α-SMA+ blood vessels are found. In the W-, DEC-, and 
DEC/SDF-1α-groups large areas of α-SMA+ myofibroblasts are found 
within the collagenous tissue. Sections are also stained with Hsp47 to 
identify activated fibroblasts (figure 2A). In the C-group only few 
activated fibroblasts are present throughout the muscle tissue. In the W-, 
DEC-, and DEC/SDF-1α-groups large areas with activated fibroblasts are 
present within collagenous tissue.  
The quantification of these areas is presented in figure 2B. The 
relative amount of collagenous tissue significantly increased from 6.3 ± 
2.0% in the C-group to 37.8 ± 6.6%, 37.5 ± 4.4%, and 41.8 ± 6.1% in the 
W-, DEC-, DEC/SDF-1α-groups, respectively. Although the largest 
amount of collagenous tissue is found in the DEC/SDF-1α-group, there 
are no significant differences between the three experimental groups. In 
the C-group the relative amount of α-SMA+ and Hsp47+ areas are 2.6 ± 
0.4% and 4.6 ± 2.3%, respectively. These areas are significantly 
increased (p < 0.05) to 19.3 ± 4.7% (α-SMA) and 15.9 ± 3.8% (Hsp47) in 
the W-group, 17.3 ± 3.9% (α-SMA) and 16.1 ± 5.1% (Hsp47) in the 
DEC-group, and 18.5 ± 6.1 (α-SMA) and 17.4 ± 5.4 (Hsp47) in the 
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DEC/SDF-1α-group. Between the three experimental groups no 
significant differences are found. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. AZAN staining, α-SMA and Hsp47 immunohistochemistry, and 
quantification. A) Sections of control (C) and wounds with empty collagen scaffolds (W), 
decorin-loaded collagen scaffolds (DEC), and decorin and SDF-1 -loaded collagen 
scaffolds (DEC/SDF) were stained to identify collagen (AZAN; muscle tissue red, collagen 
blue), α-SMA, and Hsp47 (both brown staining). B) Quantification of the surface area of 
collagen, α-SMA, and Hsp47 in the controls (C), wounds with empty collagen scaffolds 
(W), decorin-loaded collagen scaffolds (DEC), and decorin and SDF-1 -loaded collagen 
scaffolds (DEC/SDF). The area of collagen, α-SMA, and Hsp47 is expressed as a mean 
percentage ± SD compared to the total tissue area. * all wounds are significantly different 
from C (p < 0.05).The scale bar represents 1000 m and the boxed area represents the 
regenerative zone used for Pax7 and Myogenin quantification. 
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6.3.3 Pax7 and Myogenin staining 
Paraffin sections are stained with antibodies against Pax7 and Myogenin 
to identify satellite cells and differentiating myoblasts (figure 3A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Pax7 and Myogenin immunohistochemistry and quantification. A) 
Sections of control (C) and wounds with empty collagen scaffolds (W), decorin-loaded 
collagen scaffolds (DEC), and decorin and SDF-1 -loaded collagen scaffolds (DEC/SDF) 
are shown. Pictures were taken at the border of the wound in the regenerative zone as 
indicated in figure 1A. B) Quantification of Pax7
+
 and Myogenin
+
 cells in the controls 
(C), wounds with empty collagen scaffolds (W), decorin-loaded collagen scaffolds (DEC), 
and decorin and SDF-1 -loaded collagen scaffolds (DEC/SDF). The numbers of Pax7
+
 
and Myogenin
+
 cells are expressed as a mean percentage ± SD of the total numbers of 
cells.* the number of Myogenin
+
 cells of all wounds are significantly different from C (p < 
0.05). The scale bar represents 100 m. 
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In the C-group few Pax7
+
 and almost no Myogenin
+
 cells are found. In 
the regenerative zone around the wounds, more Pax7
+
 and Myogenin
+
 
cells seem to be present in all the groups. Quantification of the relative 
numbers of these cells is shown in figure 3B.  
The number of Pax7
+
 cells is around 6% in every experimental group 
and no significant differences were present. The number of Myogenin
+
 
cells is significantly increased (p < 0.05) from 0.6 ± 0.4% in the C-group 
to 5.7 ± 1.3% in the W-group, 5.7 ± 2.8% in the DEC-group, and 6.8 ± 
2.5% in the DEC/SDF-1α-group. The number of Myogenin+ cells in the 
three experimental groups was not significantly different.  
 
 
6.4 Discussion and conclusion 
 
One of the major factors involved in fibrosis is TGF-β1,25 and inhibition 
of this growth factor by injecting decorin reduced fibrosis and improved 
muscle regeneration in laceration wounds.
9,13,26
 However, the effects of 
decorin in full-thickness muscle defects that lead to large fibrotic tissue 
have not been studied. In our previous study using the fibrosis model, 
muscle regeneration and fibrosis already started within 3 days post-
surgery.
22
 Others have shown that reducing TGF-β1 activity directly after 
skin wounding prevented fibrosis.
28,29
 Therefore we hypothesized a 
beneficial effect of the application of decorin directly after injury.  
In this study, we loaded collagen scaffolds with decorin alone, or 
together with SDF-1α to induce a short-term release of decorin and SDF-
1α at the start of muscle regeneration to attract resident satellite cells 
towards the defect and to prevent fibrosis. The scaffolds are highly 
porous allowing cell ingrowth, and decorin is released for up to 3 days. 
The implantation of the decorin-loaded collagen scaffolds did not reduce 
the amount of fibrotic tissue, α-SMA+ myofibroblasts, and Hsp47+ 
fibroblasts. As also found in the previous study,
22
 the number of Pax7
+
 
and Myogenin
+
 cells was not different between the W-, DEC-, DEC/SDF-
groups. This indicates that the regeneration phase had already ended at 56 
days. Since decorin is rapidly released, it is possible that the effects are 
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only visible during the first days of regeneration. However, as shown in 
the present study, the final result still is the formation of fibrotic tissue.  
In laceration studies, the injection of decorin decreased the amount 
of fibrotic tissue. In these studies, similar amounts of decorin (50 µg) 
were injected into the muscle at 14 days post-surgery.
9,13
 Inhibiting TGF-
β1 activity at day 14, by injecting gamma interferon (γIFN) or suramin, 
an antiparasitic and antitumor drug, showed similar results.
30-33
 
Furthermore, it has been shown that transplantation of myoblasts 
transfected with decorin improves myoblast differentiation and inhibited 
fibrosis.
27
 Conversely, myoblasts transfected with TGF-β1 induce their 
differentiation into myofibroblasts, which play a role in muscle fibrosis. 
When decorin was injected 14 days after cell transplantation, the 
differentiation of myoblasts to myofibroblasts was blocked.
26
 Together 
with the present findings these data suggest that inhibition of TGF-β1 
activity might only be effective in a window between 3 and 14 days post-
surgery. Therefore, timely-tuned release scaffolds need to be developed 
to provide the release of decorin during a specific time window. 
Recently, it has been shown that by modifying the scaffold or by 
introducing microspheres a sustained release of growth factors can be 
obtained.
34-36
 Thus, by using such release systems for decorin and SDF-
1α improved muscle regeneration and reduced fibrosis might be achieved.  
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Abstract 
 
Satellite cells are key cells for post-natal muscle growth and regeneration 
and they play a central role in the search for therapies to treat muscle 
injuries. In this study the myogenic potential of muscle stem cells was 
studied in 2D- and 3D-cultures with collagen type I and Matrigel, which 
contains the niche factors laminin and collagen type IV.  
Muscle stem cells were cultured to induce proliferation and 
differentiation on collagen- or Matrigel-coated surfaces (2D) or in gels 
(3D).  
In the 2D-cultures, muscle stem cells proliferated faster on Matrigel 
than on collagen. The numbers of Pax7
+
 and MyoD
+
 cells were also 
significantly higher on Matrigel than on collagen. During differentiation, 
muscle stem cells formed more and larger MyoD
+
 and Myogenin
+
 
myotubes on Matrigel. In the 3D-cultures, muscle stem cells in Matrigel 
expressed higher mRNA levels of MyoD and Myogenin, and formed 
elongated myotubes expressing Myogenin and myosin. In collagen gels, 
the myotubes were short, rounded, and expressed only Myogenin.  
In conclusion, muscle stem cells, both in 2D and 3D, lose their 
differentiation capacity in collagen but not in Matrigel. This underscores 
the importance of niche factors for maintaining the myogenic potential of 
muscle stem cells, and for tissue engineered constructs aiming to restore 
skeletal muscle defects. 
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7.1 Introduction 
 
Satellite cells play a central role in the homeostasis and regeneration of 
skeletal muscle tissue. Upon injury, quiescent satellite cells, which 
express Pax7, up-regulate MyoD and Myf5 expression, and become 
proliferating myoblasts.
1-5
 Subsequent down-regulation of Pax7,
6,7
 and 
up-regulation of Mrf4 and Myogenin mark the onset of myoblast 
differentiation
3-5
 to form multinucleated myofibers or repair damaged 
myofibers by fusion.
8,9
 However, a fraction of the satellite cells does not 
proliferate or differentiate, but self-renews to maintain the satellite cell 
pool.
7,10-12
 Although muscle regeneration is an efficient process, scar 
tissue is often formed, which hampers muscle function.
13-15
 
The ability of satellite cells to self-renew makes them promising 
candidates for regenerative medicine approaches for muscle injury.
10,11
 
Minor muscle injuries only require the injection of satellite cell-derived 
myoblasts into the defect, but larger defects require tissue-engineered 
constructs seeded with myoblasts and/or growth factors.
16
 The injection 
of myoblasts improves muscle regeneration after injury, but this approach 
still faces major limitations. To obtain large quantities of myoblasts, 
satellite cells need to be isolated and expanded in vitro. During this 
process, satellite cells lose their myogenic potential and will therefore be 
less efficient in regenerating the injured muscle.
12,17
 Furthermore, 
massive cell death occurs directly after injection.
18
  
In vivo, satellite cells are located between, and in direct contact with 
the adjacent myofiber and the basal membrane.
19,20
 Asymmetrical cell 
division results in two daughter cells of which one remains in contact 
with the basal membrane and preserves stem cell properties, while the 
other loses contact and differentiates.
11
 Thus, the loss of their niche 
during isolation might cause the reduction of myogenic potential due to 
premature differentiation. The basal membrane consists mainly of 
laminin, collagen type IV, and heparin sulphate proteoglycans (HSPGs). 
It provides growth factors and attachment sites for the satellite cells .
21,22
 
In addition secreted products from the microvasculature, neuromuscular 
junction and immune cells also influence satellite cell behavior.
22,23
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Collagen type I, although not present in the niche, is widely used for 
culturing satellite cells.
24-27
 Matrigel, which consist mainly of laminin, 
collagen type IV and HSPGs, is also being used and improved the 
myogenic capacity of isolated satellite cells, now called muscle 
progenitor cells (MPCs).
28-30
 Collagen type I and other materials, such as 
fibrin and alginate have also been used as a scaffold to repair muscle 
defects. Although some studies show favorable results, none of these 
materials mimic the satellite cell niche.
13,31-35
 Better results might be 
achieved by using materials that mimic the satellite cell niche. Up to 
now, no data are available on the myogenic capacity of MPCs in a 3D 
environment, although this is critical to develop tissue engineered 
constructs for regenerative medicine purposes. Therefore, the aim of this 
study was to investigate the myogenic potential of MPCs in 2D and 3D 
cultures with either collagen type I or Matrigel.   
 
 
7.2 Materials and methods 
 
7.2.1 Muscle progenitor cell isolation 
MPCs were isolated from the hind limb muscles of 5-week-old male 
Sprague-Dawley rats (Janvier, Le Genest, France). The dissected muscle 
were minced in phosphate-buffered-saline (PBS) containing 5 µg/ml 
Amphotericine B (Sigma Chemical CO, St Louis, MO, USA) using 
scissors, and excessive fat and tendon were removed. Minced tissue 
fragments were incubated in 2% (w/v) Collagenase type II (Invitrogen 
HQ, San Diego, CA, USA) in Dulbecco’s Modified Eagle’s  Medium-
High Glucose (DMEM-HG; Invitrogen) for 1 hour at 37°C. Tissues were 
further homogenized by trituration using 10 ml pipettes and filtered 
through a 100 µm cell strainer to obtain single cell suspensions. The cell 
suspensions were incubated in hypotonic buffer (0.1 mM EDTA; 0.15 M 
NH4Cl; 10 mM KHCO3, pH 7.4) for 1.5 minutes to lyse the erythrocytes. 
The remaining cells were centrifuged (5 minutes at 300g) and 
resuspended in 15 ml proliferation medium: DMEM-HG containing 20% 
fetal bovine serum (FBS), 2% penicillin-streptomycin (p/s), 1 mM 
pyruvate, and 5 ng/ml bFGF (all from Invitrogen). To remove fast -
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adhering fibroblasts the cells were incubated in uncoated culture flasks 
for 1 hour (37°C, 5% CO2). Non-adhering cells were then transferred to 
tissue culture flasks coated with 1 mg/ml Matrigel (Matrigel
TM
 Basement 
Membrane Matrix, BD Bioscience, Bedbord, MA, USA), and cultured for 
4 days (37°C, 5% CO2). Proliferation medium was refreshed every day. 
After 4 days, MPCs were significantly enriched up to 60% according to 
Pax7 expression. 
 
7.2.2 Proliferation and differentiation of muscle progenitor cells 
Three batches of enriched MPCs from different rats were used for the 
2D- and 3D-experiments. For the 2D-experiments, 24-wells plates and 
Lumox dishes (Ø 35 mm; both Greiner Bio-One, Frickenhausen, 
Germany) were coated with 0.2% (w/v) collagen type I (rat tail tendon; 
Serva Electrophoresis, Heidelberg, Germany) or 1 mg/ml Matrigel for 1 
hour at 37°C. In the 24-wells plate, enriched MPCs were plated at a 
density of 10.000 cells/well and cultured in proliferation medium for 1, 2, 
and 3 days. In the collagen- and Matrigel-coated Lumox dishes, 40.000 
enriched MPCs were seeded and cultured in proliferation medium for 2 
days to induce proliferation. Enriched MPCs were also seeded at a 
density of 500.000 cells in the collagen- and Matrigel-coated Lumox 
dishes. Cells were then cultured for 1 day in proliferation medium and 
then 2 additional days in differentiation medium: DMEM-HG containing 
2% fetal FBS, 1 mM pyruvate, and 2% p/s to induce fusion. For the 3D-
experiments, 24-wells culture plates were pre-coated with 1% (w/v) 
bovine serum albumin (BSA) in PBS. Enriched MPCs were mixed with 
collagen type I solution containing 1.2 mg/ml collagen type I from rat 
tail, 10% (v/v) minimal essential medium (10x), 0.1 M 4-
(20hydroxyethyl)-1-piperazineethane-sulfonic acid (HEPES), 30 mM 
NaHCO3 (all from Invitrogen), and 2 mM NaOH, or with Matrigel (1:1) 
on ice at a density of 1*10
6
 cells/ml. In each well, 0.5 ml cell/gel 
suspension was carefully dispensed and incubated at 37°C to gelate for 
45 minutes. Then, 0.5 ml proliferation medium was added to each well to 
obtain final concentrations of 20% FBS, 1 mM pyruvate, and 2% p/s. For 
the proliferation experiments, cells were cultured for 2 days with 
proliferation medium. For the differentiation experiments, the 
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proliferation medium was replaced after 1 day and cells were cultured for 
2 additional days with differentiation medium. After the experiments, the 
cells were analyzed using DNA quantification, immunofluorescence 
staining, and quantitative PCR. 
 
7.2.3 DNA quantification 
Cell proliferation of the enriched MPCs was measured using the 
PicoGreen dsDNA Quantification assay (Molecular Probes, Eugene, OR, 
USA). At the appropriate time points, the cells were lysed in 0.1% (v/v) 
Triton X-100 in PBS and three times freeze and thaw cycles. The assay 
was performed according to the manufactures protocol. Fluorescence was 
measured in a FL600 Microplate Fluorescent Reader (Bio-Tek 
Instruments Inc., Winooski, VT, USA) at excitation 485 nm and emission 
520 nm. The amount of DNA was calculated using a standard curve 
ranging from 0 to 15000 cells.  
 
7.2.4 Immunofluorescence staining 
After the experiments, the enriched MPCs were washed with PBS and 
fixed in 4% formaldehyde in PBS for 15 minutes. After washing with 
PBS, the membranes of the Lumox dishes were cut into 5 pieces and the 
cells were permeabilized in 0.5% Triton X-100 in PBS for 20 minutes. 
The cells were washed with 0.05% (v/v) Tween-20 in PBS, and then 
incubated in blocking buffer containing 2% (w/v) bovine serum albumin 
(BSA), 2% (v/v) normal goat serum (NGS), 0.1% (v/v) Triton X-100, 
0.05% (v/v) Tween-20, and 100 mM glycine in PBS for 30 minutes. 
Then, the cells were incubated with a mouse anti-Pax7 (1:25; 
Developmental Studies Hybridoma Bank, Iowa City, CA, USA), mouse 
anti-MyoD (1:25; DAKO, Dakopatts, Glostrup, Denmark), mouse anti-
Myogenin (F5D, 1:100; Developmental Studies Hybridoma Bank), and 
mouse anti-fast myosin heavy chain (FMHC, 1:1600; Sigma Chemical 
CO, St Louis, MO, USA) in blocking buffer without glycine for 1 hour. 
For the proliferation experiments, the bound antibodies were visualized 
with AlexaFluor-488-labeled goat anti-mouse IgG (H+L) (1:200; 
Molecular Probes). For the differentiation experiments, the bound 
antibodies were visualized with AlexaFluor-488-labeled goat anti-mouse 
Chapter 7 
 152 
IgG (H+L) (1:200; Molecular Probes) combined with Texas Red-X 
Phalloidin (1:250; Molecular Probes) to stain the actin filaments. The 
cells were visualized with a Zeiss Imager.Z1 microscope and 
photographed. 
 
7.2.5 Quantification 
The fusion index, the number of myofibers containing 3-6, 7-10 or >10 
nuclei, and the number of Pax7
+
, MyoD
+
, and Mygogenin
+
 cells in the 
enriched muscle progenitor cells cultures were calculated using 8 
different representative fields of an overview image for each coating 
condition after all immunostainings (N=3 batches). All the results were 
expressed as a mean percentage ± SD of the total number of cells.  
 
7.2.6 Whole mount immunofluorescence staining  
The gels were fixed in 4% formaldehyde in PBS for 15 minutes, 
permeabilized in 0.5% Triton X-100 in PBS for 30 minutes, and 
incubated in blocking buffer for 1 hour. Then, the gels were incubated 
with the antibodies mouse anti-MyoD (1:25), mouse anti-Myogenin 
(1:100), and mouse anti-FMHC (1:1600) for 2 hours. The bound 
antibodies and actin filaments were visualized using AlexaFluor-488-
labeled goat anti-mouse IgG (H+L) (1:200) combined with Texas Red-X 
Phalloidin (1:250). The structure of the whole gels was maintained during 
sealing. The cells were analyzed using an Olympus FV1000 Confocal 
Laser Scanning Microscope (CLSM, Olympus, Center Valley, PA, USA). 
In the pictures, artifacts were removed with the NIH ImageJ software 
using the Remove Outliers and Despeckle options.  
 
7.2.7 Quantitative PCR 
The gels were washed with PBS and homogenized with 1 ml Trizol 
(Invitrogen). Then 200 µl chloroform (Sigma) was added, mixed, and 
centrifuged for 20 minutes at 4ºC. The water phase containing the RNA 
was mixed with 70% ethanol (1:1), and RNA was extracted according to 
the manufacturer’s protocol (Qiagen, Hilden, Germany) including a 
DNase I treatment. cDNA was generated with 0,5-1 µg RNA using the 
SuperScript
TM
 II system (Invitrogen) according to the manufacturer’s 
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protocol. Quantitative real-time PCR was performed in a final volume of 
25 µl containing 12.5 µl SYBR
®
Green Supermix (Bio-Rad, Hercules, 
CA, USA), 5 µl (40x diluted) cDNA, 4.5 µl RNAse-free water, 1.5 µl 
2.5M forward primer and 1.5 µl 2.5M reverse primer. The primers for β-
actin, Pax7, MyoD, Myogenin, and Myh-1 were obtained from Biolegio 
(Nijmegen, The Netherlands) and the primer sequences are provided in 
table 1. The cDNA was amplified in the C1000 Thermal Cycler (Bio-
Rad) and fluorescence was analyzed using the CFX96
TM
 Real-Time 
System (Bio-Rad). The PCR conditions were 95ºC for 3 minutes (1 
cycle), 95ºC for 15 seconds and 60ºC for 30 seconds (39 cycles), and 
finally a temperature increase starting at 65ºC to 95ºC with 0.5ºC 
intervals. RNA expression was normalized against the mRNA level of β-
actin (∆Ct) and represented as 2-∆Ct. 
 
Table 1. Primer sequences. 
 
7.2.8 Statistical analysis 
All results were tested for significance (p < 0.05 ) using a Two-Way 
ANOVA with Holm-Sidak post-hoc analysis, except for the results of the 
DNA quantification and Quantitative real-time PCR, which were not 
normally distributed. For the DNA quantification a One-Way ANOVA 
with post-hoc Holm-Sidak analysis was used (Bonferroni correction) at 
the individual time points (p < 0.01). The results of the Quantitative real -
time PCR were normally distributed after log transformation and a Two-
Way ANOVA with Holm-Sidak post-hoc analysis was used. 
 
 
 
  
Gene 
 
Forward primer 
 
Reverse primer 
 
β-actin TTCAACACCCCAGCCATGT TGTGGTACGACCAGAGGCATAC 
Pax7 AGCCGAGTGCTCAGAATCAA TCCTCTCGAAAGCCTTCTCC 
MyoD CGACTGCCTGTCCAGCATAG GGACACTGAGGGGTGGAGTC 
Myogenin AACCCAGGAGATCATTTGCT GGTGACAGACATATCCTCCA 
Myh-1 CCTGGATGATCTACACCTACTC GTCAGAGATAGAGAAGATGTGGG 
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7.3 Results 
 
7.3.1 2D-proliferation 
After processing the muscle and initial enrichment, up to 60% of the 
MPCs expressed Pax7 and MyoD. These cells proliferated on collagen 
and Matrigel coatings for an additional two days, and were then stained 
for Pax7 and MyoD (figure 1A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Pax7 and MyoD fluorescent immunohistochemistry and quantification. A) 
Proliferating MPCs cultured on collagen-I and Matrigel coatings were stained for Pax7 
or MyoD (both green) and DAPI (blue). B) Quantification of Pax7
+
 and MyoD
+ 
cells 
(expressed as a mean ± SD) on collagen-I and Matrigel coatings. C) Quantification of the 
number of cells (expressed as mean ± SD) on collagen-I and Matrigel coatings after 1, 2, 
and 3 days of culture. Scalebar represents 100 µm. * significant difference between 
collagen-I and Matrigel. 
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On Matrigel, many MPCs still express Pax7 and MyoD, whereas on 
collagen only a small fraction is positive for Pax7 and MyoD expression. 
Quantification (figure 1B) shows that, 56.5 ± 7.2% and 64.2 ± 7.0% of 
the cells are Pax7
+
 and MyoD
+
, respectively. On collagen, these numbers 
are significantly decreased to 32.5 ± 3.3% for Pax7 and 36.5 ± 7.9% for 
MyoD. Furthermore, DNA quantification shows (figure 1C) a 5-fold 
higher cell number on Matrigel than on collagen after three days of 
culture.  
 
7.3.2 2D-differentiation 
Differentiating and fused MPCs were stained for Pax7, MyoD, 
Myogenin, and actin filaments (figure 2A). According to the actin 
expression, multinucleated myotubes are formed on both collagen and 
Matrigel after two days of differentiation. However, on Matrigel, more 
and larger myotubes are found of which some showed cross-striations. 
Pax7 expression is diminished on both collagen and Matrigel, and only 
found in non-fused MPCs. On Matrigel, many MyoD
+
 and Myogenin
+
 
muscle cells are present, but on collagen only few cells express MyoD 
and Myogenin. Almost all of the MyoD
+
 and Myogenin
+
 cells are within 
the myotubes on both substrates. After quantification, only 3.5 ± 0.8% 
and 7.5 ± 0.5% Pax7
+
 cells are present on collagen and Matrigel, 
respectively (figure 2B). However, this difference was not significant. 
The fraction of MyoD
+
 cells is around 3-fold larger on Matrigel (52.9 ± 
2.5%) than on collagen (16.2 ± 4.9%). On Matrigel, the fraction of 
Myogenin
+
 cells (55.0 ± 2.4%) is around 2-fold larger than on collagen 
(24.4 ± 7.1%).  
 
More and larger FMHC
+
 myotubes are formed on Matrigel than on 
collagen (figure 3A), which confirms the results of the actin staining. 
Quantification of the number of fused nuclei and the size of the myotubes 
is presented in figure 3B. On Matrigel, 49.1 ± 1.6% of the nuclei are 
fused, while this is only 16.1 ± 6.3% on collagen. The number of large 
myotubes formed on Matrigel is up to 4-fold higher than on collagen 
(figure 3C).  
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Figure 2. Pax7, MyoD, and Myogenin fluorescent immunohistochemistry and 
quantification. A) Differentiating MPCs cultured on collagen-I and Matrigel coatings 
were stained for Pax7, MyoD, or Myogenin (all green) together with Actin (red) and 
DAPI (blue). B) Quantification of Pax7
+
, MyoD
+
, and Myogenin
+ 
cells (expressed as a 
mean ± SD) on collagen-I and Matrigel coatings.  Scalebar represents 50 µm. * 
significant difference between the collagen-I and Matrigel. 
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Figure 3. Fast Myosin Heavy Chain (FMHC) fluorescent immunohistochemistry 
and quantification. A) Differentiating MPCs cultured on collagen-I and Matrigel coatings 
were stained for FMHC (green) and DAPI (blue). B) Quantification of the number of 
fused cells (expressed as a mean ± SD) on collagen-I and Matrigel coatings. C) 
Quantification of the number of myofibers containing 3-6, 7-10, or >10 nuclei (expressed 
as a mean ± SD) on collagen-I and Matrigel coatings. Scalebar represents 50 µm. * 
significant difference between the collagen-I and Matrigel. 
 
7.3.3 3D-proliferation and differentiation 
Proliferating MPCs in the gels are stained for MyoD and actin, and the 
differentiating MPCs are stained for Myogenin, FMHC, and actin (figure 
4A). The gels of collagen contain only few proliferating MyoD
+
 cells 
whereas in the gels of Matrigel many MyoD
+
 cells are found. After 
differentiation, Myogenin
+
 cells are present in both gels and few of these 
cells have fused (arrows). In the gels of Matrigel more myotubes are 
found than in collagen, but in both gels they do express FMHC.  
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Figure 4. Fluorescent immunohistochemistry and qPCR of proliferating and 
differentiating MPCs in gels of collagen-I and Matrigel. A) Proliferating MPCs were 
stained for MyoD (green), Actin (red) and DAPI (blue). Differentiating MPCs were 
stained for MyoG or Myogenin together with Actin (red) and DAPI (blue). Gene 
expression of Pax7, MyoD, Myogenin, and Myosin Heave Chain (Myh)-1 of proliferating 
(B) and differentiating (C) MPCs in gels of collagen-I and Matrigel. Gene expression was 
expressed as 2
-∆Ct
. * significant difference between the collagen-I and Matrigel. Pictures 
were taken at a final magnification of 400x. 
Niche factors maintain satellite cell proliferation and differentiation in 2D & 3D cultures 
 159 
Morphologically, all the muscle cells and myotubes are rounded in the 
gels of collagen and more elongated in Matrigel. Since quantification of 
the immunostaining is very complicated, the mRNA levels of Pax7, 
MyoD, Myogenin, and Myh-1 was analyzed. When proliferating (figure 4 
B), low expression levels of Pax7 are found in both gels. In the gels of 
Matrigel, the expression of MyoD is 4-fold higher than in the collagen 
gels. Although Myogenin expression seems to be higher in the gels of 
Matrigel than in the collagen gels, this is not significant. Proliferating 
MPCs also express equal levels of Myh-1 in both gels. When 
differentiating (figure 4C), the muscle cells express very low levels of 
Pax7. The levels of MyoD and Myogenin expression are 3-4 times 
significant higher in the gels of Matrigel than in collagen. Myh-1 
expression is not significantly different between MPCs cultured in both 
gels. 
 
 
7.4 Discussion 
 
We showed that the presence of niche elements is crucial for the 
myogenic potential of MPCs. However, constructs for muscle 
regeneration that mimic the satellite cell niche are still lacking. On 
Matrigel coatings, Pax7 and MyoD are persistently expressed during 
proliferation, while this is reduced by half on collagen. Since Myogenin 
expression remains low on both coatings, the low number of Pax7
+
 and 
MyoD
+
 cells is not caused by early differentiation of the MPCs on 
collagen. On Matrigel, MPCs proliferate faster, but the percentage stays 
the same meaning that both cell populations divide evenly. Furthermore, 
differentiation of MPCs leads to more and larger myotubes on Matrigel 
than on collagen. These results indicate that MPCs lose their myogenic 
potential on collagen.  
In literature, such differences have not been reported up to now, and 
inconsistency exists in the effect of different ECM molecules on the 
behaviour of primary MPCs. Varying effects of ECM molecules on the 
myogenic capacity of MPCs have been reported.
28,30,36-38
 Overall, it seems 
that Matrigel and laminin have a positive effect. The dissimilarities 
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between these studies could be due to the fact that different animals, 
strains, isolation and culture protocols, and muscle cell-lines have been 
used. Two different mouse strains show a different fusion capacity of 
MPCs on Matrigel.
38
 However, we found no differences between MPCs 
isolated from Wistar or Sprague-Dawley rats (data not shown). With 
C2C12 myoblasts, hardly any differences were found in the myogenic 
capacity of these cells on collagen and Matrigel. Furthermore they were 
less efficient compared to MPCs (data not shown). Since earlier reports 
also show that differences exist in the response of myoblast cell-lines and 
MPCs,
38,39
 the results obtained with myoblast cell-lines should be 
carefully interpreted. Furthermore, different isolation protocols are used, 
probably yielding different populations of MPCs. Overall, this makes it 
difficult to compare the results.  
In none of these studies, the differentiation of MPCs in 3D gels of 
collagen and Matrigel were examined. We showed in the present study 
that MPCs have a higher myogenic capacity in the gels of Matrigel. 
Fluorescence immunostaining of whole gels shows that in the gels of 
Matrigel more MyoD
+
 and Myogenin
+
 cells are present during 
proliferation and differentiation, respectively. Quantification, as in the 
2D experiments was not possible due to difficulties in cell counting in 
3D. However, qPCR revealed that in Matrigel significantly higher MyoD 
and Myogenin levels are expressed during proliferation and 
differentiation, respectively. Although no differences were found in Myh-
1 expression, in the gels of Matrigel more myotubes are formed based on 
FMHC expression. Overall, MPCs show better myogenic potential when 
cultured with Matrigel than with collagen on both 2D-coatings and in 3D-
gels.  
This might be explained by the presence of several growth factors 
such as basic fibroblast growth factor (bFGF), insulin-like growth factor 
(IGF-I), platelet-derived growth factor (PDGF), and transforming growth 
factor (TGF)-β in Matrigel, which all exert effects on skeletal muscle 
regeneration in vivo.
15,40-42
 However, when growth factor-reduced 
Matrigel was used as a coating, similar results were obtained (data not 
shown). Furthermore, other in vitro studies showed that TGF-β, PDGF, 
IGF-I did not have any effect on the proliferation and differentiation 
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capacity of muscle cells.
38,43
 bFGF did have a positive effect on the 
proliferation, which was independent from the ECM.
38
 In the present 
study bFGF was already added to the culture medium of MPCs on both 
collagen and Matrigel, making the culturing conditions similar. 
Additionally, Matrigel contains very little PDGF and bFGF, and is 
probably not significant compared to literature. Thus the superior 
proliferation and differentiation of MPCs in Matrigel is probably not due 
to the growth factors, but to the ECM molecules present in Matrigel.  
The morphology of the myotubes on the 2D coatings, is more 
rounded without branching on collagen, while they are more elongated, 
wider, and branched on Matrigel. In the 3D gels, the myotubes were also 
small and rounded in collagen but elongated in Matrigel. These 
morphological differences suggest that the (fused) MPCs can attach to 
Matrigel, but not to collagen. Matrigel consist mainly of laminin-111 
(composed of α1, β1, γ1 chains) and collagen type IV. On the contrary, 
the basal membrane in the satellite cell niche contains laminin-211 and 
collagen type IV. Satellite cells attach to laminin-211 via the integrin 
α7β1 receptor, which is important for satellite cell functioning.44 The 
absence of integrin α7β1 and mutations in the laminin α2 chain also lead 
to congenital muscular dystrophy, which support their crucial role.
44,45
 
Integrin α7β1 can also bind to laminin-111 (present in Matrigel), and 
blocking it inhibits cell adhesion and migration.
46
 Furthermore, porcine 
MPCs express lower numbers of integrin α7β1 on collagen than on 
Matrigel.
30
 It has been suggested that after asymmetric division of the 
satellite cells, the daughter cell that stays in contact with the basal 
membrane remains quiescent, while the cell that loses contact 
differentiates and fuses with the existing myofiber.
11
 Thus the binding of 
integrin α7β1 to sites in Matrigel might preserve satellite cell proper ties 
of MPCs, but these are lost in collagen. The fact that laminin and 
collagen type IV alone are not as efficient as Matrigel
30
 suggest that 
combinations of niche factors might give better results. Furthermore, in 
the niche, the satellite cell binds to both the basal membrane via integrin 
α7β1 and to the myofiber (opposite to the basal membrane) via M-
cadherin expressed by both the satellite cell and the myofiber, which 
allows mutual binding.
3,44
 Thus, the addition of attachment sites for M-
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cadherin to the substrate might improve proliferation, differentiation and 
self-renewal capacities of isolated MPCs.  
In conclusion, our study shows that MPCs have a larger myogenic 
capacity with Matrigel than with collagen in both 2D-coatings and 3D-
gels. This might be related to the presence of integrin α7β1 binding sites 
in Matrigel but not in collagen. Matrigel contains elements of the satellite 
cell niche, which underscores the importance of including niche factors 
for culturing MPCs. For regenerative medicine purposes, constructs 
adequately mimicking the niche might improve muscle regeneration. 
Polymer constructs that contain laminin and collagen type IV and thus 
mimic the satellite cells niche might also offer new opportunities to treat 
skeletal muscle defects. 
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Abstract 
 
The restoration of muscles in the soft palate in cleft lip and/or palate 
patients is accompanied by fibrosis, which leads to speech and feeding 
problems. Treatment strategies that improve muscle regeneration and 
inhibit fibrosis have only been tested in limb muscles. Since differences 
exist between muscles from the head and limb, translation of these 
treatment strategies for head muscle injuries is needed. Therefore, the 
myogenic potential of muscle progenitor cells (MPCs) isolated from head 
and limb muscles is compared.  
MPCs were isolated from head and limb muscle of rats and cultured 
to induce proliferation and differentiation. The proliferation of MPCs was 
analysed by DNA quantification. The differentiation capacity was 
analysed by quantifying the numbers of fused cells, and by measuring the 
mRNA levels of several differentiation markers. Proliferating and 
differentiating MPCs were also stained to quantify Pax7, MyoD, and 
Myogenin expression. 
During proliferation the amount of DNA was similar in the head and 
limb MPC cultures indicating equal proliferation capabilities. 
Differentiating head and limb MPCs show a comparable number of fused 
cells and mRNA expression levels of Myh-1, -3 and -4. During 
proliferation and differentiation, the number of Pax7
+
, MyoD
+
, and 
Myogenin
+
 cells in head and limb MPCs did not differ. 
In conclusion, the head and limb MPCs show similar myogenic 
capacities. Therefore, the differences between those muscle groups rely 
on the local micro-environment and are not due to intrinsic differences in 
MPCs. The results of the treatment strategies for limb muscle injuries can 
also be used for head muscles. 
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8.1 Introduction 
 
Cleft lip and/or palate (CLP) is one of the most frequent congenital 
malformations in the facial area of man.
1
 About 45% of the CLP patients 
have a cleft in the soft palate, which consists mainly of muscle tissue.
2 
Normal functioning of these muscles is crucial for proper speech and 
feeding. The levator veli palatini (LVP) is the main muscle component of 
the soft palate required for speech and feeding.
3-5
 Surgical closure of the 
cleft in the soft palate aims to improve speech and feeding, but often 
these problems persist after surgery. The formation of scar tissue in the 
muscles of the soft palate, which also occurs after muscle injury in other 
muscles, is the most plausible cause of these problems.
6-8
 Scar tissue is 
also found after the repair of a cleft lip decreasing the function of the 
orbicular oris muscle.
9
 
The ability of skeletal muscle to regenerate itself through the action 
of satellite cells, is well established. Satellite cells are located between 
the sarcolemma and the basal lamina of the muscle fiber.
10,11
 After injury, 
these cells become activated and migrate to the site of injury, proliferate, 
differentiate, and fuse to form new myofibers or repair damaged ones. 
Eventually, the formation of scar tissue prevents complete muscle 
regeneration.
6-8,12
  
Several strategies have been evaluated to optimize and improve 
muscle regeneration. The injection of growth factors and transplantation 
of satellite cells or tissue engineered scaffolds have been used with 
varying results.
8,13-29
 These three approaches can also be combined to 
optimize treatment of muscle injuries. However, treatment with satellite 
cells still faces problems regarding their isolation and cell culture before 
and poor cell survival and limited migration after transplantation.
19,20,30,31
 
Eventually, these results can lead to optimized therapies for the 
regeneration of skeletal muscle, for example of the soft palate and lip 
after surgical closure.  
However, all studies were performed in muscles of the limb and not 
in muscles of the head, such as the soft palate. This is of importance since 
it was shown that muscles from the limbs and from the head differ. For 
example, limb muscles are derived from the somites, while the 
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brachiomeric muscles that control jaw movement, facial expression and 
pharyngeal and laryngeal function, are derived from the cranial paraxial 
mesoderm.
12,32
 During early myogenesis, Pax3, a marker for embryonic 
muscle stem cells, is only expressed in the limb muscles but not in the 
head muscles.
33
 Additionally, knocking out Pax3 in mice results only in 
the absence of limb muscles.
34,35
 It has also been shown that the 
associated satellite cells derive from separate genetic lineages and 
follows different genetic programs.
36,37
 These difference are retained in 
the myoblast progeny
38
 and also into adulthood.
39
 These developmental 
differences explain at least in part the unequal occurrence of muscle 
myopathies in different head and limb muscles.
40-44
 This might also 
explain that head muscles such as the musculus masseter regenerate 
worse than limb muscles.
45 
 
All these data indicate that dissimilarities exist in the satellite cells 
from head and limb muscles, and that they may react differently to 
muscle injury and disease. This makes it important to characterize the 
myogenic potential of satellite cells from head muscles after isolation. 
This will provide a basis for proper translation of the results from the 
limb muscle regeneration studies to specific treatment strategies for 
regenerating head muscles such as the soft palate. Therefore, the aim of 
this study is to compare the myogenic potential of muscle progenitor cells 
(MPCs) isolated from head and limb muscles.  
 
 
8.2 Materials and methods  
 
8.2.1 Muscle progenitor cell isolation 
MPCs were isolated from the hind limb muscles and musculus masseter 
of 5-week-old male Sprague-Dawley rats (Janvier, Le Genest, France). 
The dissected muscles were minced in phosphate-buffered-saline (PBS) 
containing 5 µg/ml Amphotericine B (Sigma Chemical CO, St Louis, 
MO, USA) using scissors, and excessive fat and tendon were removed. 
Minced tissue fragments were incubated in 2% (w/v) Collagenase type II 
(Invitrogen HQ, San Diego, CA, USA) in Dulbecco’s Modified Eagle’s 
Medium-High Glucose (DMEM-HG; Invitrogen) for 1 hour at 37°C. 
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Tissues were further homogenized by trituration using 10 ml pipettes and 
filtered through a 100 µm cell strainer to obtain single cell suspensions. 
The cell suspensions were incubated in hypotonic buffer (0.1 mM EDTA; 
0.15 M NH4Cl; 10 mM KHCO3, pH 7.4) for 1.5 minutes to lyse the 
erythrocytes. The remaining cells were centrifuged (5 minutes at 300g) 
and resuspended in 15 ml proliferation medium: DMEM-HG containing 
20% fetal bovine serum (FBS), 2% penicillin-streptomycin (p/s), 1 mM 
pyruvate, and 5 ng/ml bFGF (all from Invitrogen). To remove fast -
adhering fibroblasts, the cells were incubated in uncoated culture flasks 
for 1 hour (37°C, 5% CO2). Non-adhering cells were then transferred to 
tissue cultured flasks coated with 1 mg/ml Matrigel (Matrigel
TM
 
Basement Membrane Matrix, BD Bioscience, Bedbord, MA, USA), and 
cultured for 4 days (37°C, 5% CO2). Proliferation medium was refreshed 
every day. After 4 days, MPCs were significantly enriched up to 50% 
according to Pax7 expression. MPCs from 4 rats were pooled to create 
one batch. 
 
8.2.2 Proliferation and differentiation of muscle progenitor cells 
Three batches of enriched MPCs were used for the proliferation and 
differentiation experiments. For the proliferation experiments, 24-wells 
plates and Lumox dishes (Ø 35 mm; both Greiner Bio-One, 
Frickenhausen, Germany) were coated with 1 ml (1 mg/ml) Matrigel for 1 
hour at 37°C. In the 24-wells plate, enriched MPCs were plated at a 
density of 10.000 cells/well and cultured in proliferation medium for 1, 2 
and 3 days. In the Matrigel-coated Lumox dishes, 50.000 enriched MPCs 
were seeded and cultured in proliferation medium for one and three days. 
For the differentiation experiments, enriched MPCs were seeded at a 
density of 500.000 cells in the Matrigel-coated Lumox dishes. Cells were 
cultured for 1 day in proliferation medium and then in differentiation 
medium: DMEM-HG containing 2% fetal FBS, 1 mM pyruvate, and 2% 
p/s to induce fusion for 1 and 2 additional days. After the experiments, 
the MPCs were analyzed by DNA quantification, immunofluorescence 
staining, and quantitative PCR. 
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8.2.3 DNA quantification 
Cell proliferation of the enriched MPCs was measured using the 
PicoGreen dsDNA Quantification assay (Molecular Probes, Eugene, OR, 
USA). At the appropriate time points, the cells were lysed in 0.1% (v/v) 
Triton X-100 in PBS and subjected to three freeze and thaw cycles. Lysed 
cells were processed according to the manufactures protocol. 
Fluorescence was measured in a FL600 Microplate Fluorescent Reader 
(Bio-Tek Instruments Inc., Winooski, VT, USA) at excitation 485 nm and 
emission 520 nm. The amount of DNA was calculated using a standard 
curve ranging from 0 to 15000 cells.  
 
8.2.4 Immunofluorescence staining 
After the experiments, the enriched MPCs were washed with PBS and 
fixed in 4% formaldehyde in PBS for 15 minutes. After washing with 
PBS, the membranes of the Lumox dishes were cut into 5 pieces and the 
attached cells were permeabilized with 0.5% Triton X-100 in PBS for 20 
minutes. The cells were washed with 0.05% (v/v) Tween-20 in PBS, and 
then incubated in blocking buffer containing 2% (w/v) bovine serum 
albumin (BSA), 2% (v/v) normal goat serum (NGS), 0.1% (v/v) Triton X-
100, 0.05% (v/v) Tween-20, and 100 mM glycine in PBS for 30 minutes. 
Then, the cells were incubated with a mouse anti-Pax7 (1:25; 
Developmental Studies Hybridoma Bank, Iowa City, CA, USA), mouse 
anti-MyoD (1:25; DAKO, Dakopatts, Glostrup, Denmark), and mouse 
anti-Myogenin (F5D, 1:100; Developmental Studies Hybridoma Bank) in 
blocking buffer without glycine for 1 hour. For the proliferation 
experiments, the bound antibodies were visualized with AlexaFluor-488-
labeled goat anti-mouse IgG (H+L) (1:200; Molecular Probes). For the 
differentiation experiments, the bound antibodies were visualized with 
AlexaFluor-488-labeled goat anti-mouse IgG (H+L) (1:200; Molecular 
Probes) combined with Texas Red-X Phalloidin (1:250; Molecular 
Probes) to stain the actin filaments. The cells were visualized with a 
Zeiss Imager.Z1 microscope and photographed. 
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8.2.5 Quantification 
The number of Pax7
+
, MyoD
+
, and Myogenin
+
, and fused (DAPI) cells in 
the enriched MPC cultures were calculated using 8 different 
representative fields of all immunostainings (N=3 batches). All the 
results were expressed as a mean percentage ± SD of the total number of 
cells.  
 
8.2.6 Quantitative PCR 
The cells were washed with PBS and homogenized with 1 ml Trizol 
(Invitrogen). Then 200 µl chloroform (Sigma) was added, mixed, and 
centrifuged for 20 minutes at 4ºC. The water phase containing the RNA 
was mixed with 70% ethanol (1:1), and RNA was extracted according to 
the manufacturer’s protocol (Qiagen, Hilden, Germany) including a 
DNase I treatment. cDNA was generated with 1 µg RNA using the 
iScriptTM Reverse Transcriptase system (Bio-Rad, Hercules, CA, USA) 
according to the manufacturer’s protocol. Quantitative real-time PCR was 
performed in a final volume of 25 µl containing 12.5 µl SYBR®Green 
Supermix (Bio-Rad), 5 µl (40x diluted) cDNA, 4.5 µl RNAse-free water, 
1.5 µl 2.5M forward primer, and 1.5 µl 2.5M reverse primer. The primers 
for β-actin, Pax3, Pax7, MyoD, Myogenin, Myh-1, Myh-2, Myh-3, Myh-
4, and Myh-8 were obtained from Biolegio (Nijmegen, The Netherlands) 
and the primer sequences are provided in table 1.  
 
Table 1. Primer sequences. 
 
Gene 
 
Forward primer Reverse primer 
β-actin TTCAACACCCCAGCCATGT TGTGGTACGACCAGAGGCATAC 
Pax3 CTTTCACCTCAGGTAATGGGA TCTTCATGTGCTCCAATCTC 
Pax7 AGCCGAGTGCTCAGAATCAA TCCTCTCGAAAGCCTTCTCC 
MyoD CGACTGCCTGTCCAGCATAG GGACACTGAGGGGTGGAGTC 
Myogenin AACCCAGGAGATCATTTGCT GGTGACAGACATATCCTCCA 
Myh-1 CCTGGATGATCTACACCTACTC GTCAGAGATAGAGAAGATGTGGG 
Myh-2 CGAGACATATCTGCTAGAGAAG GTAATCGTATGGGTTTGTGGT 
Myh-3 CTGGATGATCTACACCTATTCAG CAGAGATGGAGAAGATGTGG 
Myh-4 GTCTTCTCCATGAACCCTCC CCCGAATAAGTGTAGATCATCC 
Myh-8 GAAACCTTGAGAAGATGTGCC AATACTCTCCTGCTTCTGTCTG 
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The cDNA was amplified in the C1000 Thermal Cycler (Bio-Rad) and 
fluorescence was analyzed using the CFX96TM Real-Time System (Bio-
Rad). The PCR conditions were 95ºC for 3 minutes (1 cycle), 95ºC for 15 
seconds and 60ºC for 30 seconds (39 cycles), and finally a temperature 
increase starting at 65ºC to 95ºC with 0.5ºC intervals. RNA expression 
was normalized against the mRNA level of β-actin (∆Ct) and presented as  
2
-∆Ct
. 
 
8.2.7 Statistical analysis 
All the results were tested for significance at every single time-point (p < 
0.05) using a Two-Way ANOVA with Holm-Sidak post-hoc analysis. The 
results of the Quantitative PCR were only normally distributed after log 
transformation. 
 
 
8.3 Results 
 
8.3.1 Cell density of proliferating head and limb muscle progenitor 
cells (MPC) 
Enriched MPCs isolated from M. masseter (head MPCs) and hindlimb 
muscles (limb MPCs) were cultured for three days. In time, head and 
limb MPCs proliferated, and quantification of their numbers reveal a 
significant 5-fold increase of both head and limb  MPCs within three days 
(figure 1). Overall, the numbers of head MPCs are always higher than the 
limb MPCs and the main differences are found at the first two days, but 
this is not statistically significant. 
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Figure 1. DNA quantification. Quantification of the number (B; expressed as mean ± 
SD) of proliferating head and limb MPCs after 1, 2, and 3 days. 
 
8.3.2 Pax7, MyoD, and Myogenin in proliferating head and limb MPCs 
After an enrichment step, the head and limb MPCs proliferated for one 
and three additional days and were stained to identify Pax7, MyoD and 
Myogenin expression (figure 2A). In time the total number of cells 
together with the numbers of Pax7
+
 and MyoD
+
 cells increased in both 
MPC cultures. Only low numbers of Myogenin
+
 cells are found within 
the cultures of both the head and limb MPCs.   
Quantification of the relative numbers of Pax7
+
, MyoD
+
, and 
Myogenin
+
 cells are shown in figure 2B and C.  After one day of 
proliferation, 62.2 ± 4.2% and 63.6 ± 8.2% of the cells in the limb MPC 
cultures are positive for Pax7 and MyoD, respectively. In the head MPC 
cultures, these numbers are slightly higher for Pax7 at 67.7 ± 4.0% and 
for MyoD at 68.9 ± 4.3%. The number of Myogenin
+
 cells is significantly 
lower in both the head MPC (4.9 ± 1.9%) and limb MPC (3.2 ± 0.5%) 
cultures.  
After three days of culture the numbers of Pax7
+
 and MyoD
+
 cells 
are decreased, but the number of Myogenin
+
 cells is increased. The 
number of Pax7
+
 cells decreased in the head and limb MPC cultures to 
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36.7 ± 5.6% and 40.2 ± 10.9%, respectively. The number of MyoD
+
 cells 
also decreased in the limb MPC cultures to 44.9 ± 6.9%, but only slightly 
in the head MPC cultures to 61.0 + 14.1%. The number of Myogenin
+
 
cells increased in the limb MPC cultures to 8.8 ± 3.3% and even more in 
the head MPC cultures to 21.5 ± 8.6%. Although the numbers of Pax7
+
, 
MyoD
+
, and Myogenin
+
 cells are always higher in the head MPC 
cultures, this was not significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Pax7, MyoD, and Myogenin fluorescent immunohistochemistry and 
quantification. A) Proliferating head and limb MPCs were stained for Pax7, MyoD, or 
Myogenin (all green) and DAPI (blue). Quantification of Pax7
+
, MyoD
+
, and Myogenin
+
 
cells (expressed as a mean ± SD) in the head and limb MPC cultures after one (B) and 
three (C) days of proliferation. Scalebar represents 100 µm. 
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8.3.3 Pax7, MyoD, and Myogenin in differentiating head and limb 
MPCs 
MPCs were stained for Pax7, MyoD, Myogenin, and actin filaments after 
one and two days of differentiation (figure 3A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Pax7, MyoD, and Myogenin fluorescent immunohistochemistry and 
quantification. A) Differentiating head and limb MPCs were stained for Pax7, MyoD, or 
Myogenin (all green) together with Actin (red) and DAPI (blue). Quantification of Pax7
+
, 
MyoD
+
, Myogenin
+
, and fused cells (expressed as a mean ± SD) in the head and limb 
MPC cultures after one (B) and two (C) days of differentiation. Scalebar represents 100 
µm. 
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The head and limb MPCs already form myotubes after one day of 
differentiation, which increased in time. In comparison to the 
proliferation phase, the number of Pax7
+
 cells dropped, the number 
MyoD
+
 cells maintained, and the number of Myogenin
+
 cells increased 
during the differentiation of both the head and limb MPCs. None of the 
Pax7
+
 cells seem to be within the myotubes, but most of the fused cells 
are positive for MyoD and Myogenin. 
Quantification of the relative numbers of Pax7
+
, MyoD
+
, Myogenin
+
, 
and fused cells are presented in figure 3B and C. Also during 
differentiation the head MPCs show more Pax7
+
, MyoD
+
, Myogenin
+
, 
and fused cells, but also now this is not significant. Specifically, after one 
day of differentiation the numbers of Pax7
+
, MyoD
+
, and Myogenin
+
 cells 
are 14.0 ± 2.7%, 51.1 ± 3.6%, and 49.4 ± 5.7%, respectively, for the limb 
MPCs. These numbers are higher in the head MPCs for Pax7 (15.9 ± 
5.0%), MyoD (54.9 ± 5.5%), and Myogenin (59.3 ± 4.4%). After two 
days of differentiation, the number of Pax7
+
 cells decreased to 6.6 ± 
0.8%, while the numbers of MyoD (51.9 ± 2.8%) and Myogenin 49.8 ± 
2.1%) did not change in the limb MPCs. In the head MPCs, the numbers 
of Pax7
+
 and Myogenin
+
 cells decreased to 10.2 ± 4.5% and 55.3 ± 5.7% , 
while the number MyoD
+
 cells increased to 61.2 ± 5.7%. 
The numbers of fused cells are 8.7 ± 2.1% for limb MPCs and 
slightly higher at 13.4 ± 3.2% for head MPCs after one day of 
differentiation. After two days of differentiation, these numbers 
significantly increased to 34.3 ± 4.9% for limb MPCs and again slightly 
higher to 41.6 ± 3.8% for head MPCs.  
 
8.3.4 Quantitative PCR in differentiating head and limb MPCs 
Of the differentiating MPCs, the mRNA levels of Pax3, Pax7, MyoD, 
Myogenin, Myh-1, Myh-2, Myh-3, Myh-4, and Myh-8 were also 
analyzed (figure 4). The expression levels of Pax3, Pax7, Myh-2, and 
Myh-8 are extremely low and can therefore not be quantified. After one 
day, low levels of MyoD and high levels of Myogenin are expressed. In 
the limb MPCs the expression of MyoD is higher while the expression of 
Myogenin is lower compared to the head MPCs. The fusion markers, 
Myh-1, -3, and -4 are expressed in both head and limb MPCs, but there is 
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a trend of higher expression in the limb MPCs. After two days, MyoD 
expression diminished in the limb MPCs while it did not change in the 
head MPCs. Myogenin expression decreased, but all the fusion markers 
Myh-1, -3, -4, -8 increased two- or three-fold in both the head and limb 
MPCs. Now there is a trend of higher expression of these markers in the 
head MPCs. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. qPCR of differentiating head and limb MPCs. Gene expression of Pax3, 
Pax7, MyoD, Myogenin, Myh-1, Myh-2, Myh-3, Myh-4, Myh-8 in head and limb MPC 
cultures after one (A) and two (B) days of differentiation. Gene expression was expressed 
as 2
-∆Ct
. 
 
 
8.4 Discussion 
 
The aim of this study was to provide a basis for translating the results of 
regeneration studies in limb muscles towards a therapy for head muscle 
injuries. Since it has been shown that satellite cells from these muscle 
groups originate from separate genetic lineages, and follow different 
genetic programs in vivo,
36,37
 we investigated their myogenic potential 
after isolation. We show that enriched MPCs from head and limb muscles 
are similarly efficient in their proliferation and differentiation capacity. 
During proliferation and differentiation the numbers of Pax7
+
, MyoD
+
, 
Myogenin
+
, and fused cells are not signifanctly different in the head and 
limb MPC cultures. Furthermore, the expression of fusion genes Myh-1, -
3 and -4 are also comparable between MPCs from head and limb muscles. 
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Therefore, the proliferation and differentiation potential is very similar 
for both types of muscle satellite cells. 
In contrast, recent research showed that, after isolation, MPCs of 
head and limb muscles do differ in their myogenic capacity.
38
 They found 
that head MPCs form myofibers at a slower rate than limb MPCs. This 
reflects the observation that the M. masseter regenerates worse than limb 
muscles.
45
 The difference between the results of this study and our results 
might be due to the different isolation protocol. Our protocol leads to a 
bulk of enriched MPCs, while Ono et al.
38
 first isolate single myofibers 
before liberating the MPCs. This might result in a higher purity of MPC 
cultures that are isolated directly from the satellite cell niche, which 
resembles the in vivo situation more closely. Our MPCs were isolated 
earlier from their niche and probably already started to adapt to the 
culture conditions.  
Muscle regeneration is different between different muscle groups. 
For example, the M. masseter regenerates worse than tibialis anterior 
muscles.
45
 Since muscle regeneration depends on many factors in the 
micro-environment such as the inflammatory response and growth 
factors,
7,46
 this might be different in head and limb muscles. For example, 
a mouse strain showing slower muscle regeneration has less FGF-2 
expression and a reduced inflammatory response.
47,48
  
This indicates that the micro-environment, and specifically the niche 
of the (activated) satellite cells plays a crucial role in their regeneration 
capacity. In our protocol, MPCs are immediately taken out of their niche 
and are therefore lack these instructing factors. Furthermore, it has been 
shown that differentiating MPCs isolated from extraocular muscles also 
do not express their specific myosin heavy chain markers in vitro. When 
injected into a hind limb muscle, they formed new muscle tissue and 
generated satellite cells, but also without their original specific markers 
(36). Additionally, transplantation of head satellite cells into a limb host 
muscle showed muscle regeneration with the same efficiency as 
transplanted limb satellite cells.
38
 It has also been found that in both head 
and limb muscles, Pax7
+
 satellite cells appear after embryogenesis.
49
 All 
these data imply that satellite cells throughout the entire body can follow 
a similar differentiation program, depending on the micro-environment. 
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The variation in the micro-environment might explain the different 
regeneration capacities of the various muscle groups. 
 
 
8.5 Conclusion 
 
Our study shows that MPCs isolated from head and limb muscles have 
similar myogenic capacities. This shows that in the absence of niche and 
micro-environmental factors in vitro, MPCs follow a similar 
differentiation program. We conclude that regeneration strategies for 
limb muscles can also be used for head muscles. However, the 
modulation of the micro-environment in the head area is of utmost 
importance for proper regeneration. Those micro-environmental cues that 
apparently differ between  head and limb require further investigation. 
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9.1 Introduction 
 
The main goal of skeletal muscle engineering is the treatment of a wide 
variety of muscle defects and diseases. Three different approaches have 
been used to improve muscle regeneration; growth factor-, cell-, and 
scaffold-based therapies, or combinations of these. For the treatment of 
large muscle defects such as the soft palate in cleft palate (CLP) patients, 
three-dimensional scaffolds are needed. Therefore, we focused on 
improving muscle regeneration using scaffold-based approaches in full-
thickness muscle defects. Specifically, our aims were: 
 
1. To develop new fibrosis models to study the effect of implanted 
scaffolds on muscle regeneration (chapters 4 & 5).  
2. To test scaffolds loaded with growth factors for their ability to 
 improve muscle regeneration and to inhibit fibrosis (chapters 5 & 
 6). 
3. To develop a 3D culture system for satellite cells to analyze the
 effects of ECM components on their myogenic capacity (chapter 7). 
4. To compare the myogenic capacity of satellite cells derived from a 
 limb and a craniofacial muscle (chapter 8).  
 
In the next sections, the results of these studies are discussed in a wider 
perspective. Specifically, the focus is on the requirements of the scaffolds 
and on the use of in vitro culture systems for satellite cells to improve 
muscle regeneration. 
 
 
9.2 Scaffolds in muscle regeneration 
 
In order to test scaffolds in full-thickness defects leading to fibrotic 
lesions such as in muscle trauma and in clefts of the soft palate, a new 
fibrosis model was required. The M. soleus in rats was used since the 
myofibers are perfectly aligned, which allows the study of the orientation 
and continuity of regenerating myofibers (chapter 4).
1
 Our full-thickness 
wound model represents large muscle defects that spontaneously develop 
Chapter 9 
 190 
fibrotic lesions (chapter 5). Furthermore, this model enabled us to 
implant scaffolds into the defect without sutures. In conclusion, the M. 
soleus model presented in this study provides a solid base to test 
scaffolds that aim to improve muscle regeneration and to inhibit fibrosis. 
A limitation of our study is that we were unable to perform functional 
testing of the regenerated muscle because of lacking equipment. It has 
been shown recently that muscle defects with large fibrotic lesions 
significantly reduce muscle function.
2
 Thus, we infer that, in our fibrosis 
model, muscle function is also severely impaired. Still, this should be 
confirmed in future studies. When experimental therapeutic interventions 
show improvement on histological basis, it becomes crucial to test 
muscle function to draw definite conclusions.  
Scaffolds that are being used in tissue engineering in general and 
specifically for muscle regeneration require certain characteristics. They 
should be biocompatible to prevent an extensive immune response and 
biodegradable in order to be replaced by host muscle tissue. Furthermore, 
the scaffolds should stimulate adhesion, proliferation, and differentiation 
of satellite cells. Collagens are the main extracellular matrix (ECM) 
molecules in the human body, and collagen type I is used widely in 
muscle engineering.
3-6
 More importantly, collagen type I can be used to 
generate biodegradable and porous scaffolds, which provide structural 
integrity and can serve as a reservoir for growth factors to attract cells 
(this thesis).
7
 Such collagen scaffolds can also be crosslinked to reduce 
degradation. These crosslinked collagen scaffolds can be used to mimic 
fibrotic tissue after implantation into the muscle, and enables us to 
investigate treatment modalities aimed at reducing existing fibrosis as in 
recurrent muscle strain injuries (chapter 4). However, we subsequently 
focused on a muscle model with spontaneous fibrosis to test non-
crosslinked collagen type I scaffolds for the prevention of fibrosis 
(chapters 5 and 6). 
Two different approaches with such non-crosslinked collagen 
scaffolds can be followed. They can either act as a carrier for isolated 
satellite cells, or they can be modified to stimulate the endogenous 
satellite cells. It is still uncertain whether the first approach is feasible, 
because of major drawbacks. Firstly, muscle biopsies, creating new 
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injuries, have to be made for the isolation of autologous satellite cells. 
Secondly, to obtain sufficient cell numbers, satellite cells need to be 
cultured, which is expensive and laborious. More importantly, in vitro 
culture is detrimental for the myogenic capacity of satellite cells.
8,9
 
Thirdly, their migration and survival after transplantation is low.
10,11
 This 
makes the use of satellite cells inefficient, and research should be aimed 
to overcome these problems. The migration and survival of transplanted 
satellite cells can be improved by loading the scaffolds with growth 
factors.
12
 Growth factors can also be used to attract resident satellite cells 
to avoid the problems associated with cultured satellite cells. 
Furthermore, growth factor-loaded scaffolds can be used off-the-shelf, 
and implanted directly into the defect during the surgery of for example 
CLP patients.  
In our muscle fibrosis model, we showed that collagen scaffolds 
loaded with SDF-1α stimulates the migration of satellite cells towards the 
regenerative zone around the defect (chapter 5). However, the satellite 
cells were unable to migrate into the scaffold. Possibly, the SDF-1α is 
already lost when the satellite cells reach the regenerative zone or the 
scaffold does not allow attachment and migration of these cells. These 
problems need to be overcome, which is discussed in the following 
sections. Eventually, the regeneration process may further be improved 
when SDF-1α is used in combination with other growth factors such as 
HGF and IGF-I that stimulate the proliferation and differentiation of the 
migrated satellite cells. However, loading the scaffolds with SDF-1α did 
not reduce fibrosis. Thus, increasing the numbers and the function of 
satellite cells is not enough to prevent fibrosis. TGF-β is the main factor 
involved in fibrosis in many tissues including skeletal muscle ,
13-15
 and 
inhibition of its activity is supposed to diminish fibrosis. We used 
decorin, which consist of a core protein, containing two binding sites for 
TGF-β, and a dermatan/chondroitin sulfate chain.16,17 Inhibition of TGF-β 
activity by decorin reduced fibrosis in many organ systems, but also in 
skeletal muscle.
14,18-21
 However, in our model decorin alone or together 
with SDF-1α did not reduce fibrosis (chapter 6). Possibly, decorin is 
already released before the anti-fibrotic effect can take place. As 
mentioned, SDF-1α did not induce the migration of satellite cells into the 
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scaffolds. These studies indicate that the release profile of (growth) 
factors is crucial. New strategies are being investigated to develop 
timely-tuned release of factors from the scaffolds. Using microspheres it 
is possible to control the release of such factors.
22,23
 With specific 
microspheres for each (growth) factor, the release of factors in a specific 
order and at the appropriate time points during muscle regeneration can 
be achieved. Furthermore, alginate-, gelatin-, and fibrin-based hydrogels 
can also induce a sustained release of factors without the use of 
microspheres, and might be combined with synthetic polymers to provide 
more mechanical strength.
24-28
 
The inability of satellite cells to migrate into the scaffold could also 
be caused by the type of scaffold material. In vivo, satellite cells attach to 
the basal lamina via the laminin receptor integrin α7β1, and to the 
myofiber via M-cadherin. Isolated satellite cells cultured in collagen type 
I gels lose their myogenic potential (chapter 7). More importantly, fused 
myofibers show a rounded phenotype indicating that collagen type I does 
not contain appropriate binding sites. This may cause the inability of 
satellite cells to migrate into the collagen scaffold after implantation. In 
matrigel, which contains laminin, satellite cells retain their differentiation 
capacity and form elongated myofibers. In vivo, the laminin and myofiber 
binding sites in the niche are on opposite sides of the satellite cell, which 
appears to be important for asymmetric self-renewal.
29,30
 This indicates 
that niche factors, and their bipolar orientation is crucial for satellite cell 
adhesion, proliferation, differentiation, and self-renewal. Thus, scaffolds 
containing binding sites for M-cadherin and integrin α7β1 should be 
created for proper satellite cell functioning and self-renewal. The binding 
site for integrin α7β1 lies within the G1-G3 domain of the E8 region of 
laminin.
31
 Although in muscle laminin-2 and -4 are predominantly 
present, satellite cells are also able to bind to laminin-1.
32
 Recently, it has 
been shown that laminin-1 can be incorporated into polymer substrates, 
which could provide binding sites for the satellite cells.
33
  
In our muscle fibrosis model, regenerating muscle fibers are also not 
able to align with the existing myofibers. Such alignment is crucial for 
coordinated contraction of all myofibers and thus for full muscle 
function. Therefore, the scaffold should also contain structural cues to 
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induce proper alignment of the regenerating myofibers. The use of 
polymers offers new opportunities to generate reproducible scaffolds with 
specific porosity, and fiber thickness and orientation that could be 
promising for skeletal muscle tissue engineering.
34,35
 Furthermore, 
biomechanical conditioning of cell-seeded scaffolds might improve the 
alignment of myofibers even more.
36,37
 
The translation of these results towards a therapy for large muscle 
defects and clefts in the soft palate will require much more research. In 
the study described here, we report that satellite cells derived from a limb 
and a craniofacial muscle show similar differentiation capacities, and that 
the environment is crucial for satellite cell functioning. New muscle 
fibrosis models should be developed for specific conditions such as clefts 
of the soft palate in rats to further optimize the scaffold-based approach.  
 
In conclusion, bioactive scaffolds that stimulate endogenous satellite 
cells abolish the need for cultured satellite cells, and might be the best 
solution for skeletal muscle tissue engineering. However, it will be 
challenging to develop appropriate bioactive scaffolds that 1) mimic the 
bipolar satellite cell niche, 2) induce timely-tuned release of factors that 
stimulate satellite cells and inhibit fibrosis, and 3) contain structural cues 
forcing the regenerating myofibers into alignment. 
 
 
9.3 Cultured muscle progenitor cells in muscle regeneration 
 
To develop bioactive scaffolds for in vivo implantation, specific in vitro 
cell culture systems are required to identify suitable niche factors and 
growth factors. In addition, isolated muscle cells can also be included in 
the scaffolds. First satellite cells, or muscle progenitor cells (MPCs), 
need to be isolated. Since many different protocols are being used that 
lead to different cell populations, it is difficult to compare the results. 
Enzymatic digestion and trituration of skeletal muscle tissue will result in 
single cell suspensions containing the satellite cells, and other cell types 
such as fibroblasts and endothelial cells. Based upon their adhesive 
properties, fibroblasts can be removed, and satellite cells can then be 
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enriched by pre-plating (chapter 7).
5,38,39
 Furthermore, different 
populations of muscle stem cells such as satellite cells and a more 
enriched population of late-adherent muscle-derived stem cells can be 
obtained using the pre-plating technique.
5
 Alternatively, FACS isolation 
can produce a highly enriched population of satellite cells, but with a low 
yield. Two different satellite cell populations have been isolated 
according to CXCR4 and integrin β1 expression ,40,41 and integrin α7 and 
CD
34
 expression.
42
 A disadvantage of generating single cell suspensions 
is the absence of the satellite cell niche during isolation. This could lead 
to the partial loss of their myogenic capacity. Isolated MPCs from limb 
and craniofacial muscle show a similar differentiation capacity in vitro 
although clear differences in regeneration exist in vivo (chapter 8). 
Therefore the presence of niche factors is important to maintain satellite 
cell properties. Single myofibers with satellite cells residing in their 
physiological niche can also be isolated from muscle tissue. From these 
myofibers, satellite cells can be liberated by trituration or by culture.
43
  
For our purpose, the optimization of scaffolds for large tissue 
defects, two isolation methods might be useful 1) enriched MPCs from 
which fast-adhering fibroblast are removed (chapter 7) and 2) single 
myofibers with satellite cells. High numbers of satellite cells are needed 
to optimize the scaffolds regarding the addition of appropriate ECM 
molecules and structural cues to induce myofiber alignment. Therefore, 
enriched MPCs, as studied in this thesis, are the cells of choice. This 
results in large numbers of 50-60% Pax7
+
 MPCs that form functional 
myofibers within two days. Our study also showed that laminin is crucial 
for adhesion and maintenance of the differentiation capacity (chapter 7). 
To identify growth factors that are able to induce proliferation and 
differentiation of resident satellite cells, and migration into the scaffolds, 
satellite cells need to be in their physiological niche after isolation. For 
these experiments, single myofibers should therefore be used. 
Furthermore, isolated myofibers are also crucial to study satellite cell 
biology during migration, activation, proliferation, and 
differentiation.
44,45
 Eventually, these experiments should lead to optimal 
scaffolds for in vivo implantation into muscle defects.  
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Another lack in the current knowledge is the specific in vitro 
conditions that maintain satellite cell self-renewal to obtain large 
numbers of cells. Further, the techniques to obtain functionally mature 
and aligned myofibers to construct muscle substitutes are also lacking. 
Future research should aim to identify specific ECM molecules that 
regulate satellite cell functioning, and to develop constructs that mimic 
the in vivo bipolar satellite cell niche. Furthermore, substrate stiffness 
and mechanical force have been shown to influence satellite cell 
behavior, and mature myofiber formation and orientation.
36,37,46-50
 A 
practical problem is that for transplantation, the cells must be cultured in 
serum-free medium. The identification of specific growth factors is 
essential to optimize satellite cell cultures without using serum.
51
 For the 
above, pure populations of satellite cells, isolated based on specific 
marker expression, are needed.  
In summary, two crucial protocols should be developed that 1) yield 
large numbers of satellite cells maintaining their myogenic potential, and 
2) generate muscle substitutes with mature and functional aligned muscle 
fibers. For the latter, however, blood vessels also need to be engineered 
to provide nutrients and oxygen after transplantation. This is an 
additional challenge to the field of muscle engineering. 
 
 
9.4 Conclusions 
 
Skeletal muscle engineering will significantly contribute to the repair of 
muscle defects by developing suitable scaffolds and in vitro culture 
systems for satellite cells. We developed a suitable model for 
spontaneous muscle fibrosis to test such scaffolds. In the studies 
described here, we show that scaffolds with growth factors are  promising 
to attract endogenous satellite cells towards the defect. However, it also 
became clear that inhibition of fibrosis is crucial to obtain functional 
muscle regeneration. Using isolated satellite cells we showed that 
elements of the satellite cell niche should be incorporated into the 
scaffolds to maintain their stem cell properties. In the future, the use of 
isolated satellite cells and/or myofibers will lead to the development of 
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smart scaffolds. Eventually, these smart scaffolds will eliminate the use 
of isolated satellite cells because they induce the endogenous satellite 
cells to migrate into the defect and form aligned myofibers. 
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In chapter 1, the background and rationale of the study is explained. The 
field of skeletal muscle engineering together with strategies to improve 
muscle regeneration is introduced and the outline of the study is 
presented. The aim of the present study was to improve muscle 
regeneration and to inhibit fibrosis in full-thickness muscle defects using 
scaffold-based approaches. 
Chapters 2 and 3 present an overview of the biological aspects of 
skeletal muscle development and regeneration with the main focus on 
satellite cells. Satellite cells regenerate the muscle tissue by migrating to 
the site of injury where they proliferate, differentiate, and form 
myofibers. The specific micro-environment of the satellite cells, the 
niche, controls satellite cell behavior. In addition, a large diversity of 
growth factors regulates satellite cell activity after injury. Since the 
formation of scar tissue can prevent the recovery of full muscle function, 
three different approaches to improve muscle regeneration and to inhibit 
fibrosis are discussed: growth factor-, cell-, and scaffold-based therapies. 
For large muscle defects mainly the scaffolds-based approach is suitable, 
which is the focus in the next studies.   
In chapter 4 an in vivo model for muscle regeneration in recurrent 
strain injury is established. The results showed that satellite cell 
activation around the defect, revealed by Pax7 and MyoD expression, 
was not affected by the implantation of a cross-linked collagen scaffold 
in the lacerated M. soleus. However, these cells were absent inside the 
scaffold and muscle regeneration inside the defect was impaired. It was 
concluded that the implantation of a cross-linked collagen scaffold into 
the lacerated M. soleus mimics a muscle discontinuity caused by a 
fibrotic wedge and can be used to evaluate new treatment modalities for 
recurrent strain injuries.  
A new wound model that mimics full-thickness muscle defects and 
induces spontaneous fibrosis is described in chapter 5. By loading non 
cross-linked collagen scaffolds with SDF-1α, an attempt was made to 
improve muscle regeneration. The results showed that in this model a 
significant amount of fibrotic tissue was formed. The implantation of 
SDF-1α-loaded collagen scaffolds induced migration of Pax7+ satellite 
cells towards the regenerative zone around the wounds within the first ten 
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days post-surgery. However, these cells did not enter the scaffold and the 
numbers of myofibroblasts and collagen deposition were not affected 
after 56 days. In conclusion, this spontaneous muscle fibrosis model can 
be used to test scaffold-based therapies. Loading scaffolds with SDF-1α 
induced satellite cell migration but did not reduce fibrosis.  
In chapter 6 the putative inhibition of fibrosis using decorin-loaded 
collagen scaffolds with or without SDF-1α in the spontaneous muscle 
fibrosis model is described. In vitro studies showed that the decorin-
loaded collagen scaffolds induced a short-term release of decorin within 
the first 3 days. In vivo, the SDF-1α and/or decorin-loaded collagen 
scaffolds did not affect the numbers of myofibroblasts, activated 
fibroblasts, satellite cells, and fused myoblasts at 56 days post-surgery. 
Moreover, fibrosis was not reduced. It is concluded that the release 
window of decorin was probably too short to prevent fibrosis.  
In chapter 7, the myogenic potential of muscle stem cells is studied 
in 2D- and 3D-cultures with collagen type I and Matrigel. The latter 
contains satellite cell niche factors. In the 2D-cultures, higher numbers of 
proliferating Pax7
+
 and MyoD
+
 cells were found on Matrigel than on 
collagen. In addition, differentiating muscle stem cells formed more and 
larger MyoD
+
 and Myogenin
+
 myotubes on Matrigel. In the 3D-cultures, 
myofibers were also longer in Matrigel, but short and rounded in 
collagen. MyoD and Myogenin mRNA levels were also higher in muscle 
stem cells cultured in Matrigel. It was concluded that muscle stem cells, 
both in 2D and 3D, lose their differentiation capacity in collagen but not 
in Matrigel, which might be caused by the presence of niche factors.  
Because differences were described for head and limb muscles, the 
myogenic potential of these muscle progenitor cells is compared in 
chapter 8. The muscle progenitor cells derived from head and limb 
muscles showed equal proliferation capabilities in vitro. During 
differentiation, head and limb muscle progenitor cells formed equal 
numbers of fused myotubes and showed comparable mRNA expression 
levels of several Myh-isoforms. The number of Pax7
+
, MyoD
+
, and 
Myogenin
+
 cells in head and limb muscle progenitor cells also did not 
differ during proliferation and differentiation. Thus, head and limb 
muscle progenitor cells show similar myogenic capacities in vitro. The 
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reported differences must therefore be due to the different micro-
environments of the muscles. 
In chapter 9, the results of the previous chapters are discussed in the 
wider perspective of skeletal muscle engineering. Suggestions for future 
research are; the further development of smart scaffolds that induce the 
migration and attachment of satellite cells. The alignment of regenerating 
myofibers should also be stimulated in the scaffolds. Furthermore, in 
vitro culture conditions need to be optimized to maintain the stem cell 
status of satellite cells, and to generate aligned functional muscle tissue.  
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In hoofdstuk 1 wordt de achtergrond en het belang van de studie 
beschreven. De verschillende strategieën voor de tissue engineering van 
skeletspieren wordt geschetst, waarna een overzicht van alle studies 
wordt gegeven. Het doel van deze studie is het verbeteren van de 
spierregeneratie en het verminderen van littekenweefsel door het 
implanteren van driedimensionale constructen. 
In de hoofdstukken 2 en 3 wordt een overzicht van de biologische 
aspecten van de ontwikkeling en regeneratie van skeletspieren gegeven. 
De focus ligt hierbij op de satellietcellen, de stamcellen van spieren, en 
op de factoren die hun activiteit reguleren. Satellietcellen migreren naar 
de wond, waar ze zich vermenigvuldigen en spiervezels vormen voor de 
spierregeneratie. De specifieke micro-omgeving van de satellietcellen, de 
niche, en de groeifactoren die vrijkomen tijdens de spierregeneratie, 
reguleren de activiteit van deze cellen. De vorming van littekenweefsel 
tijdens de spierregeneratie leidt vaak tot onvolledige spierfunctie. Het 
aanbrengen van groeifactoren, cellen, of constructen zijn drie 
verschillende methodes om de spierregeneratie te bevorderen en de 
vorming van littekenweefsel te remmen. Voor grote spierdefecten is 
voornamelijk de implantatie van constructen zinvol en dit is dus de focus  
van de beschreven studies.  
In hoofdstuk 4 wordt een in vivo model voor spierregeneratie 
ontwikkeld dat het litteken na spierscheuring nabootst. De resultaten 
tonen aan dat de activiteit van de satellietcellen, op basis van Pax7 en 
MyoD expressie, niet veranderd na de implantatie van gecrosslinkte 
collageenconstructen in een doorgesneden M. soleus. Echter, deze cellen 
zijn afwezig binnenin de constructen en de spierregeneratie is 
incompleet. Geconcludeerd wordt dat een spierscheuring met 
littekenweefsel kan worden nagebootst door een gecrosslinkte 
collageenconstruct in de doorgesneden M. soleus te implanteren. Dit 
model kan gebruikt worden om nieuwe behandelmethoden voor 
spierscheuringen te ontwikkelen. 
In hoofdstuk 5 wordt een nieuw wondmodel ontwikkeld dat 
spontaan littekenweefsel vormt door het maken van een groot spierdefect. 
De resultaten geven aan dat in deze spierdefecten grote hoeveelheden 
littekenweefsel worden gevormd. Implantatie van ongecrosslinkte 
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collageenconstructen met SDF-1α induceert de migratie van Pax7+ 
satellietcellen naar het regeneratieve gebied rondom het defect in de 
eerste 10 dagen tijdens de spierwondgenezing. Echter, de satellietcellen 
migreren niet de constructen in. Verder is het aantal myofibroblasten en 
de hoeveelheid littekenweefsel na 56 dagen niet veranderd. Dit 
wondmodel induceert dus littekenweefsel en kan gebruikt worden om 
nieuwe constructen te testen om de spierwondgenezing te verbeteren. 
Ongecrosslinkte collageenconstructen met SDF-1α induceren de migratie 
van satellietcellen, maar verminderen niet de vorming van 
littekenweefsel. 
In hoofdstuk 6 wordt het effect van ongecrosslinkte 
collageenconstructen met decorine en met of zonder SDF-1α op de 
spierwondgenezing beschreven. Uit in vitro studies blijkt dat decorine 
binnen 3 dagen vrijkomt uit de ongecrosslinkte collageen constructen. Uit 
de in vivo studies blijkt vervolgens dat de ongecrosslinkte 
collageenconstructen met SDF-1α en/of decorin geen invloed hebben op 
het aantal myofibroblasten, geactiveerde fibroblasten, satellietcellen en 
gefuseerde myoblasten na 56 dagen. Bovendien is de vorming van 
littekenweefsel ook niet verminderd. Geconcludeerd wordt dat het 
tijdsbestek waarin decorine vrijkomt uit de ongecrosslinkte collageen 
constructen waarschijnlijk te kort is om de vorming littekenweefsel te 
voorkomen.  
In hoofdstuk 7 wordt het effect van collageen type I en Matrigel, dat 
satellietcel nichefactoren bezit, op de functie van satellietcellen in 2D- en 
3D-kweeksystemen onderzocht. De resultaten tonen aan dat tijdens de 
proliferatie het aantal Pax7
+
 en MyoD
+
 cellen hoger is met Matrigel dan 
met collageen type I. Verder worden er meer en grotere MyoD
+
 en 
Myogenin
+
 spiervezels gevormd met Matrigel. In het 3D-kweeksysteem 
zijn de gevormde spiervezels ook langgerekt in Matrigel, terwijl de 
spiervezels kort en rond zijn in collageen type I. De mRNA 
expressieniveaus van MyoD en Myogenin zijn ook hoger in de 
spierstamcellen gekweekt in Matrigel. De spierstamcellen verliezen dus 
het vermogen om te differentiëren in de 2D- en 3D-kweeksystemen met 
collageen type I, maar niet met Matrigel.  
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In hoofdstuk 8 wordt het differentiatievermogen van satellietcellen 
die verkregen zijn van spieren uit het hoofd of het onderbeen met elkaar 
vergeleken. Beide soorten spierstamcellen hebben dezelfde capaciteit om 
te prolifereren. Differentiatie van deze spierstamcellen leidt tot dezelfde 
aantallen spiervezels en vergelijkbare mRNA expressie niveaus van 
verschillende Myh-genen. Tijdens de proliferatie en differentiatie van de 
spierstamcellen, geïsoleerd uit beide type spieren, worden dezelfde 
aantallen Pax7
+
, MyoD
+
, en Myogenin
+
 cellen gevonden. Spierstamcellen 
in de hoofd- en onderbeenspieren hebben dus dezelfde capaciteit om te 
prolifereren en differentiëren.  
In hoofdstuk 9 worden de resultaten van de vorige hoofdstukken in 
een breder perspectief van de tissue engineering van skeletspieren 
besproken. Verder worden er ook suggesties voor toekomstig onderzoek 
gegeven. Er moeten nieuwe constructen worden ontwikkeld die de 
migratie van satellietcellen en de uitlijning van de nieuwgevormde 
spiervezels binnen het construct induceren. Verder moeten de in vitro 
kweeksystemen worden geoptimaliseerd zodat de functie van 
satellietcellen behouden blijft en dat er parallelle functionele spiervezels 
gevormd worden in de spierconstructen. 
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Ie könt nich klapp‟n met eenen haand…. oftewel, ik wil in dit laatste 
hoofdstuk iedereen bedanken die mij heeft geholpen om dit proefschrift 
tot een goed einde te brengen. In het bijzonder wil ik de volgende 
personen bedanken: 
 
Als eerste mijn promotor, Prof. Dr. A.M. Kuijpers-Jagtman. Beste Anne 
Marie, jij gaf mij de mogelijkheid om te promoveren bij de afdeling 
Orthodontie en Craniofaciale Biologie. Bedankt dat ik de vrijheid kreeg 
om de onderzoekslijn over spierregeneratie naar eigen inzicht op te 
zetten. Ik hoop dat het onderzoek een mooi vervolg krijgt waaraan ik 
mijn steentje nog kan bijdragen.  
 
Ten tweede wil ik graag mijn beide copromotores, Dr. J.W. Von den Hoff 
en Dr. R. Torensma bedanken. Beste Hans en Ruurd, binnen 4 jaar het 
manuscript afmaken was ons doel…. en het is gelukt! Ik denk nog altijd 
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waren jullie bereid om mij van de nodige input te voorzien. Hopelijk 
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Graag wil ik ook Dr. Piet van Erp bedanken voor alle hulp met de FACS. 
Helaas hebben de vele uren uiteindelijk nog niet kunnen leiden tot een 
isolatie van satellietcellen. Desondanks heb ik veel van je geleerd en ik 
hoop dat we in de toekomst met succes blijven samenwerken. 
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Marjon, en Corien, jullie waren altijd bereid om in te springen als dat 
nodig was. Zonder jullie hulp zou het niet gelukt zijn om binnen 4 jaar 
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klaar te zijn! In het bijzonder wil ik Renéééééé bedank‟n. Zonder jouw 
immunoooooo-expertise was het boekje niet gevuld met zulke mooooooie 
plaaaaaatjes! Ondanks dat het nooooooit een crisis was, hadd‟n we „t toch 
vaak over Crysis (en andere spelletjes). Ik hoooooop dat je het leuk vindt 
om mijn paaaaaaraaaaaanimf te zijn. 
 
Debby Smits en Daphne Reijnen, jullie wil ik in het bijzonder bedanken 
voor al jullie hulp en kunde bij de uitvoering van de dierexperimenten. 
Het was altijd gezellig om bij jullie langs te komen en ik ben trots dat op 
jullie prikbord een mooie foto van Lisa mocht hangen. 
 
Zonder de gezelligheid in de werkkamer zou onderzoek doen toch 
moeilijker worden. Beste Jochem, Miriam, Niels, Ditte, Bas en Nick 
bedankt voor alle gezellige, mooie en leuke momenten! Jochem, met jou 
heb ik het langst op de kamer gezeten en ik heb erg genoten van je 
humor. Als ik nu een paraplu zie denk ik terug aan onze race door 
Dresden om zo snel mogelijk een toilet te vinden :-)! 
 
Tijdens mijn onderzoek heb ik een aantal Master studenten mogen 
begeleiden. Beste Jetty, Roel, Stijn en Hanna, jullie projecten brachten 
altijd nieuwe aanknopingspunten voor vervolgonderzoek wat soms ook 
tot een publicatie heeft geleid. Ik hoop dat jullie net zo veel geleerd 
hebben van mij als ik van jullie.  
 
Dear Rania, Xie-Rui, Yan, Jessie, Lala, Yaping, Isaac, and TanTan, thank 
you for your kindness and the joy you brought to our department. I 
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verder uitgebreid! Beste Mette en Paola, bedankt dat jullie ook in de 
wereld van de spieren zijn gedoken en het onderzoek levend houden en 
verder ontwikkelen. Hopelijk kunnen we in de toekomst samen mooie 
resultaten boeken. Heel veel succes met jullie onderzoek! 
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Alle collega‟s van Biomaterialen wil ik bedanken voor de gezelligheid op 
het lab en in de wandelgangen! Joop en Edwin, alle gesprekken over 
voetbal en dan vooral over FC Twente, Ajax, en PSV zal ik niet vergeten. 
Dat jullie beiden liever FC Twente kampioen zien worden dan “die 
andere club” vond ik bijzonder. Ik ben dan ook blij voor jullie dat FC 
Twente tenminste één keer kampioen is geworden! Vincent, bedankt voor 
al je felicitaties :-)! 
 
Bianca, bedankt dat je de opmaak van mijn proefschrift wilde verzorgen. 
Daardoor lukte het me om het boekje binnen 4 jaar in juiste opmaak bij 
de commissie in te leveren. 
 
Natuurlijk wil ik ook alle vrienden bedanken die voor de nodige 
ontspanning hebben gezorgd de afgelopen jaren. In het bijzonder wil ik 
alle (studie)vrienden uit Enschede en Nijmegen bedanken: Rob, Joost, 
Martijn, Jeanette, Monique, Remco, Dinant, Melissa en Olaf. Alle snood-
unreal-, Beekbergen- en (spannende) bowlingmomenten zal ik nooit meer 
vergeten. Hopelijk beleven we in de toekomst nog meer (Alpen) 
avonturen! 
 
Lieve papa en mama, dank voor jullie onvoorwaardelijke steun en advies, 
en voor de fietsen die in Arnhem achterbleven. Het is erg fijn dat jullie 
me de vrijheid hebben gegeven in al mijn keuzes. Erik, jij gaf mij het 
“goede” voorbeeld ;-)! Ik ben blij dat je het nu zelf ook volgt. Bedankt 
dat je mijn paranimf wilt zijn. 
 
Lieve Lisa. Je bent nog maar net in mijn leven, maar nu al weet je elke 
dag een glimlach op mijn gezicht te toveren. Een schaterlach van je is al 
genoeg om mijn dag helemaal goed te maken. Vooral de dagen dat we 
samen door het bos wandelen, maakt me erg gelukkig. Het is een genot 
om te zien hoe je de paarden en schapen met volle bewondering aanstaart 
en dat je tussendoor de bomen bijna omzaagt! Van je totale ontspanning 
tijdens het (WK-)voetbal kan ik nog veel leren! 
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Lieve Sandra, mijn steun en toeverlaat. Jij bent de stabiele factor in mijn 
leven waardoor ik de afgelopen 4 jaar zo goed als geen stress heb 
gevoeld. Bedankt voor al je geduld. We hebben samen al vele mooie 
hoogtepunten beleefd, maar we zullen samen met Lisa zeker vele nieuwe 
beleven. Ik hou van jullie!! 
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Curriculum vitae 
 
Sander Grefte werd op 11 december 1980 geboren te Hengelo (O). In 
1999 haalde hij zijn HAVO diploma en begon hij met de studie Medische 
Biochemie aan de Saxion Hogeschool Enschede. Na het behalen van zijn 
diploma in 2003 startte hij met de studie Biomedische Wetenschappen 
aan de Radboud Universiteit Nijmegen. Tijdens deze studie deed hij zijn 
onderzoeksstages op de afdeling Biochemie onder begeleiding van Dr. 
W. Koopman en bij de afdeling Tumor Immunologie onder leiding van 
Dr. R. Torensma. Dit onderzoek resulteerde in 3 publicaties. In 2006 
behaalde hij zijn Master of Science diploma met Pathobiologie als 
afstudeerrichting. In april 2007 begon hij zijn promotieonderzoek 
“Improving the regeneration of injured muscle” op de afdeling 
Orthodontie en Craniofaciale Biologie (hoofd Prof. A.M. Kuijpers-
Jagtman). De resultaten van dit onderzoek staan beschreven in dit 
proefschrift. In april 2011 werd gestart met vervolgonderzoek op de 
afdeling Orthodontie en Craniofaciale Biologie. In augustus 2011 heeft 
hij een bezoek gebracht aan de Randall Division and Molecular 
Biophysics van het King’s College in Londen onder de supervisie van Dr. 
P. Zammit. Hij heeft hiervoor een subsidie gekregen van de European 
Molecular Biology Organization en van de Koninklijke Nederlandse 
Akademie van Wetenschappen (Ter Meulen Fonds). 
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